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CHAPTER I 
INTRODUCTION 
R. Janknegt 
Multiple antibiotic resistance has become a major problem in 
many European countries and the United States. The importance of 
a rational antibiotic policy is stressed both nationally and 
internationally to prevent the possible development of resistance 
due to unjustified use of antimicrobial agents (1). 
Financial aspects also play a role in antibiotic policy. The total 
cost of the in-hospital use of antimicrobial agents has increased by 
30% from 1978 to 1986 (2). 
One of the aims of the "WHO Program for appropriate healthcare 
technology" is to reach a justified use of technologies (antibiotics) 
(3). Also the Dutch "Health Council" (Gezondheidsraad) has 
underlined the importance of a rational antibiotic policy, based on 
regular surveillance of (local) bacterial resistance patterns (4). 
Most Dutch hospitals have created so-called "antibiotic for-
mularies" with guidelines for the treatment of infectious diseases 
which are specific for that hospital or for a group of collaborating 
hospitals (regional antibiotic formularies). 
In 1988 - 1989 the Dutch Medical Audit organisation CBO 
(Centraal Begeleidingsorgaan voor de Intercollegiale Toetsing) 
investigated the availability of antibiotic formularies in Dutch 
hospitals (5). The authors concluded that most hospitals followed 
the recommendations of the Gezondheidsraad and they expected 
that the situation would improve with an increasing degree of 
automation in bacteriological laboratories. 
The antibiotic policy in Dutch hospitals is the subject of this 
thesis. 
An overview of the general contents of these antibiotic formularies 
in Dutch hospitals (in 1991) is presented in this chapter. 
The relationship between antibiotic policy guidelines and the 
actual use of antimicrobial agents has not been studied extensively. 
We have correlated the antibiotic guidelines from 20 Dutch 
hospitals with the actual use of several groups of antimicrobial 
agents, such as aminoglycosides, co-trimoxazole, second and third 
generation cephalosporins, co-amoxiclav (amoxycillin + clavulanic 
acid), macrolides, antipseudomonal penicillins and fluoroquinolo-
nes. This study is presented in Chapter 2. 
Most Belgian hospitals do not have a written antibiotic policy, but 
they use a formulary, which is adapted to the Belgian situation 
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from the antibiotic formulary written by Dr. J.P. Sanford from 
Bethesda, Maryland, USA. It is not clear whether the use of one 
formulary in the whole country offers advantages in a more 
uniform use of antimicrobial agents. In Germany most hospitals do 
not have written guidelines for the treatment of infections. Because 
the data on the actual use of antimicrobial agents in hospitals in 
several European countries are very limited, we compared the use 
of antibacterial drugs in Dutch hospitals to the use of these drugs 
in hospitals in Germany (Nordrhein Westfalen) and Belgium (both 
from the Dutch speaking and French speaking parts), expressed as 
the number of Defined Daily Doses (DDD) per 100 bed days and 
tried to correlate the differences in antibiotic use with differences 
in antibiotic policy in these countries. This study is described in 
Chapter 3. 
The recommendations of the Dutch antibiotic formularies for the 
treatment of several categories of infections are given in Chapters 
4-6. Chapter 4 presents the guidelines for the treatment of bacterial 
bronchitis, with special reference to the definitions of bronchitis 
used by these formularies. Chapter 5 contains the guidelines for 
the treatment of pneumonia. The antibiotic policy for the treatment 
of sepsis is summarized in Chapter 6. 
The recommendations of the formularies for three different types 
of bowel surgery (colorectal surgery, biliary surgery and 
gastroduodenal surgery) are reported in Chapter 7 and those for 
the prophylactic use of antibacterial drugs in gynaecological 
surgery (abdominal hysterectomy, vaginal hysterectomy and 
caesarian section) are presented in Chapter 8. 
Aminoglycosides are important antimicrobial drugs, but their use 
is limited by the relatively high incidence of nephrotoxicity and 
ototoxicity. Monitoring of these drugs is therefore considered 
necessary. Animal studies have indicated that once daily dosage of 
aminoglycosides is associated with a lower incidence of toxicity 
and this has been confirmed in several human studies. The 
guidelines for drug monitoring of aminoglycosides in clinical 
practice are still based on the conventional 3 times daily dosing 
schedule. The current guidelines in Dutch hospitals for the dosing 
schedules for aminoglycosides in relation to the recommendations 
for drug monitoring were studied by means of an inquiry among 
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hospital pharmacists. This study is described in Chapter 9. 
The choice of a drug from a more or less large pharmaceutical 
group is often based on criteria which are not always rational and 
therefore not open for discussion. A rational drug-decision making 
system has been proposed to make the criteria on which a decision 
is based transparent, the so-called System of Objective Judgement 
Analysis (SOJA-system). A number of both national (number of 
registered indications, number of formulations, cost, etc) and 
international criteria (efficacy, side-effects, pharmacokinetics, etc) 
are defined. The SOJA score for the fluoroquinolones 
ciprofloxacin, ofloxacin and Pefloxacin is presented in Chapter 10. 
The introduction of oral third generation cephalosporins, such as 
Cefixime and Cefpodoxime proxetil on the market has widened the 
possibilities for sequential therapy with intravenous and oral cep-
halosporins for infections in hospitalized patients. The theoretical 
and practical aspects of such therapy are described in Chapter 11. 
In Chapter 12 conclusions and recommendations regarding 
antibiotic policy based on the preceding chapters are given. 
MATERIALS AND METHODS 
In April/May 1991, 109 members of the Dutch Association of 
Hospital Pharmacists (NVZA) were given a short description of 
the aims of the study and they were requested to send to us the 
most recent version of the antimicrobial formulary used in their 
hospital. 
Data on antibiotic resistance patterns were requested from the 
microbiological laboratory of all hospitals from which an antibiotic 
formulary was received. 
The following items in the antibiotic formularies were recorded: 
year of publication 
composition of the editorial board of the formulary 
the "weight" of the recommendations in the formulary 
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the contents of the antibiotic formularies with regard to 
general guidelines for the duration of antibiotic 
therapy 
antiviral therapy 
dosage recommendations for children 
dosage recommendations for patients with renal 
insufficiency 
guidelines concerning the use of antimicrobial 
agents during pregnancy and lactation 
contra-indications 
drug interactions, or interactions with food. 
Regarding the resistance patterns our prime interest was in the 
availability of these data. The data were analysed to see whether 
the antibiotic susceptibility data came from one hospital only or 
were regional data. Finally, we checked whether it was possible to 
specify the susceptibility patterns per species, per sample and per 
ward. 
RESULTS 
A total of 38 formularies, in use in 78 hospitals, were received 
from 6 (out of 8) university hospitals (75%) and from 21 out of 40 
hospitals with 500 or more beds (53%). Hospitals with fewer than 
500 beds but which were part of a conglomerate of hospitals or a 
region (n = 25) were included in this category. A total of 11 
formularies were received from 34 hospitals (32%) with less than 
500 beds 
No antibiotic formulary was available from 31 hospitals: fourteen 
of these had no intention of developing their own antibiotic 
formulary, six hospitals were working on a revision of the antibi-
otic policy and they considered the present version as "too old" to 
be submitted to us. A first version of an antibiotic policy would 
"soon" be available in 9 hospitals, although no specification of the 
time was given. Two hospitals had only developed guidelines for 
the prophylactic use of antimicrobial agents. 
The year of publication ranged from 1983 to 1991. Fifteen 
antibiotic formularies were dated before 1988 (Table 1). 
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TABLE 1 
YEAR OF PUBLICATION OF ANTIBIOTIC FORMULARIES 
Year Number of formularies 
1983 1 
1984 0 
1985 2 
1986 3 
1987 9 
1988 S 
1989 6 
1990 5 
1991 7 
The editorial board of the antibiotic formularies consisted of a 
medical microbiologist and a hospital pharmacist in all cases. 
Other members of the board were internists (66%), surgeons 
(44%), paediatricians (31%) and chest physicians (19%). All other 
specialists accounted for only 6%. Twenty-two of the 38 
formularies (58%) provided some specifications of the importance 
of the guidelines. In three formularies it was stated that the 
guidelines were compulsory and 19 formularies stated that the 
formulary gave treatment recommendations. In the other 16 
formularies (42%) no specification of the importance of the guide-
lines was given. 
The contents of the formularies are given in Tabic 2. 
Guidelines for dose adaptation in patients with renal insufficiency 
and in children were given in all formularies from university 
hospitals, whereas these data were present in 40% of the 
formularies from hospitals with > 500 beds but in 67% of the 
hospitals with < 500 beds. 
Some data on bacterial resistance patterns were available from 22 
of the 78 hospitals. The degree of usefulness for the preparation of 
an antibiotic formulary was highly variable. One hospital recorded 
the susceptibility of Pseudomonas aeruginosa as an indicator 
organism for the antibiotic-resistance pattern (6). From two other 
hospitals data were available from blood isolates on the intensive 
care unit. From 14 hospitals only total susceptibility data for all 
isolates (without further specification) were available. Eleven of 
these hospitals were able to discriminate between the source 
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(blood, urine, sputum). For 42 hospitals regional susceptibility 
patterns were available, whereas 14 hospitals had no accessible 
information at all on the antibiotic susceptibility data in the 
hospital. Only 5 hospitals provided data per micro-organism, per 
material and per hospital ward or outpatient clinic. 
TABLE 2 
CHARACTERISTICS OF ANTIBIOTIC FORMULARIES 
Percentage of formularies in which a certain item is included 
Item 
Duration 
Viral infections 
Children dosage 
Renal impairment 
Pregnancy 
Contra-indications 
Interactions 
Trade names 
Daily cost 
Type 
University 
60 
80 
100 
100 
40 
40 
60 
60 
40 
of hospital 
>500 
beds 
41 
23 
74 
40 
18 
8 
36 
63 
5 
<500 
beds 
38 
23 
76 
52 
30 
23 
23 
76 
14 
DISCUSSION 
In the ideal situation the antibiotic policy should be based on the 
susceptibility data from the hospital in question with regard to 
source of the material, such as blood, urine, sputum etc. (7). Data 
on the local bacterial population are necessary, due to potential 
differences between hospitals regarding size, the number of 
intensive care beds, antibiotic policy and the patient population. 
The presence of certain specialties such as burns centres, oncology 
and transplantation surgery units will influence the antibiotic 
policy and also the antibiotic resistance patterns. 
These data were available from five hospitals only, however. It is 
not clear how strong the basis is on which the antibiotic policy of 
hospitals which have no data on antimicrobial susceptibility is 
built. This is now often based on a "general impression" from the 
laboratory results. An antibiotic formulary per hospital is recom-
mended if there are important differences between hospitals in a 
single region. 
7 
A regional antibiotic policy however, has advantages concerning 
the standardisation of antibiotic utilisation within the region in 
question. This leads to better cooperation between general practice 
and hospital use of antibiotics (8). A regional formulary may even 
be recommendable if the differences in antibiotic susceptibility 
between hospitals are taken into consideration during the 
discussion on antibiotic policy. 
The results of this inquiry show that the situation regarding the 
availability of antibiotic formularies in The Netherlands is not 
ideal. The most important motivation for an optimal use of 
antimicrobial agents is the relationship between antibiotic use and 
antibiotic resistance (9). Although various factors are involved in 
the development of resistance or in the selection of resistant 
micro-organisms an antibiotic policy is essential for preventing the 
rapid and wide-spread development of resistance. An optimal 
antimicrobial therapy, concerning choice of antimicrobial drug, 
dosage and duration, minimises the development of resistance. The 
dose should be based on the pharmacokinetic and 
pharmacodynamic properties of the agent in question, the duration 
should be determined by clinical studies and by the clinical 
situation of the patient. The choice of an antimicrobial agent for a 
specific infection should be based on the susceptibility data from 
the hospital in question. Both the WHO and the Gezondheidsraad 
have stressed the necessity of a correct use of antimicrobial agents 
(3, 4). The situation in 1991 had not greatly improved since 1988 
- 1989 (5). In 1991, 31 of the 109 hospitals had no written 
guidelines for antibiotic policy, whereas 20 of the 38 formularies 
were at least 3 years old. Taking into consideration the 
introduction of a number of new antimicrobial agents since 1988, 
such as the fluoroquinolones, new macrolides and oral third 
generation cephalosporins, it seems doubtful whether the recom-
mendations in the older formularies are still up-to-date. Only 8% 
of all formularies clearly state that the formulary is compulsory. 
The guidelines in the other 92% are not defined as being very 
strict. It is not clear whether "guidelines" for antibiotic policy will 
be followed by all clinicians. 
I recommend an active policy in the hospitals concerning the 
preparation of an antimicrobial formulary. This means that a 
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formulary should be revised every 2 years. The choice of anti-
biotics should be based on susceptibility data from the micro-
biological laboratory. It is important to define prospectively 
whether the contents of the formulary are intended as guidelines or 
whether they are binding. An input from all clinicians is essential 
in the preparation of the formulary. 
The formulary should be evaluated with the medical staff on a 
regular basis to optimise the antibiotic policy. 
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CHAPTER II 
ANTIBIOTIC GUIDELINES AND ANTIBIOTIC 
UTILISATION IN DUTCH HOSPITALS 
E. Stobberingh, R. Janknegt, W.J.A. Wijnands 
Journal of Antimicrobial Chemotherapy 1993;32:153-61 
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SUMMARY 
In April-May 1991 the availability of antibiotic formularies in 
Dutch hospitals was analysed as well as data available on anti-
biotic susceptibility patterns. In addition data on the use of diffe-
rent groups of antimicrobial agents (aminoglycosides, ß lactam 
compounds including aztreonam and imipenem, co-trimoxazole, 
vancomycin and fluoroquinolones) were collected by a question-
naire. 
Thirty-eight formularies were received which were used in 78 
hospitals. No formulary was available from 31 hospitals: 15 
hospitals dit not have the intention to set up antibiotic guidelines, 
nine hospitals started up with their first formulary and seven used 
a revised version of the existing one. 
Fifteen formularies dated from 1987 or earlier. The availability of 
antibiotic susceptibility patterns ranged from no data at all (n=14) 
to extensive data per species, per material and per ward (n=5). 
From 20 hospitals data on antibiotic usage as well as on antibiotic 
guidelines were obtained. Because several hospitals used the same 
formulary, 15 different formularies were analyzed from 20 
hospitals. Fluoroquinolones were used in all hospitals, but were 
only mentioned in the formularies of 6 hospitals. 
The data in the present study underscore the need for a col-
laborative approach of medical staff, hospital pharmacy and 
microbiologist in order to maintain a relatively low level of 
antibiotic resistance in Dutch hospitals. 
INTRODUCTION 
There is a growing concern over the increased use of antimicrobial 
agents and the subsequent increase in bacterial resistance and in 
health care costs (1, 2). Therefore worldwide attempts have been 
made to optimize the use of antibiotics (3). For instance the WHO 
participated in meetings and the Infectious Diseases Society of 
America (IDSA) prepared guidelines to improve the usage of 
antimicrobial agents (4, 5). The recommendations include the 
appointment of an antimicrobial agents team given the task of 
setting up a formulary to encourage the better use of antimicrobial 
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agents. In addition, the use of these compounds has to be analysed 
periodically to monitor whether the guidelines of the formulary are 
still being followed. In the Netherlands the "Gezondheidsraad" 
stressed the importance of an optimal use of antibiotics based on 
data obtained by regular surveillance of bacterial resistance 
patterns (6). 
In 1988 a study was performed to analyse the availability of 
antibiotic formularies in different hospitals throughout the 
Netherlands. One of the conclusions was that the situation was not 
bad but could be better (7). In 1991 an update of the situation in 
the Netherlands has been performed, the results of this are presen­
ted here. 
MATERIALS AND METHODS 
In April-May 1991 Dutch hospitals (n=109) were asked to send 
their formulary as well as data available on antibiotic susceptibility 
patterns to the authors. In addition data on the use of the following 
groups of antimicrobial agents were collected by a questionnaire: 
aminoglycosides, aztreonam, co-trimoxazole, imipenem, second-
and third-generation cephalosporins, co-amoxiclav, anti-pseudom-
onal penicillins, fluoroquinolones and vancomycin. 
For the analysis of the data the hospitals were divided into three 
groups, group A: university hospitals, groep В: hospitals with 
more than 500 beds, group C: hospitals with less than 500 beds. 
The use of antibiotics was calculated as the defined daily doses 
(DDD) per 100 bed days. The DDD is defined as the assumed 
average dose per day for a drug of antimicrobial agent used for its 
main indication in adults (8). One has to keep in mind that the 
DDD is a technical unit of measurement which is independent of 
differences in price or in preparations. Therefore the DDD can 
only be used as an approximate estimate of antibiotic 
consumption. However, it is especially useful for comparisons 
between different hospitals or countries. 
To correlate the data on the usage of antibiotics to the antibiotic 
guidelines, the DDD per 100 bed days per antibiotic were divided 
by the number of first-line indications for that particular 
compound. 
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The formularies were analysed in terms of year of publication, the 
authors and the type of guidelines the formulary set out. The 
availability of the antibiotic susceptibility patterns were reviewed 
per region, per hospital, per ward and per specimen. 
RESULTS 
Thirty-eight antibiotic formularies were received, which were used 
in 78 hospitals: six out of eight university hospitals, 21 out of 40 
hospitals (53%) with 500 beds or more. If a region was served by 
more than one hospital, together consisting of more than 500 beds, 
the hospitals were classified as one hospital belonging to group B. 
From the 34 relatively small hospitals (less than 500 beds) 11 
formularies (32%) were obtained. No formulary was available 
from 31 hospitals: 15 did not have the intention to set up 
guidelines for the use of antibiotics. Nine hospitals started up with 
their first formulary and seven were preparing an updated version 
of the existing one. 
The year of publication of the formularies ranged from 1983 (n=l) 
to spring 1991 (n=l). Fifteen formularies dated from 1987 or 
earlier. All formulary committees consisted of a hospital 
pharmacist and a medical microbiologist complemented with 
clinicians (internal medicine 66%, surgery 44% and/or pediatrics 
44%). Three of the formularies stated clearly that clinicians have 
to commit themselves to the advices given. Half of the for-
mularies mentioned that the advices have to be considered as 
guidelines only. The others did not mention the purpose of the 
proposed guidelines. 
The availability of susceptibility patterns of isolates to the 
hospitals participating in the survey ranged from no data at all 
(n=14) to extensive data per species, per material and per ward 
(n=5). Only limited data were available from the other hospitals. 
Moreover, these data were mostly derived from the region the 
hospital belongs to, and not from the hospital itself. 
From 20 out of 78 hospitals data on antibiotic usage as well as on 
antibiotic guidelines were obtained. Several hospitals used the 
same formulary e.g. hospitals Bl and CI shared one formulary 
and C2 and C3 shared another. A regional formulary was used by 
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hospitals B9, C4, C5 and C6. Therefore 15 different formularies 
were analyzed from 20 hospitals. 
The most important indications mentioned in the antibiotic 
guidelines for the use of antimicrobial agents studied are shown in 
Table 1. 
TABLE 1 
MOST IMPORTANT INDICATIONS MENTIONED IN 15 FORMULARIES (N) FOR EACH 
GROUP OF ANTIMICROBIAL AGENTS 
Group of 
antimicrobial agents 
Indication Mentioned in 
Formulary (n) 
Aminoglycosides 
Co-amoxiclav 
Antipseudomonal penicillins 
Aztreonam 
Cephalosporins 
second generation 
third generation 
Co-trimoxazole 
Fluoroquinolones 
Imipenem 
Macrolides 
Endocarditis 
Septicaemia 
Meningitis 
Pneumonia 
Pneumonia 
Septicaemia 
Pneumonia 
Septicaemia 
Septicaemia 
Septicaemia 
Pneumonia 
Meningitis 
Pneumonia 
Prostatitis (acute) 
Dysentery 
Typhoid fever 
Prostatic (acute) 
Typhoid fever 
Granulocytopaenia 
Pneumonia 
Gastroenteritis 
Tonsillitis 
Urethritis 
15 
10-13 
10 
7 
3 
8 
5 
1 
4-5 
4 
3 
5-6 
10 
10 
10 
3 
2 
2 
1 
9 
14 
10 
2 
All formularies recommended the use of aminoglycosides for the 
treatment of septicaemia. In 14 out of the 15 formularies 
macrolides were the drugs of choice for the treatment of 
Legionella pneumonia and Campylobacter gastroenteritis. In 
addition, ten formularies mentioned the same indications for 
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aminoglycosides and macrolides, i.e. meningitis and tonsillitis 
respectively. The use of co-trimoxazole for the treatment of pneu­
monia, Shigella dysentery and acute prostatitis was recommended 
with the same frequency. Only one university hospital mentioned 
an indication for the use of aztreonam and imipenem in its 
formulary. A limited indication for the use of fluoroquinolones i.e. 
acute prostatitis and typhoid fever was mentioned in only two 
formularies. 
The usage of the antimicrobial agents in these hospitals is shown 
per hospital in table 2. Considerable differences were observed 
between hospitals of the three groups. Co-amoxiclav was the drug 
of choice in one university hospital (6.6 DDD per 100 bed days), 
whereas in the other group A hospitals it was hardly used. Also 
for the groups В and С hospitals a wide variation for some com­
pounds was observed. The use of co-amoxiclav in group В 
hospitals ranged from zero to 4.4 DDD, in group С from zero to 
18 DDD per 100 bed days. For the second generation cephalospo­
rins a wide range in use was observed as well, i.e. for group В 
from 0.7 to 10 DDD and for the group С hospitals from 0.2 to 6 
DDD per 100 bed days. The variation for the other compounds 
was distinctly less. 
The ratio between the usage and the number of indications for 
which the different agents were the drug of choice is shown in 
Table 3. Remarkably, fluoroquinolones were used in all hospitals 
(Table 2) but were only mentioned in the formularies of six 
hospitals (Table 3). 
DISCUSSION 
The data in the present study demonstrate that the availability of 
antibiotic formularies and the adherence to of the recommen­
dations given require further improvement in most Dutch hos­
pitals. The statements of Barclay "Prescribing antibiotics: not 
entirely bad, but could be better" still applies for the Dutch 
situation in 1991 (9). In 1991 6/8 (75%) of the university hos­
pitals and about half (i.e. 53%) of the hospitals with 500 beds or 
less had written guidelines. However 15 out of the 38 formularies 
dated from 1987 or earlier. Taken into account the rapid develop-
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TABLE 2 
ANTIBIOTIC USAGE IN 20 DUTCH HOSPITALS 
Expressed in DDD per 100 bed days 
Hospital 
A 
1 
2 
3 
В 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
С 
1 
2 
3 
4 
Ami 
1 g 
2 9 
36 
09 
20 
17 
1 7 
08 
1 1 
1 1 
01 
10 
1 8 
00 
18 
2 6 
06 
Ctx 
4 0 
45 
4 3 
13 
23 
3 8 
30 
3 0 
2 0 
55 
1 1 
48 
18 
27 
1 7 
20 
57 
Antibiotic 
Сер 
26 
24 
16 
07 
1 1 
35 
80 
23 
5 1 
10 
07 
16 
32 
03 
02 
02 
10 
Сер 
2nd 
21 
18 
14 
1 8 
0 75 
2 0 
06 
03 
0 25 
0 8 
03 
14 
0 6 
17 
0 I 
0 2 
07 
Aug 
3rd 
2 0 
0 6 
66 
4 4 
05 
05 
09 
1 0 
-
44 
-
01 
24 
4 4 
18 
14 
-
Mac 
2 0 
0 9 
12 
06 
06 
14 
06 
I 1 
08 
1 8 
02 
0 6 
08 
00 
07 
0 2 
13 
Pen 
10 
04 
0 6 
01 
0 3 
0 0 
0 1 
01 
-
-
-
03 
01 
00 
01 
01 
03 
Qui 
41 
2,4 
45 
0 8 
2 0 
08 
13 
0 6 
2 0 
23 
23 
30 
34 
25 
0 4 
0 4 
3 0 
07 17 24 0 29 - 04 - 21 
12 10 24 010 16 15 01 07 
03 17 60 18 55 0 26 0 10 28 
Ami = aminoglyosides Ctx = co-trimoxazole Сер 2nd = second generation cephalosporins 
Сер 3rd = third generation cephalosporins Aug = co-amoxiclav 
Mac = macrolides Pen = antipseudomonal penicillins Qui = fluoroquinolones 
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TABLE 3 
RATIO BETWEEN THE NUMBER OF DDD PER 100 BED DAYS AND THE NUMBER OF 
FIRST-LINE INDICATIONS, MULTIPLIED BY 100 
Hospital 
A 
1 
2 
3 
В 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
С 
1 
2 
3 
4 
5 
6 
7 
. 
Ami 
10 
22 
21 
5 
11 
30 
7 
7 
g 
10 
0.7 
5 
10 
0.2 
8 
11 
3 
4 
6 
2 
Ctx 
80 
113 
61 
39 
46 
300 
105 
75 
43 
138 
110 
96 
65 
74 
15 
18 
114 
34 
54 
32 
Antibiotic 
Сер 
2nd 
180 
120 
-
24 
55 
17 
85 
0 
36 
114 
35 
53 
-
12 
2 
2 
33 
80 
54 
140 
antibiotic not mentioned in 
Abbreviations: see Table 2. 
Сер 
3rd 
34 
90 
28 
19 
75 
33 
33 
-
25 
-
10 
70 
10 
15 
12 
16 
35 
15 
22 
117 
formulary 
Aug 
200 
-
55 
563 
-
-
-
-
-
-
-
-
140 
563 
252 
194 
-
-
-
• 
Mac 
67 
30 
30 
-
21 
45 
30 
110 
28 
90 
10 
15 
-
-
22 
7 
33 
10 
38 
19 
Pen 
-
-
450 
27 
-
40 
-
-
-
-
18 
-
115 
83 
-
-
-
-
-
-
Qui 
33 
17 
12 
14 
16 
-
6 
-
0 
0 
-
6 
-
4 
7 
7 
6 
0 
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32 
ment of new drugs in the past five years (e.g. fluoro-quinolones 
and macrolides) a revision of the formulary on a regular basis 
(every two to three years) is highly recommended. If no up-to-date 
formulary is used it is very likely that discrepancies between 
written guidelines and real usage do occur as observed in the 
present study. All twenty hospitals used fluoroquinolones, ranging 
from 0.4 to 4.5 DDD per 100 bed days, but fluoroquinolones were 
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mentioned in only six formularies. The main reason for this discre-
pancy is that the fluoroquinolones were introduced in the Nether-
lands from 1988 and later. Therefore, all formularies before that 
date did not include quinolones but the compounds were in use in 
1991. Another remarkable discrepancy is the usage of co-
amoxiclav by almost all hospitals, whereas the compound was 
only mentioned in seven formularies. 
To our knowledge there is no generally accepted method to relate 
the overall use of antimicrobial agents to the guidelines laid down 
in the formularies. Therefore, arbitrarily, the ratio between usage 
of a compound and the times that it was recorded as the drug of 
choice was calculated. However, one has to take into account that 
the prevalences of the indications mentioned in the formularies are 
not at all similar. Therefore comparing the figures between the 
different groups of antimicrobial agents is unhelpful. However, 
one can compare ratio figures between hospitals within one group 
of agents. The wide variations observed in table 3 for almost all 
agents studied are obvious, although for aminoglycosides and the 
antipseudomonal penicillins the ratios were within a narrower 
range. 
There are several reasons for the wide variation for the other 
agents in the different hospitals. One reason is the prophylactic use 
of a compound in surgery. The calculation of the ratio figures was 
based only on therapeutic indications and not prophylactic use. It 
is known that co-amoxiclav had been used as prophylactic agent in 
hospitals Bl, B4, CI, C2 and C3 from 1989 (personal communica-
tions). The same is true for the use of second generation 
cephalosporins in hospital C7. A second reason is differences in 
the patient population of the various hospitals. Hospitals Bl and 
CI used the same formulary. Hospital CI is a low care hospital 
and as expected (table 2) there were lower ratios for aminoglyco-
sides, second generation cephalosporins and antipseudomonal 
penicillins in hospital CI than in hospital Bl. However, the 
reverse was true for co-trimoxazole and the oral fluoroquinolones, 
whereas the ratio for co-amoxiclav was similar for both hospitals. 
Interesting data were also found for hospitals B4, C4, C5 and C6. 
All four hospitals shared the same formulary. Although hospital 
B4 is the largest, only for third generation cephalosporins was the 
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highest ratio observed in this hospital (70 compared to 35, 15 and 
22 in the other hospitals). However, hospital C4 showed the 
highest ratio for co-trimoxazole, and for hospitals C4 and C6 it 
was for the macrolides. For the antipseudomonal penicillins 
hospital C6 showed the highest ratio and hospital C5 for the 
second generation cephalosporins. Thus, differences in patient 
population of the hospitals alone could not explain the wide 
variation in ratios (Table 3). Finally, one has to take into account 
that the wide variation might be due to discrepancies between 
actual usage and the recommendations given in the formularies. 
This is obviously the case for the fluoroquinolones. Other workers 
have also reported such inappropriate use (Table 4). Inappropriate 
use was usually defined as use not according to the guidelines of 
that hospital, administration of the agent without signs of an 
infection, incorrect dosage or inappropriate route of administration. 
In the studies cited in Table 4, inappropriate use ranged from 11% 
in a survey in 1971 up to 62% in a survey performed from 1967-
1969 in seven community hospitals in the USA. The figures for 
England were hardly any better, the highest percentage of 
inappropriate use (50%) being found in a survey of treatment of 
urinary tract infections (15). Furthermore, analysis by service 
showed that in the medical departments inappropriate use was 
distinctly lower than in the surgical or gynaecological department 
(11, 19). In the Netherlands there has been one study comparing 
the choice of antibiotic therapy for the treatment of septicaemia 
with the guidelines of the formulary. Discrepancies were observed 
in 30% of all prescriptions (21). 
Most of the studies concluded that a formulary alone is not 
sufficient to improve the use of antibiotics. Education is con-
sidered to be very important (22). Educational programmes might 
show so' ie effect, but conflicting data do exist (23-25). 
Continuing readily available consultation of the microbiologists 
and pharmacists is considered to be an effective method (26). Also 
higly recommended by the IDSA is periodic information for 
medical staff concerning antibiotic usage, as well as trends in 
antibiotic susceptibility patterns of the own hospital isolates (4). 
Control of antibiotic usage will reduce antibiotic resistance and 
reduce costs (23, 27, 28). The IDSA stressed the importance that 
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antibiotic formularies should be based on antibiotic susceptibility 
patteras of the own hospital isolates (4). These data include 
susceptibility pattern by ward, by specimen and by species. Only 5 
of the 78 Dutch hospitals participating in the study had these data 
readily available. Two-thirds of the hospitals were able to provide 
data on susceptibility patterns of isolates from the region the 
hospital belongs to but not from the hospital itself. 
TABLE 4 
INAPPROPRIATE USE OF ANTIMICROBIAL AGENTS IN DIFFERENT SURVEYS 
References year of survey inappropriate use (%) 
10 
II 
12 
13 
14 
15-17 
18 
19 
20 
21 
1952-1956 
1967-1969 
1975 
1978 
1971 
1979 
1978 
1980 
1980 
1979 
1980 
1987 
52 
62 
41 
22 
II 
20 
40-50 
14 
2 
28 
35 
30 
Although the present study did not include all Dutch hospitals, it 
is not very likely that the hospitals participating in the study are 
unrepresentative of the situation in Dutch hospitals in general. Fur-
thermore, it is to be expected that the implementation of computa-
rized data management systems in many microbiological 
laboratories will in due course improve the availability of (ex-
tensive) antibiotic susceptibility patterns. 
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The data in the present study underscore the need for an active 
collaborative approach between medical staff, hospital pharmacy 
and microbiological laboratory (29, 30) in order to maintain a 
relatively low level of antibiotic resistance in Dutch hospitals (31). 
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SUMMARY 
Data on the use of antimicrobial drugs was collected by means of 
an inquiry to 30 hospitals in Belgium (15 in Dutch sector and 15 
in the French sector), 21 hospitals in Germany and 20 hospitals in 
the Netherlands. The use of these drugs was expressed as the 
number of defined daily doses (DDD) per 100 bed days by the 
anatomical therapeutical chemical classification system. The total 
use of antimicrobial agents was significantly (p < 0.001) higher in 
both parts of Belgium (55.6 and 52.0 DDD per 100 bed days) than 
in Germany (37.9 DDD per 100 bed days) or the Netherlands 
(34.1 DDD per 100 bed days). In particular co-amoxiclav, the first 
and second generation cephalosporins, aminoglycosides and 
fluoroquinolones were used more in Belgium than in either of the 
other countries. At least part of the differences observed in 
antimicrobial drug use could be explained by differences in written 
antibiotic policy. 
INTRODUCTION 
There is worldwide concern about the increased bacterial 
resistance to various antimicrobial agents, including resistance to 
recently introduced compounds (1). It is widely accepted that this 
increased resistance is mainly due to the use of antibiotics (2). 
Moreover, the correlation between the prevalence of multiple 
resistant microorganisms and the total use of broad-spectrum 
antibiotics (e.g. cephalosporins) has been documented (3). 
Variations in levels of resistance between different countries and 
between hospitals have been demonstrated (4, 5). Distinct 
differences in resistance to various beta-lactam compounds of 
Gram-negative blood culture rods isolated from hospitals in 
Germany, Belgium and the Netherlands have been described by 
the European Study Group on Antimicrobial Resistance (6). 
Unfortunately, only limited data on the total use of antimicrobial 
agents in hospitals in various countries are available. Martini et al. 
(7) studied the use of these drugs in ten hospitals in Italy, seven in 
Portugal and nine in Spain. Data on antimicrobial drug use in 
northern Europe are scarce and usually limited to that from 
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university hospitals (8) or from only small numbers of hospitals 
(9), which may not be representative of the use of these drugs in 
other hospitals. 
In a multi-regional European project, antimicrobial drug use in 
hospitals in the Netherlands, Belgium and Germany (Nordrhein 
Westfalen) was studied. In addition, an attempt was made to relate 
the usage of antibiotics to the levels of antibiotic resistance in 
these three countries. 
MATERIALS AND METHODS 
Data on the use of antimicrobial agents in hospitals in Belgium, 
the Netherlands and Germany (state of Nordrhein Westfalen) were 
collected by means of a written inquiry distributed to hospital 
pharmacists in these countries in the year 1990. A total of 30 
Belgian hospitals (15 from Dutch sectors of Belgium and 15 from 
French sectors), 20 Dutch hospitals and 21 German hospitals 
participated in the survey. The use of antimicrobial agents was 
expressed as the number of defined daily dosages (DDD) per 100 
bed days for the anatomical therapeutical chemical (ATC)-
subclasses G04A (urinary antiseptics) and J01 (systemic 
antibacterial agents). The cephalosporins were divided into three 
generations. The first generation consisted of cephadroxil, 
cephalexin, cefaclor, cefradine, cephalothin, cefazolin and 
cephaloridine. The second generation consisted of cefamandole, 
cefuroxime and cefoxitin, whereas all others were classified as 
third generation cephalosporins. 
The number of beds, the number of hospitalisation days and the 
number of admissions in 1990 were recorded for each hospital. 
The number of bed days was obtained by subtracting the number 
of admissions from the total number of hospitalisation days. The 
duration of hospitalisation was obtained by dividing the total 
number of hospitalisation days by the number of admissions. 
All drugs available in (at least one of) the three countries were 
specified by trade name, generic name, strength and mode of 
administration (injection or oral). The specified use of each dosage 
form was recorded in the survey. The sources of available 
preparations used were as follows: "Rote Liste 1991" (Germany), 
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Repertoire commente des medicaments 1991 (Belgium) and 
Repertorium 1991 (The Netherlands). The use of norfloxacin was 
scored separately from the other fluoroquinolones because 
norfloxacin is used only for urinary tract infections, whereas the 
other fluoroquinolones are also used for other indications. 
Statistical analysis of the data was performed by Student's t-test 
(10, 11). 
RESULTS 
The number of hospitals, hospital beds and bed days and the 
duration of hospitalisation in the three countries are shown in 
Table 1. 
TABLE I 
CHARACTERISTICS OF THE HOSPITALS PARTICIPATING IN THE SURVEY 
Characteristic 
Mean no of beds 
(range) 
Mean no of bed 
days in thousands 
(range) 
Mean duration of 
hospitalisation 
in days (range) 
No of university 
hospitals/total 
Belgium 
Dutch sector 
510 
(125-1675) 
140 
(37.0-400) 
11 13 
(7 86-16 62) 
3/15 
French sector 
313 
(84-906) 
88 9 
(24 0-259 2) 
10 34 
(6 30-13 29) 
2/15 
Germany 
720 
(230-1907) 
196 
(67 0-530) 
12 17 
(8 19-15 70) 
2/21 
The Netherlands 
550 
(120-1249) 
141 
(29 7-350) 
10 63 
(7 32-12.76) 
2/20 
The number of hospital beds was significantly lower in the French 
sector of Belgium than in Germany (p < 0.001) or in the 
Netherlands (p < 0.02). The number of bed days was also lower in 
the French sector of Belgium in comparison with Germany (p < 
0.001) or the Netherlands (p < 0.05). The duration of 
hospitalisation was longer in Germany than in the Netherlands (p 
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< 0.01) or the French sector of Belgium (p < 0.05). The number of 
university hospitals was similar in the study groups. 
The use of the antimicrobial agents in the three countries, 
expressed as DDD/100 bed days for each АТС subclass, is shown 
in Table 2. The combined data on the use of penicillins, 
cephalosporins, total beta-lactam antibiotics and total 
fluoroquinolones are given in Table 3. Significant differences in 
the use of almost all compounds were observed between both parts 
of Belgium and the use in Germany and the Netherlands. The 
statistical significance of the differences observed is summarized 
in Table 4. Table 5 shows the use of each group of antimicrobial 
agents as a percentage of total antimicrobial drug use in each 
country. 
The total use of antimicrobial drugs was significantly higher in 
hospitals in both parts of Belgium in comparison with that in 
Germany or the Netherlands (p < 0.001). The differences observed 
are mainly due to differences in the use of co-amoxiclav, first and 
second generation cephalosporins, aminoglycosides and total 
fluoroquinolones (i.e. norfloxacin and other fluoroquinolones). In 
contrast, only marginal differences in use were observed between 
the hospitals in the French and Dutch sectors of Belgium. 
Significant differences were found only in the use of second 
generation cephalosporins and macrolides (Tables 2 and 4). 
The use of narrow-spectrum penicillinase-sensitive penicillins such 
as benzylpenicillin was higher in Germany than in either of the 
other two countries. The same was true for the use of 
antipseudomonal penicillins such as azlocillin and piperacillin. In 
contrast, in Germany the use of co-amoxiclav was lower than in 
Belgium and the Netherlands, although the difference between 
Germany and the Netherlands did not reach statistical significance 
(Tables 2 and 4). 
Different patterns in cephalosporin use were observed in the three 
countries. In Belgium, the total use of cephalosporins was 
significantly higher in comparison with Germany and the 
Netherlands (Tables 3 and 4). Differences in the use of second and 
third generation cephalosporins in the three countries were 
observed as well. The use of second generation cephalosporins 
(mostly cefuroxime) was approximately tenfold lower in Germany 
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compared to Belgium. In contrast, in Germany the use of third 
generation cephalosporins was almost twice as high as in Belgium 
and fourfold higher than in the Netherlands. 
Monobactams and carbapenems are used to a very limited extent 
in the three countries, although the range in their use was 
relatively wide. In some Belgian university hospitals a relatively 
high use of aztreonam (1.41 DDD/bed days) and 
imipenem/cilastatin (0.80 DDD/100 bed days) was observed. 
Vancomycin is used more frequently in Belgium than in the two 
other countries, although only the difference between the 
Netherlands and the Dutch sector of Belgium reached statistical 
significance. 
TABLE 2 
ANTIMICROBIAL DRUG USE IN DEFINED DAILY DOSAGES PER 100 BED DAYS ± 
STANDARD DEVIATION (RANGE) 
Group Belgium Germany The Netherlands 
Dutch sector French sector 
Tetracyclines 3 43 ± 2 38 1 94 ± 1 32 4 12 ± 2 53 2 18 ± 1 5 1 
(0 8 9 - 8 56) (0 0 5 - 4 57) (0 9 3 - 9 45) (0 2 1 - 7 06) 
Chloramphenicol/ 0 32 ± 0 90 0 08 ± 0 11 0 02 ± 0 02 0 04 ± 0 06 
thiamphemcol ( 0 - 3 78) ( 0 - 0 39) ( 0 - 0 09) ( 0 - 0 20) 
Ampicillins 5 85 ± 3 43 5 63 ± 3 98 6 54 ± 3 71 8 24 ± 3 89 
( 1 3 5 - 1 1 6 ) (0 8 9 - 1 6 4) ( 1 2 1 - 1 4 8) (2 58 -19 6) 
Ureido-penicillins 0 5 5 ± 0 48 0 7 6 ± 0 56 1 39 + 0 89 0 13 ± 0 17 
(0 08 - 2 08) (0 23 - 1 94) (0 - 3 60) ( 0 - 0 72) 
Penicillins 1 76 ± 1 27 1 33 ± 1 65 4 88 ± 3 29 1 97 ± 1 48 
(penicillinase sens) (0 05 - 4 06) (0 - 6 02) (1 37 - 12 8) (0 37 - 4 83) 
Penicillins 2 60 ± 1 71 1 79 ± 1 13 1 08 ± 081 2 64 ± 1 52 
(penicillinase res) (0 6 9 - 6 25) (0 1 2 - 3 79) (0 0 8 - 2 86) (0 6 9 - 6 08) 
Clavulanate 11 9 ± 5 3 8 11 6 ± 5 48 1 53 ± 1 91 3 50 ± 5 56 
penicillin-comb (0 - 22 9) (0 23 - 19 4) ( 0 - 6 53) (0 05 - 22 1) 
1st generation 5 76 ± 5 30 7 16 ± 2 54 2 76 ± 2 75 1 17 ± 1 76 
cephalosporins ( 1 0 2 - 2 1 1 ) (3 0 5 - 1 1 5 ) ( 0 - 1 0 8) ( 0 - 5 97) 
2nd generation 7 08 ± 4 70 5 42 ± 3 19 0 66 ± 0 80 3 38 ± 2 48 
cephalosporins ( 1 2 6 - 1 8 1 ) ( 2 0 6 - 1 2 4 ) ( 0 - 2 2 0 ) (009 -959 ) 
3rd generation 3 00 ± 3 22 2 46 ± 1 6 7 4 96 ± 3 44 I 12 ± 0 82 
cephalosporins ( 0 3 3 - 1 1 9 ) (0 1 6 - 5 34) (0 7 4 - 1 0 3) (0 0 7 - 2 41) 
Monobactams 0 18 ± 0 30 0 27 ± 0 20 0 00 ± 0 01 0 04 ± 0 12 
(0 - 1 41) ( 0 - 0 69) (0 - 0 02) ( 0 - 0 42) 
Carbapenems 0 18 ± 0 2 2 020 + 021 0 13 ± 0 10 0 10 ± 0 12 
( 0 - 0 74) ( 0 - 0 80) ( 0 - 0 31) ( 0 - 0 36) 
Trimethoprim 0 04 ± 0 07 0 01 ± 0 02 0 0 17 ± 0 45 
( 0 - 0 25) ( 0 - 0 10) (0) (0 -164) 
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TABLE 2 (continued) 
ANTIMICROBIAL DRUG USE IN DEFINED DAILY DOSAGES PER 100 BED DAYS ± 
STANDARD DEVIATION (RANGE) 
Group Belgium 
Dutch sector French sector 
Germany The Netherlands 
Co-tnmoxazole 
Macrolides 
Lincomycins 
Aminoglycosides 
Fluoroquinolones 
Norfloxacin 
Vancomycin 
Metronidazole 
Anticystitis drugs 
Total 
2 67 ± 1 57 
(131 - 5 53) 
1 04 ± 0 55 
(0 39 - 2 47 
0 2 2 1 0 1 7 
(0 - 0 64) 
2 42 ± 101 
(1 1 5 - 4 93) 
2 23 ± 1 50 
(0 07 ± 4 73) 
1 84 ± 1 06 
(0 1 6 - 4 04) 
0 33 ± 0 43 
(0 - 1 49) 
1 45 ± 0 97 
(0 - 3 61) 
0 65 ± 0 78 
(0 - 2 36) 
55.6 ± 9.99 
(38.6 - 70.0) 
2 14 ± 141 
(0 25 - 5 26) 
2 16 ± 1 59 
( 0 2 6 - 5 70) 
0 33 + 041 
(0 - 1 67) 
251 ± 1 14 
(0 83 - 4 71) 
1 65 ± 1 31 
(0 - 4 59) 
2 08 ± 150 
(0 - 5 08) 
0 25 ± 0 43 
(0 03 - 1 62) 
1 17 ± 064 
(0 2 6 - 2 3 1 ) 
0 86 ± 0 81 
(0 - 1 94) 
52.0 ± 12.7 
(32.6 - 81.4) 
3 97 + 2 08 
(0 - 8 49) 
0 85 ± 0 77 
(0 10 - 2 73) 
0 37 ± 0 33 
(0 04 - 1 04) 
1 06 ± 0 74 
(0 1 0 - 3 31) 
2 14 ± 155 
(0 70 - 5 96) 
0 22 ± 0 44 
(0 - 1 68) 
0 10 ± 0 17 
(0 - 0 65) 
071 ± 0 4 1 
(0 - 1 98) 
0 29 ± 0 90 
( 0 - 4 15) 
37.9 ± 7.09 
(27.5 - 55.4) 
3 13 ± 091 
(151 - 4 72) 
1 12 ± 0 48 
(0 31 - 2 36 
0 19 ± 0 26 
(0 - 1 14) 
1 34 ± 0 93 
(0 03 - 3 94) 
0 75 ± 0 63 
(0 0 3 - 2 11) 
0 69 + 0 61 
(0 - 2 39) 
0 07 ± 0 13 
(0 - 0 52) 
1 00 ± 0 90 
(0 - 1 75) 
0 96 ± 1 00 
(0 - 3 22) 
34.1 ± 6.98 
(23.0 - 46.6) 
TABLE 3 
ANTIMICROBIAL DRUG-GROUP USE IN DEFINED DAILY DOSAGES PER 100 BED 
DAYS (STANDARD DEVIATION) 
Drug group Belgium 
Dutch sector French sector 
Germany The Netherlands 
Penicillins 
Cephalosporins 
Total beta-lactam 
agents 
Fluoroquinolones 
22 7 (7 25) 
15 7(6 71) 
38 9 (7 65) 
4 08 (2 00) 
21 1 (7 99) 
15 1 (5 11) 
36 7(113) 
3 73 (1 67) 
15 4(5 35) 
8 39 (3 35) 
24 1 (5 48) 
2 36(150) 
16 7(5 99) 
5 68 (2 95) 
22 5 (6 41) 
1 44 (0 88) 
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TABLE 4 
SIGNIFICANT DIFFERENCES IN ANTIMICROBIAL DRUG USE BETWEEN THE 
COUNTRIES PARTICIPATING IN THE SURVEY 
Drug group B-F 
D 
B-F 
NL 
B-NL 
D 
B-NL 
NL 
D 
NL 
Tetracyclines < 001 
Ureido-penicillins < 0 02 
Penicillins 
(penicillinase sensitive) < 0 001 
Penicillins 
(Penicillinase resistant) < 0 005 
Clavulanate/sulbactam 
penicillin combinations < 0 001 
1st generation 
cephalosporins < 0 001 
2nd generation 
cephalosporins < 0.001 
3rd generation 
cephalosporins < 0 001 
Aztreonam < 0.001 
Co-trimoxazole < 0 01 
Macrolides < 0 01 
Lincomycins 
Aminoglycosides < 0 001 
Fluoroquinolones 
Norfloxacin < 0 001 
Vancomycin 
Metronidazole < 0.05 
Anticystitis drugs < 0 05 
Penicillins < 0 05 
Cephalosporins <0001 
Total beta-lactam agents < 0 001 
Total fluoroquionolones < 0 02 
Total < 0 001 
< 0 001 
<0.05 
< 0 001 
< 0 001 
< 0 05 
< 001 
< 0 05 
< 0 02 
< 001 
< 0 02 
< 0 001 
< 0 001 
< 0 001 
< 0 001 
< 0 001 
< 0 001 
< 0 001 
< 001 
< 0 001 
<0.01 
< 0 05 
< 0 001 
< 0 001 
< 0 01 
< 001 
< 0 001 
< 0 001 
< 001 
< 0 001 
< 001 
<0 001 
< 001 
< 0 05 
<0 001 
< 0 01 
< 0 001 
< 0 05 
< 0 02 
< 0 001 
< 0 001 
< 0 001 
<0 001 
< 001 
< 0 001 
< 0 001 
< 0 001 
< 0 05 
< 0 001 
< 0 001 
< 0 001 
<0 05 
<0 001 
< 001 
< 0 05 
<001 
< 0 05 
B-F 
B-NL 
D 
NL 
French speaking part of Belgium 
Dutch speaking part of Belgium 
Germany 
The Netherlands 
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TABLE 5 
USE OF VARIOUS GROUPS OF ANTIMICROBIAL AGENTS AS A PERCENTAGE OF 
TOTAL ANTIMICROBIAL DRUG USE IN THE COUNTRIES PARTICIPATING IN THE 
SURVEY 
Drug group Belgium The Netherlands Germany 
French sector Dutch sector 
Penicillins 
Cephalosporins 
Beta-lactam agents 
Tetracyclines 
Aminoglycosides 
Qumolones 
Macrohdes 
Co-trimoxazole 
Metronidazole 
Others 
Total 
40 6 
28 9 
70 5 
37 
4 8 
72 
4 2 
41 
2 2 
33 
100 
40 8 
28 2 
70 0 
62 
4 4 
73 
18 
4 8 
2 6 
2 9 
100 
48 9 
16 7 
66 1 
64 
3 9 
4 2 
33 
92 
2 9 
4 0 
100 
40 8 
22 1 
63 7 
109 
2 8 
62 
2 2 
105 
19 
18 
100 
DISCUSSION 
In the present study, the consumption of antimicrobial drugs was 
expressed as the number of DDD per 100 bed days, which is a 
very useful method for comparative studies of drug utilisation in 
different hospitals (12). The classification of drugs is commonly 
performed according to the АТС system. This is an internationally 
used classification system, monitored by the WHO Collaboratoring 
Centre for Drug Statistics Methodology in Oslo, Norway (13). 
Data on drug use expressed as DDD per 100 bed days and 
classified according to the АТС code which are obtained in one 
country are therefore directly comparable to the data from other 
countries. 
It was not possible to explain all the differences observed in 
antimicrobial drug use in both parts of Belgium, Germany and the 
Netherlands, because no studies comparing the antimicrobial drug 
policy in hospitals in the three countries have been published thus 
far. 
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In the Netherlands, most hospitals have written antibiotic 
formularies, specific for that hospital or a group of collaborating 
hospitals. 
In Belgium most hospitals use the Belgian edition of J.P. 
Sanford's Guide to Antimicrobial Therapy (14). This guide is of 
American origin and adapted to the Belgian situation in close 
cooperation with representatives and opinionleaders from 
university and other hospitals throughout the country. If this guide 
was followed closely in all Belgian hospitals, a relatively low 
standard deviation should be found in the use of various (groups 
of) antimicrobial drugs in comparison with use in the Netherlands, 
where most hospitals have composed their own antibiotic 
formularies. This was not observed in our study, however (Tables 
2 and 3). 
In Germany, most hospitals have their own antibiotic policies, but 
written antibiotic formularies are hardly available and are usually 
confined to a listing of the antibiotics which are in use in the 
hospital in question, without giving specific guidelines for each 
infection (W. Brandenburg, personal communication). Although 
written antibiotic formularies in the Netherlands are much more 
common than in Germany, it is surprising that the total use of 
antibiotics in Germany and the Netherlands is similar. 
In the Belgium formulary (Sanford), co-amoxiclav is 
recommended as the drug of choice in sinusitis, otitis media, acute 
exacerbations of chronic bronchitis, pelvic inflammatory disease, 
cholangitis and pyelonephritis. The indications for its use in 
respiratory tract infections in the Netherlands are much more 
limited. In 30 antibiotic formularies from Dutch hospitals, co-
amoxiclav was advised in only four formularies for acutely 
exacerbated obstructive lung disease, in three formularies for acute 
sinusitis and in four formularies for otitis media. 
Most formularies contain no clear guidelines for duration of 
treatment with co-amoxiclav. Thus the different indications for this 
drug may contribute to its more frequent use in Belgian hospitals. 
The prevalence of beta-lactamase producing Haemophilus 
influenzae (often involved in respiratory tract infections) is higher 
in Belgium than in the Netherlands or Germany, which justifies its 
use in respiratory tract infections in Belgium. 
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First generation cephalosporins are indicated in Belgium as a first-
line agent in pyelonephritis and sepsis and as a second-line agent 
in otitis media, cholangitis and sinusitis. In the Netherlands, the 
use of these drugs is usually limited to antibiotic prophylaxis in 
surgery. 
The fluoroquinolones are used in Belgium for the treatment of 
prostatitis, gonorrhea, pyelonephritis and hospital-acquired 
pneumonia (14). These drugs were not mentioned in most Dutch 
formularies, mainly because 14 of the 30 formularies were dated 
1988 or earlier, while ciprofloxacin was first introduced on the 
Dutch market in the second half of 1988. Only six of the 30 Dutch 
formularies mention the use of fluoroquinolones for acute 
pyelonephritis, whereas fluoroquinolones are indicated for acute 
prostatitis in 15 out of 30 formularies. 
At least part of the differences observed in the use of co-
amoxiclav, first generation cephalosporins and fluoroquinolones 
may therefore be explained by different indications for these 
drugs. 
Another important factor influencing the use of antibiotics is the 
decision whether an infection should be treated with antibiotics 
and if so, how long treatment should last. Most formularies did 
not mention any data on these important criteria. 
Cultural differences may play a very important role in the use of 
antibiotics. The use of antimicrobial drugs is much higher in the 
U.S.A. than in Germany, because of different approaches to the 
treatment of infections in both countries. In Germany most doctors 
are reluctant to prescribe antibiotics for mild infections, whereas in 
the U.S.A. the "fear of microbes" results in a high rate of 
prescription of antibiotics (15). No data from such "cultural" 
aspects of antibiotic policy are available from the Netherlands and 
Belgium. 
The size of the hospital and the number of beds for intensive care 
treatment may also influence the use of antimicrobial agents. In an 
earlier study a significantly higher use of antimicrobial drugs was 
observed in Dutch university hospitals in comparison with non-
university hospitals, regardless of the number of beds in these 
hospitals (16). In the present study the use of antimicrobial agents 
in three university hospitals was 41.3 - 70.0 DDD per 100 bed 
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days in the Dutch sector of Belgium, 32.6 and 66.7 in two 
university hospitals in the French sector of Belgium, 51.6 and 55.4 
in the two German university hospitals, and 44.3 and 46.6 in the 
university hospitals in the Netherlands. The average use of 
antimicrobial agents in university hospitals was therefore higher 
than that in the other hospitals in Germany and in the Netherlands, 
but not in Belgium. It must be borne in mind that some Belgian 
hospitals are called "university hospitals" although only a few beds 
(sometimes <10%) have the status of "university beds". This may 
explain the relatively wide variation in antimicrobial drug use in 
Belgian university hospitals (M. Caprasse, personal 
communication). As the number of university hospitals was 
comparable in the four study groups, this could not explain the 
differences observed in antimicrobial drug use. Hekster and Barrett 
(9) have compared the use of antimicrobial drugs in nine 
university hospitals and 14 non-university hospitals in eight 
European countries. The use of parenteral cephalosporins was 
higher in the university hospitals (6-8 DDD/100 bed days) than in 
the other hospitals (3.0 DDD/100 bed days). 
The total use of antimicrobial drugs in the Dutch hospitals in our 
survey is comparable to that observed in four Dutch university 
hospitals in 1985 - 1986. Schuitenmaker and Versluis (8) found a 
total use of 36 - 52 DDD/100 bed days in these hospitals. They 
also found relatively low use of 29 DDD/100 bed days in a 
Belgian university hospital. This low use of antimicrobial drugs in 
Belgium was not confirmed by our study. The authors found a 
total use of 43 and 62 DDD/100 bed days in two Swedish 
university hospitals. Few detailed data from other countries exist. 
In a study performed in 1987, Martini and coworkers (7) found a 
high total average antimicrobial drug consumption in three 
Mediterranean countries: 58.6 (range 33.8 - 69.5) in ten Italian 
hospitals, 89.7 (range 38.8 - 149.2) in seven Portuguese hospitals 
and 83.5 (range 57.4 - 109.5) in nine Spanish hospitals (7). The 
antimicrobial drug use in Italy was comparable to that found in the 
present study in Belgium. The total use of cephalosporins in their 
study (10.7 - 13.6 DDD/100 bed days) was comparable to our data 
from Belgium. The use of aminoglycosides (3.5; 6.9 and 9.3 
DDD/100 bed days in Italy, Portugal and Spain respectively) was 
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much higher than that observed in Belgium, Germany and the 
Netherlands in the present study. One has to consider that the data 
from the Mediterranean study were collected three years before 
our study, so it is not possible to make a direct comparison of the 
data from the two studies. 
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ABSTRACT 
Guidelines for therapy in bacterial bronchitis from 41 antibiotic 
formularies in use in 91 Dutch hospitals were analysed. The 
classification of bronchitis and the terminology used were highly 
variable and were not clearly defined in many cases. Most for-
mularies made no statements about the indication for antibiotic 
treatment of bacterial bronchitis. Only a few formularies empha-
sized the importance of adequate assessment and treatment of the 
underlying pulmonary disease, such as a chronic obstructive 
pulmonary disease. In view of the low percentage of antibiotic 
resistance of Streptococcus pneumoniae and Haemophilus influ-
enzae in the Netherlands, amoxycillin, doxycycline and co-
trimoxazole are still agents of first choice in the treatment of 
bacterial bronchitis. Most of the formularies did not comment on 
the duration of treatment. Very few studies have been performed 
that investigate adequate dosage and duration of therapy for bacte-
rial bronchitis. Based on the results of this analysis, 
recommendations are made for a more adequate formulary advice 
in bacterial bronchitis. 
INTRODUCTION 
Most Dutch hospitals have created antibiotic formularies, with 
guidelines for antimicrobial therapy which are specific for one 
hospital or for a group of collaborating hospitals in the same 
region (1). 
Respiratory tract infections are quantitatively the most important 
indications for antimicrobial agents, both in general practice and in 
hospitals. As there are important differences in the antibiotic 
requirements in the treatment of upper and lower respiratory tract 
infections and between bacterial bronchitis and pneumonia, we 
will focus on the therapy recommendations in Dutch antibiotic for-
mularies for bacterial bronchitis. 
METHODS 
By means of a written request to members of the Dutch As-
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sociation of Hospital Pharmacists (NVZA), we have collected 
antibiotic formularies from hospitals from all over the country. 
Only those hospitals were included in the survey, that included 
bronchitis in these formularies. The following aspects of the an-
tibiotic formularies were recorded: 
- the terminology 
- division of bacterial bronchitis into subcategories 
- the choice, dosage and duration of antibiotic therapy 
- general guidelines and advice concerning diagnosis and inter-
vention strategies in lower respiratory tract infections. 
RESULTS 
Materials 
We received a total of 43 antibiotic formularies. One formulary 
was excluded, because it was too old (1983) to be a reliable guide 
for antimicrobial therapy and one formulary did not contain a 
chapter on bacterial bronchitis. Forty-one formularies used in 91 
Dutch hospitals, including 6 university hospitals, were analysed. 
The year of publication of these formularies was as follows: 
1985 
1986 
1987 
1988 
1989 
1990 
1991 
1992 
1993 
1 
1 
3 
1 
3 
7 
9 
10 
6 
Terminology 
As shown in Table 1, the terminology for description of the type 
of bronchial infection was highly variable. A definition of the 
terms used was lacking in all formularies. 
Lower respiratory tract infections were divided into bronchitis and 
pneumonia in 39 out of 41 formularies. In the other 2 formularies 
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no distinction between pneumonia and bronchitis was made and 
only general guidelines for the treatment of lower respiratory tract 
infections were given. Thirty-two formularies made a distinction 
between acute bronchitis and acute exacerbations of chronic 
obstructive pulmonary disease (COPD). 
TABLE 1 
TERMINOLOGY USED FOR DESCRIPTION OF BACTERIAL BRONCHITIS IN DUTCH 
ANTIBIOTIC FORMULARIES 
The numbers correspond with the number of formularies in which the term is used. 
Acute bronchitis 
Exacerbation of chronic bronchitis 
Acute exacerbation of chronic bronchitis 
Exacerbation of COPD 
Bronchitis 
Chronic bronchitis or emphysema 
Bacterial bronchitis 
Acute bacterial bronchitis 
Acute bronchitis (exacerbation) 
Uncomplicated acute bronchitis 
Acute exacerbation of COPD 
Chronic asthmatic bronchitis and bronchiectasis 
Acute tracheobronchitis 
Chronic bronchitis and/or emphysema with purulent 
sputum 
30 
19 
7 
5 
2 
2 
2 
1 
1 
1 
1 
1 
1 
1 
Diagnostic aspects 
Twenty-two formularies gave no guidelines for a distinction 
between bacterial bronchitis and viral bronchitis, although some 
formularies stated that acute bronchitis was usually of viral origin. 
Four formularies strongly recommended the collection of bronchial 
secretion to support the proposed bacterial infection. A Gram-stain 
of the sputum or culture was recommended by 17 formularies. 
Three formularies stressed the importance to distinguish 
colonisation from infection, but did not mention criteria. One 
formulary stated that the mere presence of (especially Gram-
negative) bacteria in the sputum was not an indication for 
antibacterial therapy and advised interpreting the microbiological 
data in a clinical context. One formulary recommended a 
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throrough physical examination to distinguish acute infection from 
an exacerbation of chronic infection. 
Therapy recommendations 
The differentiation between acute bronchitis and acute exacer-
bations of chronic bronchitis had little impact on the therapy 
guidelines in the formularies. The guidelines for both "types" of 
bronchitis were similar in 27 of 32 formularies (84%) in which 
this distinction was made and different in five formularies. Culture 
results (specified per hospital ward) and clinical or outpatient 
samples, were presented by only one formulary. 
Eight formularies specified guidelines for the treatment of 
bronchitis caused by either Streptococcus pneumoniae, Haemophi-
lus influenzae or Moraxella catarrhalis. Two formularies also 
specified Mycoplasma pneumoniae as a possible causative or-
ganism. 
Most formularies presented guidelines for the treatment of 
(presumed bacterial) bronchitis with (as yet) unknown pathogens, 
as shown in Table 2. 
TABLE 2 
ANTIMICROBIAL AGENTS USED IN THE TREATMENT OF BACTERIAL BRONCHITIS 
IN DUTCH ANTIBIOTIC FORMULARIES. 
Tht numbers correspond with the number of formularies in which the antibiotic is used. 
Amoxycillin 
Doxycycline 
Co-trimoxazole 
Co-amoxiclav 
Benzylpenicillin 
Erythromycin 
Cefuroxime 
Trimethoprim 
First 
choice 
29 
9 
7 
3 
1 
2 
Second 
choice 
4 
13 
5 
1 
1 
1 
2 
Third 
choice 
3 
2 
13 
1 
1 
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Some formularies used amoxycillin, doxycycline and/or cotri-
moxazole as equal alternatives for the treatment of bacterial 
bronchitis, but most formularies specified drugs of first, second or 
third choice for the treatment of infections. Motivation for this 
follow-order was lacking in all but one of the formularies. 
Four formularies did not recommend any specific antimicrobial 
drug, but mentioned that therapy must be based on culture results. 
Therapy recommendations for betalactamase-producing H. influen-
zae or M.catarrhalis were given in 14 formularies (Table 3). 
TABLE 3 
RECOMMENDED DRUGS FOR THE TREATMENT OF BRONCHITIS CAUSED BY 
BETALACTAMASE-PRODUCING H.INFLVENZAE OR M.CATARRHALIS. 
The numbers correspond with the number of formularies in which the antibiotic is used. 
Co-amoxiclav 8 
Co-amoxiclav or doxycyline or co-trimoxazole 3 
Doxycycline or erythromycin I 
Doxycycline or co-trimoxazole or 1 
erythromycin 
Cefuroxime or co-trimoxazole 1 
One formulary recommended amoxycillin as the drug of choice in 
acute bronchitis and co-amoxiclav as the drug of choice in exacer-
bations of chronic bronchitis. 
Guidelines for the long-term treatment of chronic bronchitis were 
given in 5 formularies. Co-trimoxazole (dose 480 mg twice daily), 
doxycyline (100 mg once daily) and amoxycillin (375 mg 3 times 
daily) were the drugs of choice for this indication, but most 
formularies did recommend against their long-term use in chronic 
bronchitis. 
Dosage 
The dosages suggested for amoxycillin and doxycycline are pre-
sented in Table 4. The vast majority of all formularies recom-
mended for amoxycillin a dosage of 750 mg 3 times daily for the 
treatment of bacterial bronchitis, whereas a variety of other 
dosages was found in a few formularies. The dose recommenda-
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tions for doxycyline were also similar in most formularies: 200 mg 
on the first day, followed by 100 mg once daily thereafter. The 
dose recommendations for co-trimoxazole were also completely 
uniform: 960 mg twice daily in all formularies that included this 
drug for the treatment of bacterial bronchitis. Although the usual 
dose for co-amoxiclav was 625 mg 3 times daily, one formulary 
recommended a dose of 1250 mg 3 times daily. Erythromycin was 
used in some formularies in case of penicillin allergy. The daily 
dosage was 2 g in all formularies, divided into 2-4 doses. 
Recently introduced antibiotics such as fluoroquinolones, new 
macrolides, azalides or third generation oral cephalosporins were 
not recommended in any formulary. 
TABLE 4 
DOSE RECOMMENDATIONS FOR AMOXYCILLIN AND DOXYCYCLINE IN ANTI-
BIOTIC FORMULARIES FROM DUTCH HOSPITALS. 
The numbers correspond with the number of formularies in which the antibiotic is used. 
Amoxycillin 
750 mg 3 times daily 27 
375-750 mg 4 times daily 2 
375-750 mg 3 times daily 1 
375 mg 3-4 times daily 1 
375 mg 3 times daily 1 
500 mg 4 times daily 1 
1000 mg 4 times daily 1 
750 mg twice daily 1 
750-1000 mg 3 times daily 1 
Doxycycline 
200 mg qd first day, 21 
followed by 100 mg once daily 
200 mg once daily 2 
100 mg twice daily 2 
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Treatment duration 
Data on the optimal duration of treatment were presented in only 
12 formularies. The recommendations were as follows: 
- 5 days 1 formulary 
- 7 days 3 formularies 
-7-10 days 2 formularies 
- 10 days 6 formularies 
One formulary mentioned different guidelines for the duration of 
treatment for acute bronchitis (5-7 days) and obstructive 
pulmonary disease (at least 10 days). Another formulary did not 
give clear guidelines but stressed the importance of the clinical 
course. 
General comments in the formularies 
General remarks concerning diagnosis or the necessity of giving 
antibiotics in the treatment of bacterial bronchitis were absent in 
24 formularies (59%). The comments in the other formularies 
varied from very short to extensive. Ten formularies stated that 
acute bronchitis without underlying pulmonary disease is almost 
always of viral origin and that this infection should only be treated 
with antibiotics after confirmation of a secondary bacterial 
infection. 
The comments concerning "exacerbations of COPD" were quite 
variable. Five formularies stated that not only acute bronchitis, but 
also exacerbations of chronic bronchitis are usually of viral origin. 
One formulary concluded that antibiotics for the treatment of 
bronchitis are often useless and even harmful. Several other 
formularies stressed that antibiotics should be given only "if 
needed", without presenting clear criteria for the decision when to 
treat bronchitis with antibiotics. 
Although two formularies mentioned that acute exacerbations are 
of viral origin in 75% of all cases, antibiotics should be started as 
soon as possible. Unfortunately the reasons for antimicrobial 
therapy were not specified (prevention of secondary bacterial 
infection?). One formulary recommended conservative treatment of 
an exacerbation without antibiotics. Another formulary specified 
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the indications for antimicrobial treatment of bacterial bronchitis: 
the patient must have at least two of the following three 
symptoms: fever, purulent sputum and dyspnoea. 
Four formularies did not support maintenance treatment of chronic 
bronchitis with antibiotics and recommended that only 
exacerbations should be treated with antibiotics. Seven formularies 
presented guidelines for prophylactic use of antibiotics in chronic 
bronchitis, and three of these specified that this was only indicated 
in a very limited number of cases. Five formularies stated that 
repeated or long-term use of antibiotics in chronic bronchitis may 
result in changes of the bacterial flora and bring about the 
selection of resistant strains. 
One formulary stressed attention to predisposing factors, such as 
underlying pulmonary disease or the presence of foreign bodies. 
The use of bronchodilators or inhaled corticosteroids in acute 
exacerbations of COPD was not discussed in the comments of any 
of the antimicrobial formularies. 
DISCUSSION 
Antibiotic policies for the treatment of bronchitis have been 
debated for many years. In determining the place of different 
antibiotics in lower respiratory tract infections, one is confronted 
with several problems: the terminology used, the diagnosis of 
bacterial bronchitis and the contribution of antimicrobial therapy to 
the short-term and the long-term prognosis. This study confirms 
the many inconsistencies concerning terminology, the need for 
antimicrobial treatment, duration of treatment, choice of drug and 
dosage. 
The terminology that is used by the Dutch formularies was not 
consistent and was partly overlapping. A number of the terms 
used, such as chronic bronchitis, does not imply an infectious 
morbidity. The term "acute (tracheo)bronchitis" in microbiological 
literature refers to a diffuse inflammation of the trachea and larger 
bronchi, mostly seen in the winter months and is almost always of 
viral origin (2). Antibiotics are therefore not indicated in this 
disease. It is highly unlikely that this is the infection that is 
referred to in 79% of all Dutch formularies as "acute bronchitis" 
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and this term will probably refer to primary bacterial bronchitis in 
patients without underlying pulmonary disease. These infections 
are not very common however. Bacterial bronchitis is usually seen 
in patients with underlying pulmonary disease, most often COPD, 
characterised by expiratory obstruction with bronchospasm, 
excessive mucous production, bronchial inflammation and/or loss 
of elasticity in the small airways. Antibiotics are commonly used 
in the treatment of acute exacerbations of such chronic obstructive 
pulmonary disease. The term "exacerbation" is often related to 
"bacterial infection", although clear evidence for a bacteriological 
cause of the disease is lacking. In fact, the term "exacerbation" 
refers to a recent deterioration of the pulmonary complaints, 
without referring to the aetiology. 
An objective diagnosis of bacterial bronchitis in patients with 
obstructive pulmonary disease is very difficult (3, 4). Fever or 
specific complaints are often lacking. The production of purulent 
sputum may be an indication of a bacterial infection, but in a 
number of cases no potentially pathogenic bacteria can be recove-
red from macroscopically purulent sputum (5). On the other hand 
the recovery of bacteria from sputum does not necessarily provide 
evidence for a bacterial aetiology, as 60% of all patients with 
COPD are colonised with bacteria. The remarks on the 
interpretation of the culture results of sputum in some formularies 
may therefore be justified. 
There is still debate about the clinical and microbiological 
endpoints as efficacy parameters in the treatment of acute 
exacerbations of chronic bronchitis. A recent report by the FDA 
recommends two types of studies, one in which both clinical and 
microbiological endpoints are used and studies in which clinical 
criteria (return to baseline) are the only criteria (6). 
The treatment of an exacerbation should be focussed primarily on 
reduction of bronchial inflammation and bronchospasm. This 
improves the mucociliary clearance and local defence factors, 
which will be sufficient for a number of patients to cure a 
potential bacterial infection. If signs of a bacterial infection (such 
as the production of purulent sputum) remain manifest after 2-3 
days and no clinical improvement is observed, an antibiotic may 
be added to the therapeutic regimen after some days. Antibiotics 
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should be given earlier in patients with severe respiratory 
insufficiency and signs of lower respiratory tract infection. 
In a surveillance study performed in 1989 by the Dutch Institute 
for Public Health and Environmental Protection, 5% of strains of 
S.pneumoniae were considered less susceptible to penicillin, 
whereas 6% of the tested strains of H. influenzae were resistant to 
amoxycillin through betalactamase production (7). 
The amoxycillin dosages recommended in the Dutch antibiotic 
formularies were variable, although most formularies 
recommended a dose of 750 mg 3 times daily. 
The recommended duration of treatment was more variable, al-
though guidelines for the duration of treatment were only available 
in a small minority of the formularies. There is no consensus in 
the literature on this topic. Some studies recommend a short-term 
use (3-5 days) of antibiotics in exacerbation of chronic bronchitis, 
except in the case of severe bronchial disease (8, 9). More studies 
are needed before clear guidelines for the duration of treatment 
can be given. 
The efficacy of antibiotics in exacerbation of chronic bronchitis is 
not very impressive in comparison with placebo, due to bias in 
patient-selection. Many studies have not clearly specified inclusion 
criteria. Only patients with a recent deterioriation of pulmonary 
complaints, purulent sputum and fever should be included in 
studies (4). It is very difficult to study sufficient numbers of pa-
tients to show differences between the efficacy of different 
dosages or different durations of treatment with the same anti-
biotic, especially if microbiological controls are also required (10). 
It has been claimed that bacterial infections or colonisation of the 
respiratory tract are not causal factors in obstructive pulmonary 
disease nor do they have any effect on the natural course of 
COPD (11). The prophylactic use of antibiotics in patients with 
chronic bronchitis, bronchiectasis or emphysema, should therefore 
be abandoned and recommendations for the use of prophylactic 
antibiotics in antibiotic formularies should be omitted. 
RECOMMENDATIONS 
There appear to be few reasons to divide bacterial bronchitis into 
different subcategories, also because the antibiotic policy for both 
types of bronchitis is similar. We therefore suggest grouping lower 
respiratory tract infections into bacterial bronchitis and pneumonia. 
We strongly recommend a more uniform nomenclature. The large 
variations in the description of bronchial infections between the 
formularies lead to confusion for the user of these formularies and 
we suggest the term bacterial bronchitis. 
The relevance of the underlying bronchopulmonary pathology for 
the diagnosis of bacterial bronchitis, the necessity of treatment 
with antibiotics and the interpretation of the potential effects of 
antibiotics must be considered in the formularies. 
A number of antibiotics, such as amoxycillin, doxycycline and co-
trimoxazole, are used in almost all Dutch antibiotic formularies. It 
is useful to present data on local resistance patterns in the 
formulary to document the antibiotic policy in the hospital in 
question. Regular epidemiologic surveillance of community-
acquired respiratory tract isolates will support optimal empiric 
therapy for patients with bacterial bronchitis. 
The diagnosis of bacterial bronchitis is not easy and the indication 
for starting antimicrobial treatment is not clearly described in any 
of the formularies. 
The inclusion of relevant critical comments concerning the diagno-
sis and the indication for treatment with antibiotics in the 
formularies will probably result in a more rational use of these 
drugs and should stimulate discussion within the hospital. Such 
comments could be: 
- Underlying pulmonary pathology should be considered in 
patients recurrently presenting with signs and symptoms of 
(possible) bacterial bronchitis and therapy should primarily be 
focussed on the treatment of the underlying pathology. 
- Most episodes of acute (tracheo)bronchitis are of viral origin. 
- The role of antibiotics in bacterial bronchitis in patients with 
COPD is unclear. 
- Antibiotics are generally not indicated in patients with mucoid 
sputum. 
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- Repeated courses of antibiotics may lead to flora changes and the 
selection of resistant bacteria. 
- There is no indication for antimicrobial prophylaxis in patients 
with COPD. 
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SUMMARY 
The guidelines for the treatment of pneumonia as described in 
antibiotic formularies from Dutch hospitals are described. A total 
of 42 formularies, used in 92 Dutch hospitals were collected. 
Amoxycillin was the most frequently used agent in the treatment 
of community-acquired pneumonia and a wide variety of drugs 
was used for the treatment of nosocomial pneumonia, of these 
cefuroxime, alone or in combination with an amino-glycoside, was 
used most often. Benzylpenicillin was the most frequently used 
drug in community-acquired aspiration pneumonia; this drug, in 
combination with an aminoglycoside, was also the drug of choice 
in hospital-acquired aspiration pneumonia. A number of pneu-
monias with identified or presumed causative micro-organisms was 
also surveyed (the most usual drug of choice), such as 
pneumococci (benzylpenicillin), staphylococci (flucloxacillin), 
H.influenzae (amoxycillin), Enterobacteriaceae (cefuroxime), 
Pneumocystis carinii (co-trimoxazole), Mycoplasma pneumoniae 
(doxycycline and erythromycin) and Legionella pneumophila (e-
rythromycin). Relatively wide variations in dosage-guidelines were 
observed for benzylpenicillin and amoxycillin. Only a limited 
number of formularies gave guidelines for the duration of 
treatment. 
INTRODUCTION 
Antibiotic policy is of great importance to reduce the development 
of (multiple)-resistant bacteria in hospitals and to achieve 
acceptable costs with adequate cover. Therefore, most Dutch 
hospitals (over 70%) have created antibiotic formularies with 
guidelines for the treatment of infections, specific for that hospital 
or for a group of collaborating hospitals. 
Lower respiratory tract infections, such as bacterial bronchitis and 
pneumonia are very common in hospitals and are included in most 
antibiotic formularies. The recommendations for the treatment of 
pneumonia are reviewed in this article. 
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MATERIALS AND METHODS 
By means of a written request to the members of the Dutch 
Association of Hospital Pharmacists (NVZA) we collected the 
antibiotic formularies from Dutch hospitals. The guidelines in 
these formularies were intended primarily for the treatment of 
hospitalised patients. 
The following aspects of the antibiotic formularies were recorded: 
- the classification of pneumonias (aetiology, causative micro-
organisms). 
- general recommendations concerning diagnosis and interventions 
in lower respiratory tract infections. 
- guidelines concerning choice of antimicrobial drugs, dosage and 
duration of therapy for each individual infection. 
RESULTS 
A total of 43 antibiotic formularies was collected. One formulary 
was excluded, because it was too old (from 1983) to be a realistic 
guide for antimicrobial therapy. 
Forty-two formularies from 92 Dutch hospitals (69% of all Dutch 
hospitals) were included in the study. The year of publication of 
these guidelines was as follows: 
1985 
1986 
1987 
1988 
1989 
1990 
1991 
1992 
1993 
1 
1 
3 
1 
3 
7 
9 
10 
7 
Data on the classification of specific lower respiratory tract 
infections in the Dutch antibiotic formularies are presented in 
Table 1. 
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TABLE 1 
FORMULARIES THAT GIVE GUIDELINES FOR THE TREATMENT OF CERTAIN 
LOWER RESPIRATORY TRACT INFECTIONS 
Infection Percentage of 
formularies 
Community-acquired pneumonia 93 
(unknown pathogen) 
Hospital-acquired pneumonia 76 
(unknown pathogen) 
Aspiration pneumonia (community acquired) КЗ 
(unknown pathogen) 
Aspiration pneumonia (hospital-acquired) 76 
(unknown pathogen) 
Pneumonia with identified pathogen: 
- Streptococcus pneumoniae 90 
- staphylococci 87 
- Haemophilus influenzae 40 
- Moraxella calarrhalis 26 
- Enlerobacteriaceae 76 
- Pseudomonas aeruginosa 50 
- Anaerobes 10 
- Pneumocystis 67 
- Mycoplasma pneumoniae 93 
- Chlamydia spp 29 
- Legionella pneumophila 88 
- Psittacosis 50 
- Ornithosis 36 
- Coxiella burnetii 12 
- Mycobacterium tuberculosis 60 
- Aspergillus spp 36 
- Candida albicans 29 
Cystic fibrosis 19 
Pulmonary abcess 57 
Empyema 62 
Community-acquired pneumonia 
Community-acquired pneumonia with unknown pathogen was 
included in almost all antibiotic formularies. No data on the 
desired microbiological sampling (timing and number of sputum 
cultures) were presented in the formularies. Nineteen of the 
formularies (45%) stated that therapy should be based on the 
results of the Gram-stain of sputum, whereas one formulary stated 
that the diagnostic value of Gram-stain was very limited. Only 
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seven formularies commented on the aetiology of community-
acquired pneumonia. Streptococcus pneumoniae and Haemophilus 
influenzae were mentioned as possible causative micro-organisms 
in 7 formularies each, Mycoplasma pneumoniae was mentioned in 
three. Four formularies stated that also Klebsiella pneumoniae play 
a role in community-acquired pneumonia in alcoholics and 8 
formularies specified that post-influenza pneumonia is usually 
caused by Staphylococcus aureus. Only one formulary presented 
detailed data on the susceptibility patterns in the hospital in questi-
on. 
The drugs of choice for the treatment of community-acquired 
pneumonia are listed in Table 2. 
TABLE 2 
ANTIMICROBIAL AGENTS RECOMMENDED AS DRUGS OF CHOICE IN THE 
TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA WITH UNIDENTIFIED 
PATHOGEN IN 39 ANTIBIOTIC FORMULARIES FROM DUTCH HOSPITALS 
Drug Percentage of formularies * 
Amoxycillin 
Ampicillin 
Benzylpenicillin 
Co-amoxiclav 
Amoxycillin-gentamicin 
Benzylpenicillin-flucloxacillin 
Co-amox iclav-ery thromycin 
Co-amoxiclav-tobramycin 
Cefuroxime 
Cefotaxime 
Erythromycin 
Co-trimoxazole 
41 
5 
15 
8 
3 
3 
3 
3 
13 
3 
8 
8 
* the sum of the percentages is higher than 100, because some formularies recommended more than 
1 drug as equal choices for this infection. 
Amoxycillin is by far the most commonly used antibiotic, 
followed by benzylpenicillin and cefuroxime. Most formularies 
recommended an intravenous start of the treatment, with a switch 
to oral administration as soon as the condition of the patient had 
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improved. The dose recommendations for all antibiotics were quite 
variable. The amoxycillin dose varied from 375 mg orally 3 times 
daily to 1-2 g iv 4 times daily. Thirty percent of all formularies 
recommended an amoxycillin dose of 1 g 4 times daily. The dose 
guidelines for benzylpenicillin varied from 0.25 million IU 4 times 
daily to 2 million IU every four hours. The most usual dose 
recommendations were 0.5 or 1 million IU 4 times daily, which 
were used in 48% of all formularies. 
Ten formularies presented data on the duration of therapy. This 
ranged from 5-10 days in 8 formularies, whereas 2 others stated 
that therapy should be continued until 3 or 5 days after the patient 
became afebrile. 
Hospital-acquired pneumonia 
Hospital-acquired pneumonia with unidentified pathogen was 
included in 76% of the formularies. Only seven formularies 
commented on the microbiological aetiology of this form of pneu-
monia. All these formularies stated that Gram-negative bacilli were 
the most important causative micro-organisms in hospital-acquired 
pneumonia. Three of these formularies specified that the recovery 
of Gram-negative bacilli from sputum does not necessarily prove 
an infection. 
A wide variety of treatment recommendations was given by the 
formularies and are summarized in Table 3. Although the wide 
variation is obvious from the Table, all treatment regimens provide 
at least some coverage against Gram-negative bacilli. All drugs 
were given by the intravenous route. 
For those formularies that used intravenous cefuroxime as drug of 
choice, 38% recommended a dose of 750-1500 mg 3 times daily, 
38% used a dose of 1500 mg 3 times daily, whereas 12% each 
used a dose of 750 mg 3 times daily, or a 1500 mg starting dose, 
followed by 750 mg 3 times daily. Almost all formularies 
recommended this treatment-regimen only as long as the culture 
results were unknown and to change to an appropriate regimen on 
the basis of these results. Only two formularies gave guidelines for 
the duration of treatment, this was 7 days in one formulary and 10 
days in another. 
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TABLE 3 
ANTIMICROBIAL AGENTS USED AS DRUGS OF CHOICE IN THE TREATMENT OF 
HOSPITAL-ACQUIRED PNEUMONIA WITH UNIDENTIFIED PATHOGEN IN 32 
ANTIBIOTIC FORMULARIES FROM DUTCH HOSPITALS 
Drug Percentage of formularies 
Co-amoxiclav 
Amoxycillin/gentamicin 
Benzylpenicillin/gentamicin 
Co-amoxiclav/gentamicin 
Co-amoxiclav/tobramycin 
Cefuroxime 
Cefotaxime 
Ceflizoximc 
Cefazolin/tobramycin 
Cefuroxime/gentamicin 
Cefuroxime/netilmicin 
Cefuroxime/pefloxacin 
Cefamandole/gentamicin 
Cefotaxime/erythromycin 
Ceftriaxone/netilmicin 
Co-trimoxazole 
6 
9 
3 
6 
6 
22 
3 
3 
3 
19 
3 
3 
3 
3 
3 
6 
Aspiration pneumonia 
Nine formularies made statements on the microbiological aetiology 
of aspiration pneumonia. Their conclusions were quite similar: 
Community-acquired aspiration pneumonia is caused primarily by 
anaerobic bacteria, susceptible to benzylpenicillin. In case of near-
drowning, especially in polluted water, coverage against 
Pseudomonas spp. was considered important. Hospital-acquired 
aspiration pneumonia was caused both by anaerobes and by Gram-
negative bacilli. Three of the formularies specified that in case of 
aspiration antibiotics should only be given in case of a 
documented pneumonia. 
The treatment recommendations for community-acquired aspiration 
pneumonia and hospital-acquired pneumonia are summarized in 
Tables 4 and 5. The initial treatment was given by the intravenous 
route in all cases. Benzylpenicillin was the most widely used agent 
in cases of community-acquired aspiration pneumonia. Penicillin-
based regimens were used in 87% of the Dutch antibiotic 
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TABLE 4 
ANTIMICROBIAL AGENTS RECOMMENDED AS DRUGS OF CHOICE IN THE 
TREATMENT OF COMMUNITY-ACQUIRED ASPIRATION PNEUMONIA WITH 
UNIDENTIFIED PATHOGEN IN 35 ANTIBIOTIC FORMULARIES FROM DUTCH 
HOSPITALS 
Drug Percentage of formularies 
Benzylpenicillin 
Amoxycillin 
Ampicillin 
Co-amoxiclav 
Amoxycillin/gentamicin 
Benzylpenicillin/Clindamycin 
Benzylpenicillin/netilmicin 
Piperacillin 
Cefiiroxime 
Cefiiroxime/metrontdazole 
Clindamycin 
46 
9 
3 
17 
3 
3 
3 
3 
3 
3 
9 
formularies for this infection. All regimens provided coverage 
against anaerobes, with the possible exception of one formulary 
that recommended cefuroxime for this indication. Eight 
formularies presented guidelines for the duration of treatment for 
community-acquired aspiration pneumonia, ranging between seven 
and at least ten days. 
A wider variety of treatment guidelines is observed in hospital-
acquired aspiration pneumonia. All drugs were given intra-
venously. Benzylpenicillin plus an aminoglycoside or co-amoxi-
clav were the most often applied therapies. Penicillin-based 
regimens were used in 65% of all formularies, cephalosporin-
based regimens in 21%, and 73% of all regimens included an 
aminoglycoside. Four formularies commented on the duration of 
treatment and this ranged between at least seven days and at least 
ten days. 
TABLE 5 
ANTIMICROBIAL AGENTS RECOMMENDED AS DRUGS OF CHOICE IN THE 
TREATMENT OF HOSPITAL-ACQUIRED ASPIRATION PNEUMONIA WITH 
UNIDENTIFIED PATHOGEN IN 32 ANTIBIOTIC FORMULARIES FROM DUTCH 
HOSPITALS 
Drug Percentage of formularies 
Co-amoxiclav 
Piperacillin 
Benzylpenicillin/gentamicin 
Bcnzylpenicillin/tobramycin 
Benzylpenicillin/netilmicin 
Amoxycillin/gentamicin 
Co-amoxiclav/gentamicin 
Co-amoxiclav/tobramycin 
Cefazolin/metronidazole 
Cefuroxime/metronidazole 
Cefuroxime/gentamicin 
Ceturoxime/netilmicin 
Cefuroxime/metronidazole/pefloxacin 
Cefamandole/gentamicin 
Cefotaxime/clindamycin 
CI indamycin/gentamicin 
Clindamycin/tobramycin 
Clindamycin/netilmicin 
culture results , 
13 
3 
22 
6 
3 
3 
9 
6 
3 
3 
3 
3 
3 
3 
3 
3 
6 
3 
3 
Pneumococcal pneumonia 
There was a consensus on the treatment of pneumococcal 
pneumonia. Benzylpenicillin was the drug of choice in all but one 
formulary, which recommended amoxycillin. Erythromycin was 
the most usual alternative drug in case of penicillin-allergy. The 
guidelines for the dosage of benzylpenicillin ranged between 1 and 
12 million units per day. The majority of the formularies 
recommended a dosage of 2-4 million units benzylpenicillin per 
day. Eight formularies made statements on the duration of treat-
ment. This ranged between five and ten days in six formularies 
and two formularies recommended continuation of therapy until 5 
days after the patient became afebrile. 
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Staphylococcal pneumonia 
Flucloxacillin was by far the most often recommended drug for 
the treatment of staphylococcal pneumonia. It was used alone in 
33 formularies and in combination with gentamicin in three others. 
One formulary each recommended cloxacillin or cefuroxime. Ten 
formularies preferred benzylpenicillin to flucloxacillin in the case 
of a non-betalactamase producing Staphylococcus aureus. 
Vancomycin was not used for this indication. The dose recommen-
dations for flucloxacillin ranged between 1 g 4 times daily and 2 g 
every four hours. Dosages of 1 g or 1-2 g every four hours were 
prescribed most often. Six formularies gave guidelines for the 
duration of treatment. This ranged between 7 and 21 days, with a 
mean of 14 days. 
Pneumonia caused by Haemophilus influenzae 
Amoxycillin was the drug of choice in this infection. It was used 
as drug of first choice in 15 out of 17 formularies, in doses 
ranging from 375 mg 3 times daily orally to 1 g 4 times daily 
intravenously, depending on the severity of the infection. Doxy-
cycline was used by 5 formularies (several formularies presented 
more than one antimicrobial agent as equal alternatives) in a dose 
of 100 mg orally per day after a 200 mg loading dose. Co-
trimoxazole and co-amoxiclav were used by 3 formularies each. 
The duration of treatment ranged between 7 and 14 days in 6 
formularies. 
Pneumonia caused by Moraxella catarrhalis 
Pneumonia with Moraxella catarrhalis as causative organism was 
included in a relatively small number of antibiotic formularies. Of 
these, amoxycillin was used in 36%, benzylpenicillin in 9%, 
phenethicillin in 18%, co-amoxiclav in 18% and cefuroxime in 
18%. Most formularies recommended both iv and oral admini-
stration, without giving clear guidelines when oral therapy was 
possible. A guideline for the duration of therapy was given in only 
2 formularies. Both recommended a duration of 7 days. 
Pneumonia caused by Enterobacteriaceae 
Pneumonia caused by Gram-negative bacilli is an important 
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nosocomial infection. As stated above, three formularies specified 
that the recovery of Gram-negative bacilli from sputum is not an 
absolute evidence of a causal relationship between these bacteria 
and the symptoms of a respiratory tract infection. 
The antibiotics used in the treatment of pneumonia caused by 
Gram-negative bacilli are presented in Table 6. 
TABLE 6 
ANTIMICROBIAL AGENTS RECOMMENDED AS DRUGS OF CHOICE IN THE 
TREATMENT OF PNEUMONIA CAUSED BY ENTEROBACTERIACEAE IN 32 ANTI-
BIOTIC FORMULARIES FROM DUTCH HOSPITALS 
Drug Percentage of formularies 
Co-amoxiclav 
Amoxycillin/gentamicin 
Co-amoxiclav/gentamicin 
Co-amoxiclav/lobramycin 
Cefurox ime 
Cefotaxime 
Cefazolin/gentamicin 
Ccfazolin/tobramycin 
Cefuroxime/gentamicin 
Cefuroxime/netilmicin 
Cefamandole/gentamicin 
Cefamandole/netilmicin 
Ceftriaxone/netilmicin 
Co-trimoxazole 
6 
6 
6 
3 
19 
13 
6 
3 
16 
3 
3 
3 
3 
9 
Twenty-one percent of the formularies recommended a penicillin-
containing regimen, whereas 69% recommended a cephalosporin-
based therapy. Aminoglycosides were used in 52% of all formu-
laries. There was no clear relationship between the year of 
publication of the formulary and the preference for penicillins or 
cephalosporins. The dose of cefotaxime advised ranged between 3 
and 6 g per day in 3-6 doses. Guidelines for the duration of 
therapy were given in only 3 formularies, ranging from 10 to 21 
days. 
One formulary presented data on the susceptibility of E.coli, 
Klebsiella and Enterobacter cloacae to first and second generation 
cephalosporins in that hospital. The susceptibility of E.coli was 
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85% to first generation cephalosporins and 100% to cefuroxime. 
The susceptibility of Klebsiella spp. was similar: 94% to the first 
generation and 96% to cefuroxime. Forty percent of all strains of 
Enterobacter cloacae were susceptible to first generation cephalo-
sporins, whereas the susceptibility to cefuroxime was 70%. On the 
basis of these findings this hospital used a combination of cefu-
roxime and gentamicin for this indication. 
Pneumonia caused by Pseudomonas aeruginosa 
The guidelines for the treatment of this form of pneumonia are 
presented in Table 7. 
TABLE 7 
ANTIMICROBIAL AGENTS RECOMMENDED AS DRUGS OF CHOICE IN THE 
TREATMENT OF PNEUMONIA CAUSED BY PSEUDOMONAS AERUGINOSA IN 21 
ANTIBIOTIC FORMULARIES FROM DUTCH HOSPITALS 
Drug Percentage of formularies 
Amoxycillin/tobramycin 5 
Piperacillin 5 
Piperacillin/gentamicin 14 
Piperacillin/tobramycin 38 
Piperacillin/netilmicin 5 
Ticarcillin/gentamicin 10 
Ticarcillin/tobramycin S 
Cefsulodin S 
Ceftazidime/tobramycin 5 
Ceftazidime/netilmicin 5 
Ciprofloxacin/tobramycin 5 
The roles of cephalosporins and fluoroquinolones in this infection 
are still limited. Cephalosporins were used in only 15% of all 
formularies and ciprofloxacin in only one. This drug was 
recommended as drag of second choice in 2 formularies (10%). 
The vast majority (92%) of all formularies used an 
aminoglycoside-containing regimen for this indication. 
Pneumocystis carinii pneumonia 
There was a consensus on the drug of choice for the treatment of 
pneumonia caused by Pneumocystis carinii. All 28 formularies 
that included this infection, recommended co-trimoxazole as the 
drug of choice. Fifteen of these (54%) used a dosage of 1920 mg 
(1600 mg sulfamethoxazole plus 320 mg trimethoprim) 3 times 
daily orally or intravenously. A variety of other dosages was used 
in the other formularies, ranging from 480 mg 5 times daily to 
2280 mg twice daily. Pentamidine was used as an alternative drug 
in 5 formularies. 
Atypical pneumonia 
Atypical pneumonia, caused by Mycoplasma pneumoniae, Chla-
mydia pneumoniae, C.psittaci or Legionella pneumophila, was 
included in most formularies. 
Doxycycline was the drug of choice in 77% of the formularies for 
mycoplasmal pneumonia and erythromycin in 69% (several 
formularies considered both drugs as equal). Roxithromycin was 
preferred to erythromycin in one formulary. One formulary used 
erythromycin when intravenous administration was considered 
necessary and roxithromycin if oral dosage was possible. The daily 
dose for erythromycin was 2 g in 25 formularies and 4 g in two 
formularies. The daily dose for doxycycline was 100 mg (after a 
200 mg loading dose) in 23 formularies and 200 mg in nine 
formularies. Sixteen formularies included data on duration of 
treatment and nine of them recommended a duration of two weeks, 
whereas the others varied from 7 days until at least 21 days. 
Erythromycin was the drug of choice in case of pneumonia caused 
by Legionella pneumophila in all but one formularies. In severe 
cases, rifampicin was added to the regimen. Pefloxacin was the 
drug of choice in one formulary. The dose of erythromycin was 1 
g 4 times daily intravenously in 32 out of 36 formularies that used 
this drug. In the other formularies, a daily dose of 2-4 g was used. 
Seventeen formularies gave guidelines for the duration of treat-
ment. Ten of these recommended a duration of treatment of 21 
days, the guidelines in the other formularies ranged from 7 to 28 
days. 
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Psittacosis and ornithosis were treated with doxycycline in all but 
one cases: one formulary preferred tetracycline. The daily dose of 
doxycycline was 100 mg (after a starting dose of 200 mg) in 83% 
of cases and 200 mg in 17%. Guidelines on duration of therapy 
were given in 11 formularies. These ranged from 7 to 21 days. 
Pneumonia caused by yeasts or fungi 
Invasive aspergillosis was included in a limited number of for­
mularies. In all cases amphotericin В was considered to be the 
drug of choice. In 64% of these the drug was combined with 
flucytosine. Itraconazole was used as alternative drug in 4 formu­
laries. Dose recommendations and guidelines for the duration of 
treatment were given in a limited number of formularies. Most 
formularies recommended consultation with a medical microbio­
logist in case of this infection. Invasive candidiasis was also 
treated with a combination of amphotericin В and flucytosine. One 
formulary preferred ketoconazole and three used this as an 
alternative drug to the amphotericin B-flucytosine combination. 
Guidelines on duration of therapy were lacking. 
Pulmonary abcess 
Most formularies considered drainage of the abcess as the primary 
treatment. Of the 24 formularies that mentioned this disease, eight 
(33%) recommended treatment only on culture results. Of the 
remaining 16 formularies, 5 (31%) used benzylpenicillin for this 
indication. The dosages of benzylpenicillin were higher than those 
used for (proven or suspected) pneumococcal pneumonia and 
ranged between 6 and 24 million units per day. A wide variety of 
other drugs was used in one formulary each. 
DISCUSSION 
Successful treatment of pneumonia depends on a variety of 
patient-related factors, such as the status of host-defence, under­
lying disease and age, on the type and severity of the infection, the 
pathogenicity and susceptibility of the offending pathogen and the 
choice of antimicrobial therapy (1). 
Most Dutch hospitals have created guidelines for the treatment of 
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infections. None of the antibiotic formularies that we studied gave 
clear references on which the recommendations for the treatment 
of pneumonia were based. Only 2 of the formularies explained 
their choice of antimicrobials by means of a discussion section of 
which one also presented susceptibility data, specific for that 
hospital. In the ideal situation the choice of antimicrobial drugs in 
the hospital should be based on well defined susceptibility data in 
the hospital in question. In an earlier survey we have shown that 
these data, specified by source, ward and the incidence of various 
pathogens in a specific infection were readily available from only 
5 out of 78 Dutch hospitals (2). As these data are lacking it is not 
possible to comment on all the choices that are made by the Dutch 
hospitals. 
The most important causative micro-organisms involved in 
community-acquired pneumonia are S.pneumoniae, H. influenzae 
M.pneumoniae and M.catarrhalis. S.pneumoniae is most frequently 
isolated (3, 4). Bacterial pneumonia, especially pneumococcal 
pneumonia usually presents the typical signs and symptoms of 
acute onset, high fever, pleuritic pain, productive cough, marked 
leukocytosis and lobar infiltrations on the chest X-ray. The so-
called "atypical" pneumonia will present less acutely with a 
prodromal phase and with milder symptoms. In addition to 
interstitial infiltrates and nonproductive cough, the fever is limited 
and there is usually only moderate leukocytosis. In many cases the 
signs and symptoms are frequently not as characteristic as 
described previously (5). Mycoplasma pneumonia is seen most 
frequently in children over the age of six and in young adults (6). 
The susceptibility of S.pneumoniae and H.influenzae to 
amoxycillin in the Netherlands is still very good, with >99% of 
S.pneumoniae and >95% of H. influenzae being susceptible. Sixty-
five percent the isolates of M.catarrhalis was resistant to amoxy-
cillin (7). Although amoxycillin is generally considered to be inac-
tive against Chlamydia pneumoniae and M.pneumoniae, recent 
studies suggest that both amoxycillin and co-amoxiclav possess in-
vivo activity against Chlamydia trachomatis (8). 
The choice of amoxycillin for community-acquired pneumonia, 
also considering the very wide clinical experience with the drug, 
appears to be a rational one, although all the antibiotics included 
67 
in Table 3 possess activity against the great majority of causative 
micro-organisms. A disadvantage of erythromycin is the limited 
activity against H. influenzae. Its intravenous form is very costly 
and drug administration is not always problem free. Legionella 
pneumophila is rarely observed in community-acquired 
pneumonia, except in patients who have recently been abroad. As 
the number of double-blind comparative studies between two or 
more antibiotics in community-acquired pneumonia is very small, 
no clear statements can be made concerning the choice, dosage 
and duration of treatment. The wide variation in recommendations 
found in the formularies therefore reflects the lack of well-
designed clinical studies. 
The predominant micro-organisms involved in nosocomial 
pneumonia are Gram-negative bacilli (such as E.coli, ¡(..pneumo-
niae, E. cloacae and P. aeruginosa), followed by S.pneumoniae and 
S.aureus, but a wide variety of other micro-organisms can be seen 
(1). Most Dutch hospitals use second generation cephalosporins 
alone or in combination with an aminoglycoside. In a survey 
performed by the Dutch National Institute of Public Health and 
Environmental Protection (RIVM) in 1988, the percentages of 
resistance of E.coli to first, second and third generation cephalo-
sporins were 8%, 2% and 1%, respectively, whereas the percenta-
ges for Klebsiella spp. were 9%, 8% and 1%, respectively. The 
situation was quite different for Enterobacter spp., where 74%, 
16% and 3% were resistant. The activity of gentamicin against 
these bacteria was excellent, with only 4% of Enterobacter being 
resistant to the drug (9). As recent nation-wide and published local 
data on the susceptibility of Enterobacteriaceae are lacking, it is 
impossible to comment on the recommendations made in the 
formularies. 
Some formularies specify that the recovery of Gram-negative 
bacilli from sputum is not absolute evidence for the presence of an 
infection caused by these bacteria. The oropharynx of patients who 
stay in the hospital for longer than a few days is often colonized 
by Gram-negative bacilli. The presence of Gram-negative bacilli 
must therefore always be considered in a clinical context (10). 
The choice of benzylpenicillin for community-acquired aspiration 
pneumonia is similar to that Reese and Douglas from the USA 
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(11). These authors however advise a cephalosporin plus an 
aminoglycoside in case of a hospital-acquired aspiration pneu-
monia. This regimen is used in only one of the Dutch antibiotic 
formularies. The Belgian guidelines (1) recommend imipenem or 
ticarcillin-clavulanic acid for this infection. None of the Dutch 
antibiotic formularies used this approach. 
There is a consensus on the choice of an agent for pneumococcal 
pneumonia, although the guidelines for dosages of benzylpenicillin 
were highly variable. Studies that specifically investigated the dose 
and duration of therapy with benzylpenicillin are lacking. Aoun 
and Klastersky (1) recommend a dose of 8 million units daily, but 
it is not clear what is the basis of their guidelines, whereas Reese 
and Douglas (11) recommend a dose of 1.2 to 2.4 million units 
per day. 
Staphylococcal pneumonia is a very serious disease, with a high 
rate of mortality. Staphylococcal pneumonia is seen frequently as a 
secondary bacterial infection after an initial viral infection of the 
respiratory tract (post-influenza pneumonia). Aggressive antibiotic 
treatment is necessary. It is not clear whether combination 
treatment with an aminoglycoside yields better results than mono-
therapy with a betalactam antibiotic with sufficient activity against 
staphylococci. 
The vast majority of S.aureus isolates are susceptible to flucloxa-
cillin and the choice of this drug in Dutch hospitals is therefore a 
logical one. Some formularies recommend the use of benzylpeni-
cillin in case of a documented infection with a non-betalactamase 
producing strain. The incidence of methicillin-resistant S.aureus 
(MRSA) is very low in the Netherlands, so there is no reason to 
recommend the routine use of vancomycin or teicoplanin for 
staphylococcal pneumonia. Again the wide variety in dose 
recommendations reflects the lack of controlled studies in this rare 
infection. 
Most formularies made no clear distinction between infections for 
which it has been proven that H.influenzae or M.catarrhalis are 
the causative bacteria, with a well defined susceptibility pattern 
and infections probably caused by these bacteria, without any data 
on susceptibility. Pneumonia primarily caused by one of these 
bacteria is rare, however. The choice of amoxycillin is correct if 
69 
susceptibility to this antibiotic has been demonstrated, but it is not 
a correct initial treatment for infections probably caused by 
M.catarrhalis, without knowledge of the susceptibility to the drug, 
as about 65% of all strains were resistant to amoxycillin (7). 
Both second and third generation cephalosporins, with or without 
an aminoglycoside were recommended for the treatment of 
pneumonia caused by Gram-negative bacilli in the Dutch formu-
laries. In Belgium, third generation cephalosporins or aztreonam 
were recommended for this indication (1). A greater use of broad-
spectrum antimicrobial agents, such as the third generation 
cephalosporins, aminoglycosides, fluoroquinolones, imipenem and 
aztreonam in Belgium has been described in comparison with the 
Netherlands (12). As there are large differences in susceptibility to 
antibiotics between different countries, the results of comparative 
studies from the United States, Japan or southern Europe are not 
necessarily also valid for the Dutch situation. The same is true for 
recommendation from other countries. This is also recognised by 
Reese and Douglas from the USA, who recommend a cepha-
losporin plus an aminoglycoside for this indication, but leave the 
choice of the type of cephalosporin to the individual hospital, to 
be based on local susceptibility data (11). 
The low use of ceftazidime for the treatment of pseudomonal 
pneumonia is surprising, considering the relatively large number of 
studies with this agent. Most Dutch formularies prefer a 
combination of piperacillin and an aminoglycoside, as do Reese 
and Douglas (11). 
Fluoroquinolones have not yet become an important group of 
drugs for this indication, despite their good in-vitro activity and 
good penetration of lung tissue. 
The guidelines for the treatment of infections in the formularies 
caused by Pneumocystis carinii are well in accordance with Dutch 
guidelines (13) and international recommendations for the 
treatment of these infections (14) : 90-120 mg/kg oral or intra-
venous co-trimoxazole daily. 
Cost should play an important role in the selection of anti-
microbial agents in hospital. The realistic acquisition costs for a 
number of antimicrobial agents, valid for the average Dutch 
hospital are shown in Table 8. 
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TABLE 8 
COST OF ANTIMICROBIAL AGENTS (mean realistic cost, including VAT, for an average 
Dutch hospital) 
Drug Daily dose (g) Daily cost (NLG) 
Benzylpenicillin 
Amoxycillin 
Ampicillin 
Co-amoxiclav 
Flucloxacillin 
Cefazolin 
Cefuroxime 
Cefuroxime axetil 
Cefotaxime 
Cefpodoxime 
Ceftazidime 
Piperacillin 
Metronidazole 
Gentamicin 
Erythromycin 
Roxithromycin 
Ofloxacin 
4 million IU 
4 (iv) 
2 (oral) 
4(iv) 
3 6 (iv) 
6 (iv) 
4 (oral) 
4(iv) 
4 5 (iv) 
1 0 (oral) 
3(iv) 
0 4 (oral) 
3 (iv) 
12 (iv) 
1 5 (iv) 
1 S (oral) 
0 24 (iv) 
4(iv) 
0 3 (oral) 
0 6 (iv) 
0 6 (oral) 
7 
IS 
3 
12 
30 
38 
8 
18 
72 
10 
66 
10 
115 
110 
12 
2 
10 
120 
6 
120 
8 
These prices are sometimes quite different from the official 
wholesale prices, especially in case of cefazolin and gentamicin. 
The acquisition costs of ampicillin injections are lower than those 
of amoxycillin, although both penicillins are relatively 
inexpensive. The clinical efficacy and tolerance of both drugs after 
parenteral administration is quite similar. The cost of co-amoxiclav 
is about double that of amoxycillin-injections. In the Dutch 
situation, there is no great difference in cost between cefuroxime 
and cefotaxime. The latter agent is in many hospitals even less 
expensive, when dosages of 1.5 g cefuroxime 3 times daily and 
cefotaxime 1 g 3 times daily are compared. 
For all antimicrobial drugs the oral forms are much cheaper than 
the parenteral formulations. This is especially true for the 
fluoroquinolones, the macrolides and also for the cephalosporins. 
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It is not always necessary to start with intravenous antibiotics. 
This depends mainly on the clinical condition of the patient, 
although there are no generally accepted guidelines for which 
patients should receive parenteral antibiotics. Intravenous ad-
ministration is considered necessary in case of dehydration, dis-
turbed bowel motility or circulatory instability. Almost all Dutch 
antibiotic formularies recommended initial treatment with paren-
teral antibiotics and only a limited number of formularies con-
tained statements about a switch to oral antibiotics, when the 
condition of the patient had improved. Although the potential 
savings of an early switch from parenteral to oral cephalosporins 
are enormous (15), virtually no literature is available on this 
subject. 
Studies are also lacking on the dosage and duration of antibiotic 
treatment for the treatment of the different forms of pneumonia. 
Most Dutch formularies contained no statements on the important 
subject of duration of therapy. It is common practice in Dutch 
hospitals to continue antibiotic treatment until 48 h after the 
patient becomes afebrile (personal communications). This is 
however not clearly stated in the formularies. 
CONCLUSIONS 
The classification of pneumonia in the Dutch antibiotic formularies 
is quite diverse. Guidelines for the treatment of pneumonia with 
unknown pathogen are probably of greater importance than those 
with an identified pathogen with a well defined susceptibility 
pattern. The therapy for the latter group of pneumonias will be 
based also on culture results. A more uniform approach to the 
classification of pneumonias is recommendable. 
The wide variety in dose recommendations and the very limited 
information on the duration of antimicrobial therapy reflects the 
absence of controlled clinical studies investigating the importance 
of dosage, dosage frequency, route of administration and duration 
of treatment. This is mainly caused by the fact that studies of this 
kind are usually not sponsored by the pharmaceutical industry. 
As available data on susceptibility patterns of bacteria are lacking, 
it is not possible to comment on the choice of antimicrobial agents 
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in the Dutch formularies. It is generally agreed that these data 
must form the basis of the antimicrobial policy in the hospital. 
These susceptibility data should therefore be readily available in 
the preparation of antimicrobial policy and they may also provide 
insight whether there is any scientific basis for the wide variety of 
treatment recommendations which have been observed in this 
study. 
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CHAPTER VI 
ANTIBIOTIC POLICY IN DUTCH HOSPITALS 
The treatment of sepsis 
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SUMMARY 
The guidelines for the treatment of sepsis as described in antibiotic 
formularies from Dutch hospitals are reviewed. A total of 39 
formularies, used in 88 Dutch hospitals were collected and 
analysed. The guidelines for the treatment of sepsis of unknown 
aetiology or sepsis with a focus in the urinary tract, respiratory 
tract or intra-abdominal sepsis are discussed. Betalactam 
antibiotics (especially amoxycillin and cefuroxime), almost always 
in combination with an aminoglycoside, were the preferred agents 
for the treatment of sepsis with an unidentified pathogen. Ami-
noglycosides were included in most schedules for all presentations 
of sepsis. Substantial differences were observed in the choice and 
dosage of antimicrobial agents for the treatment of sepsis. Due to 
the lack of local data on the susceptibility of blood isolates from 
Dutch hospitals, the guidelines are not properly interpretable, 
although data from a Dutch surveillance study suggested that the 
resistance of Enterobacteriaceae to cefuroxime and co-trimoxazole 
was quite variable. 
INTRODUCTION 
Bacteraemia refers to the detection of bacteria in the blood. It is 
therefore a microbiological laboratory finding which gives little 
information about the clinical situation of the patient. While 
bacteraemia can be transient, self-limiting and of little clinical 
significance, sepsis constitutes a vital medical emergency, that 
needs a systematic diagnostic approach and aggressive therapy 
aimed at terminating bloodstream invasion by the infecting micro-
organism and correction of the pathophysiological sequelae (1). 
Adequate guidelines for the treatment of sepsis are therefore of 
great importance (2). 
Most Dutch hospitals have created antibiotic formularies with 
written guidelines for antibiotic policy, specific for that hospital or 
for a group of collaborating hospitals (3). In this article the 
guidelines for the treatment of sepsis in Dutch antibiotic formula-
ries are analysed and discussed. 
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MATEMALS AND METHODS 
By means of a written request to the members of the Dutch 
Association of Hospital Pharmacists (NVZA) we collected the 
antibiotic formularies from Dutch hospitals. Only those for-
mularies were included in the study in which guidelines for the 
treatment of sepsis were given. This analysis focussed on guide-
lines for the treatment of sepsis with unidentified pathogen. 
The following aspects were recorded: 
- the definition of sepsis. 
- general recommendations concerning diagnosis and interventions 
in sepsis. 
- guidelines concerning choice of antimicrobial drugs, dosage and 
duration of therapy for the treatment of sepsis with unknown 
aetiology or with a known focus. 
Guidelines for the treatment of neutropenic patients were not 
included in the study. 
RESULTS 
A total of 42 antibiotic formularies were collected. Three formu-
laries contained no guidelines for the treatment of sepsis and were 
therefore excluded. 
Thirty-nine formularies used in 88 Dutch hospitals were included 
in the study. The years of publication of these guidelines were as 
follows: 
N 
1983 1 
1985 1 
1986 1 
1987 3 
1988 1 
1989 3 
1990 7 
1991 8 
1992 9 
1993 5 
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The percentage of formularies that contained guidelines for various 
subtypes of sepsis with unknown pathogen is summarized in Table 
1. 
TABLE 1 
GUIDELINES FOR THE TREATMENT OF SEPSIS WITH UNKNOWN PATHOGEN IN 
DUTCH ANTIBIOTIC FORMULARIES 
Type of sepsis No. of formularies (%) 
in which it is included 
unknown 
Urinary tract 
Respiratory tract 
Upper gastrointestinal tract 
Lower gastrointestinal tract 
Biliary tract 
Skin 
Female genital tract 
Intravenous line 
Osteomyelitis 
31 (79%) 
24 (62%) 
21 (54%) 
18 (46%) 
26 (67%) 
21 (54%) 
12 (31%) 
14 (36%) 
7(18%) 
4 (10%) 
The most commonly included presentations of sepsis were sepsis 
of unknown aetiology and source, which was included in 31 
formularies (79%) and sepsis with a known or suspected focus in 
the lower gastrointestinal tract, included in 26 formularies (67%). 
A definition of sepsis was given in one formulary only. One out of 
the three formularies that did not provide guidelines for the treat-
ment of sepsis was a "preliminary" version. Although it did not 
yet give recommendations for the treatment of sepsis, it contained 
detailed data on the culture results in the hospital in question. 
None of the other formularies provided any data on the culture 
results or the susceptibility patterns of the hospital. 
Eleven formularies presented guidelines for the microbiological 
sampling of patients with clinical signs and symptoms of sepsis. A 
minimum of 3 blood cultures was recommended by eight of these 
formularies. 
The guidelines for the treatment of sepsis of unknown aetiology 
are presented in Table 2. 
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TABLE 2 
DRUGS OF CHOICE FOR THE TREATMENT OF SEPSIS OF UNKNOWN AETIOLOGY 
(included in 31 formularies) 
Amoxycillin 
Ampicillin 
Co-amoxiclav 
Piperacillin 
Cefazolin 
Cefalothin 
Cefuroxime 
Ce ramandole 
Cefotaxime 
Ceftriaxone 
Cefuroxime/pefloxacin 
As such 
2 
1 
1 
Combination 
amino 
Combination 
metro 
1 
Combination 
amino and metro 
1 
1 
Amino = aminoglycoside 
Metro = metronidazole 
Some formularies present more than one option 
Aminoglycosides were included in the therapeutic regimen in 28 
of 31 formularies (90%) that provided guidelines for this form of 
sepsis. Of these, gentamicin was the aminoglycoside of choice in 
20 formularies, tobramycin in five and netilmicin in three. 
Amikacin was not used as initial aminoglycoside in any of the 
hospitals. All regimens contained a penicillin or a cephalosporin. 
Cefuroxime and amoxycillin or ampicillin were the most popular 
betalactam antibiotics. The dose of cefuroxime was 1500 mg 3 
times daily in 10 of 12 formularies, whereas the dose of 
amoxycillin and ampicillin ranged between 1 g 4 times daily (the 
most commonly used dose) and 2 g 6 times daily. All antibiotics 
were given by the intravenous route. 
The guidelines for the treatment of urosepsis are summarized in 
Table 3. Three formularies commented on the microbiological 
aetiology of urosepsis. All these stated that the most likely 
pathogens involved in urosepsis were Enterobacteriaceae, entero-
cocci and (less frequently) P. aeruginosa. 
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TABLE 3 
DRUGS OF CHOICE FOR THE TREATMENT OF UROSEPSIS 
(included in 24 formularies) 
As such Combination with 
aminoglycoside 
Amoxycillin 4 
Ampicillin 1 
Co-amoxiclav 1 1 
Cefazolin 1 2 
Cefuroxime 5 6 
Cefotaxime 1 
Cotrimoxazole 1 
Pefloxacin 1 
Aminoglycoside 2 
Some formularies present more than one option 
Aminoglycosides were added to betalactam antibiotic less 
frequently than was the case for sepsis of unknown aetiology. In 
four formularies, a regimen without a betalactam antibiotic was 
recommended. One formulary used a fluoroquinolone (pefloxacin) 
for this indication. Another formulary initially used cefotaxime, 
with a switch to oral ofloxacin after about 3 days. All other 
formularies recommended antibiotics to be given by the intra-
venous route for the total duration of therapy. 
A wide variety of treatment recommendations was observed for 
sepsis originating from the female genital tract. Of 14 for-
mularies, two recommended monotherapy with co-amoxiclav, three 
used a combination of either co-amoxiclav, cefuroxime or piper-
acillin with an aminoglycoside. Three formularies used an ami-
noglycoside with metronidazole and three other formularies 
recommended these drugs in combination with a betalactam 
antibiotic. The remaining formularies preferred a combination of a 
betalactam antibiotic and metronidazole. 
The recommendations for the treatment of sepsis probably 
originating from the respiratory tract are presented in Table 4. 
80 
TABLE 4 
DRUGS OF CHOICE FOR THE TREATMENT OF SEPSIS, WITH A SUSPECTED FOCUS 
IN THE RESPIRATORY TRACT 
(included in 21 formularies) 
As such Combination with 
aminoglycoside 
Amoxycillin 
Ampicillin 
Benzylpenicillin 
Co-amoxiclav 
Amoxycillin/erythromycin 
Flucloxacillin 
Cefiiroxime 
Cefuroxime/erythromycin 
Cefuroxime/pefloxacin 
4 
4 
2 
3 
7 
Some formularies present more than one option 
One formulary specified that coverage against Gram-positive cocci 
and H. influenzae was important, whereas two other formularies 
stated that the most likely pathogen was S.pneumoniae, either 
alone or in combination with other bacteria, such as P. aeruginosa 
or enterococci. A betalactam antibiotic was included in all regi-
mens. Of the cephalosporins, only cefuroxime was used in the 
formularies, whereas a variety of penicillins were recommended. 
Aminoglycosides were added to the regimens in 16 of 18 
formularies. Two formularies stated that the use of amino-
glycosides was necessary in severe cases of sepsis. Erythromycin 
was added to amoxycillin or cefuroxime in two formularies, 
probably for coverage of atypical pathogens, such as Chlamydia 
pneumoniae, Mycoplasma pneumoniae or Legionella pneumo-
phila. 
The guidelines for the treatment of sepsis originating from the 
upper or lower digestive tract are presented in Table 5. The three 
formularies that provided information on the most likely pathogens 
all stated that coverage of Gram-negative bacilli, including 
Salmonella spp., enterococci and anaerobes was important. 
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TABLE S 
DRUGS OF CHOICE FOR THE TREATMENT OF INTRA-ABDOMINAL SEPSIS, WITH A 
SUSPECTED FOCUS IN THE UPPER OR LOWER DIGESTIVE TRACT 
(included in 26 formularies) 
UPPER DIGESTIVE TRACT 
Amoxycillin 
Ampicillin 
Benzylpenicillin 
Co-amoxiclav 
Piperacillin 
Cefuroxime 
Co-trimoxazole 
Clindamycin 
Pefloxacin 
As such 
1 
1 
1 
1 
LOWER DIGESTIVE TRACT 
Amoxycillin 
Co-amoxiclav 
Piperacillin 
Cefuroxime 
Cefotaxime 
Clindamycin 
Pefloxacin 
... 
As such 
2 
Combination 
amino 
3 
1 
1 
1 
1 
Combination 
amino 
1 
1 
1 
1 
Combination 
metro 
1 
Combination 
metro 
3 
1 
Combination 
amino and metro 
2 
1 
2 
1 
Combination 
amino and metro 
3 
1 
3 
1 
9 
A wide variety of treatment recommendations were given in the 
formularies for sepsis originating from the upper digestive tract. 
No more than 3 formularies gave similar recommendations, but 
even for these the dosage guidelines differed. Aminoglycosides 
were used in 13 of 18 formularies (72%) and metronidazole or 
clindamycin were used in 8 of 18 (44%). 
A coverage of anaerobic bacteria was recommended by more 
formularies for the treatment of sepsis originating from the lower 
digestive tract: Metronidazole or clindamycin were used by 81% 
82 
of the formularies and an aminoglycoside was also recommended 
by 81%. A combination of an aminoglycoside (mostly gentamicin) 
and metronidazole (1500 mg daily in 1-3 doses in all cases) 
without a betalactam antibiotic was used in 33% of the formu­
laries. 
Twenty-one formularies presented recommendations for biliary 
sepsis. A similar pattern of causative micro-organisms was de­
scribed for biliary sepsis as was that for sepsis originating from 
the digestive tract in three formularies. Monotherapy with betalac­
tam antibiotics (1 χ piperacillin and 1 χ cefazolin) was given in 
only two formularies. A combination of a betalactam antibiotic 
and an aminoglycoside was used in 12 formularies, of which five 
used a combination of amoxycillin and gentamicin. Co-amoxiclav 
and an aminoglycoside were recommended in three formularies. 
The other formularies recommended a combination of a betalactam 
antibiotic, an aminoglycoside and metronidazole. 
Sepsis originating from the skin was treated with a penicillin in 10 
of 12 formularies, flucloxacillin being used in all but two cases. 
The dose of flucloxacillin ranged between 4 and 12 g per day, a 
dose of 1-2 g 6 times daily was used most frequently. In two 
formularies flucloxacillin was used in combination with amoxy­
cillin or benzylpenicillin and in two other formularies the drug 
was combined with gentamicin. Staphylococci were mentioned as 
most likely pathogens by three formularies. 
Only seven formularies included guidelines for the treatment of 
sepsis originating from an intravenous or arterial line. Flucloxa­
cillin was used most often (four times), followed by cefuroxime 
(lx), vancomycin (lx) and vancomycin + gentamicin (lx). 
The intravenous route was recommended by the formularies for all 
forms of sepsis. The antibiotics were usually given by intermittent 
infusion; two formularies recommended continuous infusion of 
betalactam antibiotics as an alternative to intermittent infusion. 
One of these used similar dosages for continuous and intermittent 
infusion, whereas the other formulary used lower dosages with 
continuous infusion. 
Only nine formularies (23%) gave recommendations for the durati­
on of therapy. This ranged from 10-14 days in eight formularies; 
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continuation of therapy for 3-5 days after clinical improvement 
was advised in one formulary. 
DISCUSSION 
Two groups of formularies can be distinguished. In one group, 
representing approximately 2/3 of all formularies, guidelines for 
the treatment of sepsis are given depending of the focus of an 
infection, as is described in Tables 1-5. Besides this, guidelines are 
also given for the treatment of sepsis with an established causative 
micro-organism. The other formularies, about 1/3 of all, only 
present data on those forms of sepsis in which the causative 
micro-organism has been demonstrated or suspected. Guidelines 
for the treatment of sepsis caused by S. aureus are present in 33 
formularies, enterococci in 25, Enterobacteriaceae in 23 and E.coli 
in 21. 
The antibiotic formularies from Dutch hospitals present guidelines 
for the antimicrobial treatment of the infectious process. No 
recommendations for the supportive therapy are given in any 
formulary. 
Microbiological sampling 
Those formularies that contain statements on the micro-biological 
sampling of patients with sepsis all recommend sampling of at 
least 3 blood cultures. This is well in accordance with the 
recommendations given in the literature. Washington et al. and 
Weinstein et al. clearly showed the value of obtaining more than 
one single blood culture (4, 5). Detection of more than 99% of the 
positive blood cultures required two or three blood cultures mainly 
because the yield largely depends on the volume of blood cultured. 
Causative micro-organisms 
One antibiotic formulary in this study contained data on the preva-
lence of bacteria in positive blood cultures. In that hospital 67% of 
all positive blood cultures yielded Gram-positive bacteria and 29% 
Gram-negative bacteria. The most frequently isolated bacteria were 
S.epidermidis (25%), S.aureus (13%), streptococci (8%) and E.coli 
(16%). P.aeruginosa was found in only 1% of all 330 isolates. In 
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an earlier study from Germany, performed in 1982, about 50% of 
all causative bacteria were Gram-positive and the other half were 
Gram-negative (6). E.coli was by far the most important Gram-
negative isolate, representing over 50% of all Gram-negative 
bacteria. P.aeruginosa was found in about 5% of all Gram-
negative isolates. For the empiric therapy, a distinction must also 
be made between community-acquired sepsis and hospital-acquired 
sepsis. Gram-negative bacteria (including P.aeruginosa) and fungi 
are isolated more often in hospital-acquired sepsis than in 
community-acquired sepsis (7). 
Gram-negative, Gram-positive and fungal infections may all have 
similar clinical presentations. If there is no clear focus of infection 
and the patient has no obvious underlying disease, the most 
probable micro-organisms are Gram-positive cocci and Gram-
negative bacilli (7). An analysis of 500 episodes of bacteraemia in 
adults showed that two-thirds of the isolates were hospital-
acquired (4). In a more recent study from the United Kingdom, 
60% were hospital-acquired (8). Pneumococci were community-
acquired in 81%. Enterobacteriaceae were usually hospital-
acquired, except E.coli, which were community-acquired in more 
than 40%. 
Most Dutch formularies made no distinction between hospital- and 
community acquired sepsis. According to the study of Weinstein et 
al. (4) pneumococci, S.aureus and P.aeruginosa were the species 
most frequently isolated in case the sepsis originated from the 
respiratory tract, followed by streptococci and Enterobacteriaceae, 
which were isolated with equal frequency. The seasonal variations 
of pneumococcal isolation, peaking in late winter was striking (4). 
In the study of Eykin (8) 22% of the community-acquired septi-
caemias were caused by S.pneumoniae, mostly (80%) originated 
from the respiratory tract. 
A variety of bacteria is found in intra-abdominal sepsis. This form 
of sepsis is almost always polymicrobial. The most frequent 
isolates are E.coli (57%), Bacteroides spp. (43%), streptococci 
(25%), enterococci (23%), Clostridium spp. (18%), Klebsiella 
(15%) and Pseudomonas spp. (15%). Surgery plays an important 
role in the treatment (9). 
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Availability of susceptibility data in Dutch hospitals 
In an earlier study (3), we have shown that the situation regarding 
the availability of susceptibility data from Dutch hospitals is far 
from ideal. Therapy for the treatment of sepsis of unknown 
aetiology should be based primarily on the prevalance of bacteria 
causing sepsis and on the relative susceptibility of these bacteria to 
different antimicrobial agents. An epidemiological surveillance of 
the antibiotic resistance in the hospital is very important for 
assessment of a blind antibiotic policy (10) and the Dutch situation 
is therefore open to improvement. 
Recently, the data from a large-scale surveillance study performed 
by De Neeling et al. in the Netherlands became available, with 
susceptibility data from 7 microbiological laboratories 
(representing approximately 25% of the Dutch population) in the 
period 1990-1992 (11). Over 377,000 isolates were included in 
this study. Of these, 51% were clinical isolates, 27% from out-pa-
tient clinics, 8% from nursing homes and 14% from general 
practice. 
Amoxycillin had only modest activity against Enterobacteriaceae, 
but no significant resistance of pneumococci to this agent has been 
shown. Co-amoxiclav showed excellent in-vitro activity against the 
tested respiratory tract pathogens, but its activity against Entero-
bacteriaceae was limited, especially at the "low" breakpoint. 
Important differences were observed in susceptibility of Ente-
robacteriaceae to cephalosporins of the first (cefazolin), second 
(cefuroxime) and third generation (cefotaxime and ceftazidime). 
This was especially the case for the "low" breakpoints of 4 mg/1. 
If the "high" breakpoint of 16 mg/1 is maintained, cefuroxime 
showed good in-vitro activity. All cephalosporins showed excellent 
activity against S. aureus and S.pneumoniae. The resistance to 
cefuroxime was not at all similar in the seven microbiological 
laboratories, using the low breakpoint: E.coli (2 to 31%), 
K.pneumoniae (1 to 24%), Enterobacter cloacae (13 to 81%) and 
P.rettgeri (0 to 52%). The resistance of Enterobacteriaceae to 
cefotaxime and ceftazidime was very low in all laboratories. 
Co-trimoxazole showed good activity against most of the tested 
strains, although a relatively wide variation was seen between the 
laboratories: E.coli (9 to 24%), C.freundii (1 to 21%), 
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S.marcescens (O to 22%), Neisseria meningitidis (2 to 78%), 
M.catarrhalis (3 to 72%), Enterococcus spp. (4 to 28%) and 
S.epidermidis (3 to 48%). 
Gentamicin and tobramycin were active against almost all strains 
of Enterobacteriaceae. 
The data from this surveillance study are difficult to interpret as 
they are a mixture of clinical isolates and community-acquired 
isolates and repeated isolates from the same patient were also 
included. The differences in susceptibility to second-generation 
cephalosporins and co-trimoxazole between the Dutch micro-
biological laboratories may well have a major impact on the 
selection of an antimicrobial agent for the treatment of sepsis with 
an unidentified pathogen. As stated above, these data are not 
readily available from most Dutch hospitals. 
Drug selection 
In the Dutch hospitals, a combination therapy of a betalactam 
antibiotic (mostly amoxycillin, ampicillin, co-amoxiclav or cefu-
roxime) with an aminoglycoside is the preferred regimen for most 
forms of sepsis. The role of third generation cephalosporins is still 
limited. 
Most formularies use gentamicin as the aminoglycoside of choice. 
The activity of gentamicin and tobramycin against 
Enterobacteriaceae is usually similar but the acquisition cost of 
gentamicin is lower. There are no major differences in toxicity 
between the two aminoglycosides (12). In the Dutch hospitals 
these drugs are usually given twice daily, despite the fact that 
clinical studies with twice daily gentamicin, tobramycin or 
netilmicin have not been published. This is to be considered as a 
compromise between microbiologists and hospital pharmacists, 
who favour once daily administration and clinicians who prefer the 
conventional 3 times daily dosing (13). 
In urosepsis, Gram-negative bacilli play an essential role (7). Most 
formularies recommended cefuroxime with or without an 
aminoglycoside. The coverage of amoxycillin or ampicillin against 
Enterobacteriaceae is incomplete, but in the Dutch hospitals 
gentamicin is still very active against most strains of Gram-
negative bacilli. 
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Despite the introduction of new agents such as the fluoro-
quinolones, imipenem and broad-spectrum cephalosporins and 
penicillins, the mortality of Gram-negative sepsis has not 
decreased dramatically in the last 20 years (14). 
Sepsis originating from the respiratory tract is often difficult to 
prove as infiltrations on chest X-ray are not always of infectious 
origin. Reliance on sputum Gram-stain and culture is an im-portant 
guide to antimicrobial therapy. 
Most Dutch formularies provided coverage against the most likely 
pathogens involved in intra-abdominal sepsis. The recommenda-
tions for sepsis originating from the lower or upper digestive tract 
were similar in 14 formularies and different in 6 formularies. In 
three of these the main difference was the addition of metronida-
zole in case of sepsis originating from the lower digestive tract 
and in the three other formularies different antimicrobial drugs 
were used for the two forms of intra-abdominal sepsis. A specific 
anti-anaerobic drug such as metronidazole was added to the 
regime in more formularies in case of intra-abdominal sepsis 
originating from the lower digestive tract. In this case, Bacteroides 
spp. are likely to be involved in the infection (7, 9, 15). The re-
commendations for biliary sepsis were usually different from those 
for abdominal sepsis. Ten formularies provided different guideli-
nes, whereas six formularies showed similar recommendations. 
Sepsis originating from the skin or from an intravenous or intra-
arterial line is most likely to be caused by S. aureus or 
S.epidermidis. Due to the low prevalence of methicillin-resistant 
S.aureus (MRSA) in the Netherlands, an initial choice for 
flucloxacillin or another antistaphylococcal penicillin is correct, 
although also first and second generation cephalosporins and co-
amoxiclav are active against S.aureus (16). Strains of 
S.epidermidis are frequently resistant to many commonly 
prescribed antimicrobial agents, so that the empiric therapy may 
need to be changed when the susceptibility data are available. 
The dose recommendations for flucloxacillin in the Dutch antibio-
tic formularies were quite variable. 
Route of administration 
The intravenous route was chosen by all formularies. This is 
logical, considering the severity of the infection and the poor 
clinical condition of the patient and the very limited experience 
with oral antibiotics in septic patients. The fluoroquinolones, such 
as cipro-floxacin and ofloxacin, might be given orally after 2-3 
days of initial intravenous administration, but only a limited 
number of studies are available on this subject (17). Studies with 
oral cephalosporins, such as cefuroxime axetil, Cefixime and 
Cefpodoxime proxetil are also lacking (18). One formulary 
recommended the use of oral ofloxacin in Gram-negative sepsis, 
after an initial treatment with iv cefotaxime during 3 days. 
Two formularies recommended continuous infusion for betalactam 
antibiotics. Animal studies with continuous infusion (especially in 
neutropenic models) suggest indeed that continuous infusion is 
more effective than intermittent dosing of cephalosporins or 
penicillins, but clinical studies are lacking (19, 20). A dose 
reduction of cephalosporins or penicillins in patients receiving 
continuous infusions seems premature, due to the lack of clinical 
studies. 
Dosage and duration of treatment 
A wide variety in dose recommendations between the formularies 
was observed, especially for amoxycillin. As the prognosis of 
severe sepsis is dependent on many factors (14, 21, 22) of which 
antimicrobial therapy is only one, no clear-cut guidelines for the 
dosage of antibiotics in sepsis can be given, also due to a lack of 
studies investigating the relationship between dose of antimicrobial 
drugs and clinical efficacy. The number of formularies that provi-
ded guidelines for the duration of treatment was limited. The 
recommendations (10-14 days or until 3-5 days after clinical 
improvement) were similar in these formularies. 
Cost 
An important consideration in the choice of antibacterial therapy is 
also the cost. Antibiotics represent about 20% of total drug costs 
in hospitals. The mean prices for various antibiotics are listed in 
Table 6. 
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TABLE б 
ACQUISITION COST OF PARENTERAL ANTIMICROBIAL AGENTS 
Mean realistic cost, including VAT, for an average Dutch hospital 
Drug Daily dose (g) Daily cost (NLG) 
Amoxycillin 
Co-amoxiclav 
Flucloxacillin 
Cefazolin 
Cefuroxime 
Cefotaxime 
Piperacillin 
Metronidazole 
Gentamicin 
Tobramycin 
4 
3 6 
6 
4 
4 5 
3 
12 
15 
0 24 
0 24 
15 
30 
38 
18 
72 
66 
110 
12 
10 
25 
These data are quite different from the official prices, especially in 
case of cefazolin and gentamicin. For university hospitals and 
large non-university hospitals lower prices are achievable. 
Gentamicin, metronidazole, amoxycillin and cefazolin are the 
cheapest antibiotics. In the Netherlands, there is no important 
difference in cost between the second and third generation cepha­
losporins and the cost of cefotaxime is usually even lower than 
that of cefuroxime. The first generation cephalosporin cefazolin is 
considerably cheaper than the newer cephalosporins. First generati­
on cephalosporins play a very modest role in Dutch antibiotic 
policy. Only two formularies recommended cefazolin or cephalo-
thin in combination with an aminoglycoside for the initial 
treatment of sepsis of unknown aetiology. If first generation 
cephalosporins can be used for the treatment of sepsis with 
unknown pathogen on the basis of culture results and antibiotic 
susceptibility data from the hospital, considerable savings on 
antibiotic costs are achievable considering the average use of 3.38 
Defined Daily Doses (DDD) per 100 bed days of second 
generation and 1.12 DDD per 100 bed days of third generation 
cephalosporins in Dutch hospitals (23). 
90 
CONCLUSIONS 
The pathophysiology of sepsis is highly complex; antimicrobial 
treatment plays an important role in therapy, but many other 
factors are involved in the prognosis. 
The guidelines for the treatment of sepsis in Dutch antibiotic 
formularies appear to provide coverage against the most likely 
pathogens involved in these infections, although substantial 
differences were observed in the choice of antimicrobial agents for 
the treatment of sepsis. Most Dutch hospitals have a "conser-
vative" antibiotic policy and newer broad-spectrum antimicrobial 
agents are used to a limited extent. Dose recommendations for 
amoxycillin and fiucloxacillin were quite variable. The for-
mularies cannot be fully interpreted, due to the lack of data on the 
prevalence of causative micro-organisms and the relative suscep-
tibility of bacteria to different classes of antimicrobial agents. Data 
from the Dutch surveillance study showed that the resistance of 
Enterobacteriaceae to co-trimoxazole and cefuroxime was quite 
variable. As a rule, the levels of resistance to cephalosporins and 
aminoglycosides are still low. It is impossible to give clear guide-
lines for the choice of antimicrobial agents, dosage and duration of 
treatment, because of the lack of controlled clinical studies and the 
fact that reliable local susceptibility patterns for the Dutch 
hospitals were not available. We hope that the increasing degree of 
automation of the microbiological laboratories will provide this 
information in the near future. 
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CHAPTER VII 
ANTIBIOTIC PROPHYLAXIS IN SURGERY IN THE 
NETHERLANDS 
Antimicrobial prophylaxis in bowel surgery 
R. Janknegt, W.J.A. Wijnands, E. Stobberingh 
European Journal of Clinical Microbiology and Infectious 
Diseases, accepted for publication 
SUMMARY 
The guidelines for antimicrobial prophylaxis in various types of 
bowel surgery (colorectal, biliary and gastroduodenal) in 33 Dutch 
antibiotic formularies, used by 89 Dutch hospitals, were studied. 
The majority of the formularies recommended drugs with adequate 
antibiotic coverage of the bacteria that are most frequently seen in 
surgical wound infection. Co-amoxiclav and first or second 
generation cephalosporins, with or without metronidazole, were 
most often used. The use of third generation cephalosporins and 
broad spectrum penicillins was low. A relatively high proportion 
(between 52 and 66%) of the formularies recommended multiple-
dose regimens. 
Most Dutch hospitals have written guidelines for the use of 
antimicrobial agents for the prophylaxis and therapy of infections. 
These antibiotic formularies reflect the views on antimicrobial 
therapy of the medical staff and the guidelines are usually well 
maintained. The formularies are specific for the hospital in 
question or for a number of hospitals in the same region (regional 
formularies). 
In this study we have investigated the formulary recommendations 
in Dutch hospitals for the use of antimicrobial prophylaxis in 
bowel surgery to gain insight into the antibiotic policies in Dutch 
hospitals. 
MATERIALS AND METHODS 
By means of a letter to the members of the Dutch Association of 
Hospital Pharmacists, the most recent version of the antibiotic 
formulary, utilized in the hospital, was requested. 
According to the information from the formularies received several 
forms of bowel surgery (colorectal, biliary and gastroduodenal) 
were investigated. 
The following items were recorded for each surgical procedure: 
the number of formularies in which the given surgical procedure 
was included, whether or not antibiotic prophylaxis was used, the 
drug or drug combination of choice, dosage, route of 
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administration, timing of administration and the duration of 
prophylactic use of antimicrobials. All remarks concerning special 
indications or limitations to the use of antibiotics in surgery were 
also recorded for each individual formulary. 
The antibiotic formularies were divided into two groups: Group I: 
formularies dating from before 1991 and Group II with 
formularies dating from 1991 to 1993. 
RESULTS AND DISCUSSION 
A total of 33 formularies as used by 89 Dutch hospitals were 
received. Of these, 13 were dated before 1991 and 20 were from 
the years 1991 to 1993. 
The distribution of the formularies was as follows: 
1993 (n=2), 1992 (n=12), 1991 (n=6), 1990 (n=5), 1989 (n=3), 
1988 (n=l), 1987 (n=2), 1986 (n=l), 1985 (n=l). 
All antibiotics were given by the intravenous route for all types of 
surgery. In case of multiple dosing, the dosage interval was 8 
hours. 
Specification of antibiotics used in colorectal surgery is given in 
Table 1. The first dose was given 30-60 minutes before surgery in 
all formularies. 
Colorectal surgery was included in all formularies. 
In all hospitals prophylactic antibiotics were combined with 
"preparation" of the gastro-intestinal tract with oral antibiotics. 
Specification of these drugs was usually not given. 
In one formulary (dating from 1986) orthograde bowel lavage with 
metronidazole and neomycin was used, without systemic antibiotic 
coverage. 
Of the six formularies in which co-amoxiclav was recommended, 
4 advised a single dose of 2.2 g, 1 formulary used 3 χ 1.2 g and 
one formulary recommended a 2.2 g dose, followed by two doses 
of 1.2 g. A variety of dosage-recommendations was given for the 
combination cefuroxime-metronidazole and even more so for the 
combination of gentamicin and metronidazole. Five different 
dosage regimens were used in the 7 formularies, where this 
combination was used. 
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TABLE 1 
COLORECTAL SURGERY 
Prophylactic antibiotics recommended by 33 antibiotic formularies from Dutch hospitals 
No. of formularies making recommendations 
Group I Group II Total 
Duration recommended 
1 dose 1 
3 doses 11 
Drugs recommended 
Co-amoxiclav 1 
Cefuroxime/metronidazole 3 
Cefamandole/metronidazole 1 
Cefazolin/metronidazole 2 
Ceftriaxone/metronidazole 1 
Cefotetan 
Gentamicin/metronidazole 4 
Co-trimoxazole/metronidazole 
Gentamicin/clindamycin 1 
Group I Formularies dating from before 1991 
Group II Formularies from 1991-1993 
The total gentamicin dose ranged from 2 mg/kg to 4.6 mg/kg and 
the metronidazole dose ranged between 500 mg and 1.5 g. 
The need for prophylaxis in colorectal surgery is clear if one looks 
at the very high rate of wound infections without antibiotic 
prophylaxis (1-4). In the USA oral antibiotics such as neomycin 
and erythromycin base are used, often without systemic coverage 
with antibiotics (2). In the Netherlands this therapy is used in only 
one hospital. 
Co-amoxiclav, cefuroxime + metronidazole and gentamicin + 
metronidazole are the most commonly used drugs. All regimens 
used in the 32 formularies provide good coverage against 
Enterobacteriaceae and anaerobes. 
The choice of antibiotics for prophylaxis in colorectal surgery in 
The Netherlands compares favourably with a survey which was 
performed in 1989 in Germany (5), where correct prophylaxis 
(defined as good coverage against Enterobacteriaceae and 
10 
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anaerobes, using agents that did not have an important place in the 
treatment of infections) was given in only 29% of the hospitals. 
Neither first generation cephalosporins plus metronidazole nor co-
amoxiclav were used in the German hospitals. 
A single dose prophylaxis was as effective as multiple dose 
regimens (2, 3, 6). A single dose is used in 50% of all new Dutch 
formularies, but in only 8% of the older formularies, which shows 
the increasing awareness of the efficacy of single dose regimens. 
A single dose was used in 43% of the German hospitals (5). 
The details on the use of antibiotics, and the duration of 
prophylaxis in biliary surgery are given in Table 2. 
TABLE 2 
BILIARY SURGERY 
Prophylactic antibiotics recommended by 33 antibiotic formularies from Dutch hospitals 
Duration recommended 
1 dose 
1-3 doses 
2 doses 
3 doses 
4 doses 
5 days 
Drugs recommended 
Co-amoxiclav 
Co-amoxiclav/gentamicin 
Amoxycillin/gentamicin 
Piperacillin 
Cefazolin 
Cefiiroxime 
Cefotetan 
Cefamandole/metronidazole 
Cefazolin/metronidazole 
Gentamicin/clindamycin 
No. of formularies 
Group 1 
4 
1 
4 
1 
2 
4 
2 
making recommendations 
Group II 
6 
1 
7 
3 
1 
7 
1 
2 
1 
2 
1 
1 
1 
1 
1 
Total 
10 
1 
1 
11 
3 
1 
8 
1 
2 
1 
4 
5 
1 
1 
3 
1 
Group I Formularies dating from before 1991 
Group II Formularies from 1991-1993 
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Guidelines for antimicrobial prophylaxis were given in all 
formularies in which biliary tract surgery was included. 
Four old and nine new formularies stated that antibiotic 
prophylaxis was only indicated in high-risk groups. This was 
specified as age above 70 years (n=7), acute cholecystitis (n=8), 
biliary tract obstruction (n=6), choledocholithiasis (n=5), 
cholangitis (n=4), reintervention (n=4), choledochotomy (n=3), 
icterus (n=2) and diabetes mellitus (n=2). 
Two formularies specified that the prophylaxis was aimed at 
aerobic bowel flora and enterococci. One of these also aimed the 
prophylaxis at anaerobic bowel flora. 
Co-amoxiclav was used in eight formularies at six different 
dosages, ranging from a 2.2 g single dose to 3 χ 2.2 g. The 
presence of bacteria in bile correlates with the risk of 
postoperative surgical wound infections. Patients with infected bile 
should receive prophylactic antibiotics (7). It is not easy to 
identify patients at risk, but risk factors include acute cholecystitis 
or cholangitis, obstructive jaundice, choledocholithiasis or 
strictures, repeated surgery, diabetes and age greater than 70 years 
(2, 8). These indications are also mentioned by Dutch formularies. 
Similar indications for prophylaxis were included in an earlier 
investigation in Dutch hospitals (7). 
Prophylaxis is aimed at the prevention of surgical wound 
infections and septic complications and it has not been proved that 
penetration into bile is of importance (9). 
In one study (10) mezlocillin, which penetrates very well into bile, 
was more effective than ampicillin/gentamicin in the treatment of 
patients with cholangitis. Coverage of E.coli and Klebsiella spp. is 
most important, Although E.faecalis and B.fragilis are found as 
well in infected bile, first and second generation cephalosporins 
have proved to be effective prophylactic agents in biliary surgery, 
although they have no significant activity against the latter two 
species (2, 11). In the Dutch formularies, co-amoxiclav, 
cefuroxime and cefazolin were the most popular agents for 
prophylaxis. Co-amoxiclav was used more often in the new 
formularies than in the older ones. Broad-spectrum penicillins 
(piperacillin) were used in only one formulary. Besides its high 
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cost, the variable activity against E.coli is a disadvantage of the 
drug. Broad spectrum penicillins were used extensively in the 
German study (5). 
The recommendations for the duration of prophylaxis were again 
variable. A single dose prophylaxis was recommended by 37% of 
the formularies and a triple dose regimen was used in 42% of 
these. In the German survey, 50% of all hospitals used a single 
dose regimen (5). Single dose prophylaxis appears to be as 
effective as multiple dose regimens, although a large proportion of 
comparative trials were performed with relatively long acting 
cephalosporins (12). A recent large-scale comparative study 
looking at single dose versus triple dose cefuroxime in over 1000 
high-risk patients showed similar efficacy of both regimens (13). 
The antibiotics used in gastroduodenal surgery, and the duration of 
prophylaxis, are presented in Table 3. 
All formularies that included gastroduodenal surgery recommended 
prophylaxis. 
Six out of nine old (67%) and 11 of 16 (69%) new formularies 
stated that prophylaxis was indicated in high-risk patients. This 
was specified as those with a diminished production of gastric acid 
(n=9), gastric haemorrhage (n=4), gastric carcinoma (n=5) and age 
above 70 years (n=l). Five other indications were given in one 
formulary each. 
A similar dosage range to that seen in biliary tract surgery was 
used in gastroduodenal surgery. 
The pattern of antibiotic use was similar to that in the prophylaxis 
of biliary tract surgery, co-amoxiclav, cefuroxime and cefazolin 
being the most commonly used drugs. A combination of these 
drugs with an aminoglycoside or metronidazole was used in about 
30% of all formularies. Most formularies stated that prophylaxis is 
only indicated in high risk patients. 
The Dutch policy is different from that in Germany. In the 
German survey a relatively high proportion of hospitals used third 
generation cephalosporins or broad spectrum penicillins with or 
without metronidazole (5). 
Single-dose prophylaxis was given in 48% of all Dutch 
formularies. A similar percentage was seen in Germany (5). 
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Although comparative studies are scarce, single dose prophylaxis 
appears to be as effective as multiple dose schedules (2). 
TABLE 3 
GASTRODUODENAL SURGERY 
Prophylactic antibiotics recommended by 33 antibiotic formularies from Dutch hospitals 
No. of formularies making recommendations 
Group I Group II Total 
Duration recommended 
1 dose 5 
1-3 doses 1 
2 doses 
3 doses 3 
4 doses 
Choice of drugs 
Co-amoxiclav 
Amoxycillin 
Benzylpenicillin 1 
Cefazolin 3 
Ceñiroxime 2 
Cefotetan 
Cefamandole/metronidazole 
Cefazolin/metronidazole 1 
Cefuroxime/metronidazole I 
Gentamicin/metronidazole 1 
Gentamicin/clindamycin 
Group I Formularies dating from before 1991 
Group II Formularies from 1991-1993 
CONCLUSIONS 
Most Dutch formularies recommended drugs with proven clinical 
efficacy and a correct antimicrobial activity in surgical procedures. 
Co-amoxiclav was recommended frequently as well as first and 
second generation cephalosporins with or without metronidazole. 
A variety of dose recommendations has been found, and this 
illustrates the variability of the dosages used in clinical studies. 
12 
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There was no consensus on the duration of the prophylaxis. Many 
formularies recommended multiple dose prophylaxis. 
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CHAPTER Vili 
ANTIBIOTIC PROPHYLAXIS IN SURGERY IN THE 
NETHERLANDS 
Antimicrobial prophylaxis in gynaecological surgery 
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SUMMARY 
The guidelines for antibiotic prophylaxis in gynaecological surgery 
in 33 Dutch antibiotic formularies, representing 89 Dutch 
hospitals, were studied. All formularies recommended routine 
antibiotic prophylaxis in vaginal hysterectomies, whereas some 
formularies defined "high risk" groups that should receive 
prophylaxis as including abdominal hysterectomy and caesarian 
section. Co-amoxiclav was the drug of choice in 73% of the 
formularies that recommended antibiotic prophylaxis for 
abdominal hysterectomy, in 64% for vaginal hysterectomy and in 
60% for caesarian section. The majority of formularies used a 
single dose: the rates for this were 73% in abdominal 
hysterectomy, 64% in vaginal hysterectomy and 50% in caesarian 
section. A single dose was used more often in new formularies 
(dating from 1991 to 1993) than in older formularies. 
INTRODUCTION 
Antimicrobial prophylaxis is considered useful in clean-
contaminated surgery such as gynaecological operations. 
There is no consensus on the choice of drugs, the duration of 
prophylaxis and the dosage of prophylactic antibiotics during 
gynaecological surgery (1-13). 
The usefulness of prophylactic antibiotics in abdominal 
hysterectomy is still uncertain, although a meta-analysis combining 
the data from 17 prospective, randomized, blinded, placebo-
controlled studies (14 of these using first and second generation 
cephalosporins), confirmed that antibiotic prophylaxis did reduce 
the infectious morbidity following elective abdominal 
hysterectomy (14). 
Most Dutch hospitals use written guidelines for the use of 
antimicrobial drugs for prophylaxis and treatment of infections, 
and these are specific for the hospital in question or for a group of 
collaborating hospitals (regional formulary). 
In this study, we have investigated the guidelines for the use of 
antimicrobial prophylaxis in gynaecological surgery in Dutch 
hospitals. 
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METHODS 
In 1993, a letter was written to members of the Dutch Association 
of Hospital Pharmacists with a request to send to us the most 
recent version of the antibiotic formulary in use in the hospital in 
question. 
After receipt of the formularies, the following types of surgical 
procedures were investigated: 
- abdominal hysterectomy 
- vaginal hysterectomy 
- caesarian section 
For each of these procedures, the following aspects were recorded: 
the number of formularies in which the particular surgical 
procedure was included, whether or not antibiotic prophylaxis was 
used, the drug or drug-combination of first choice, dosage, route 
of administration, timing of administration and the duration of 
prophylactic use of antimicrobials. All remarks concerning special 
indications or limitations of the use of antibiotics in surgical 
prophylaxis were also recorded for each individual formulary. 
The antibiotic formularies were arbitrarily divided into two groups: 
"old" formularies dating from before 1991 and "new" formularies 
dating from 1991 to 1993. 
RESULTS 
A total of 33 antibiotic formularies were received. Of these, 13 
"old" formularies were dated before 1991 and 20 "new" ones were 
from the period 1991 to 1993. The 33 formularies were used in a 
total of 89 hospitals, of which 6 were university hospitals. 
Abdominal hysterectomy was included in 7/13 (54%) old formula-
ries and in 18/20 (90%) new formularies. Prophylaxis was given 
in 2/7 (29%) old formularies and in 13/18 (72%) of the new ones. 
The choice of drugs and duration of prophylaxis is given in Table 
1. 
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TABLE 1 
ABDOMINAL HYSTERECTOMY 
Prophylactic antibiotics recommended by 33 antibiotic formularies from Dutch hospitals 
Old formularies New formularies Total 
1 dose 1 
2 doses 1 
3 doses 
Choice of drugs 
Co-amoxiclav 1 
Cefuroxime/metronidazole 
Cefazolin/metronidazole 1 
10 
3 
10 
3 
11 
1 
3 
II 
3 
1 
All drugs were given intravenously. 
In the 11 formularies in which co-amoxiclav was used, the dosage 
of this drug-combination was a single 2.2 g dose in 8 formularies 
and 1 χ 1.2 g; 3 χ 1.2 g and 2 χ 2.2 g in one formulary each. 
There were 3 different dosages for the combination cefuroxime + 
metronidazole in the 3 formularies in which this combination was 
used: 3 χ (1.5 g cefuroxime + 500 mg metronidazole); 1 χ (1.5 g 
cefuroxime + 1.5 g metronidazole) and 1 χ 1.5 g, followed by 2 χ 
750 mg cefuroxime in combination with 3 χ 500 mg metronidazo­
le. Of the new formularies in which prophylactic antibiotics were 
given for abdominal hysterectomy, 5/13 (38%) stated that the 
prophylaxis should not be given routinely and that its use should 
be limited to "high risk" patients. A specification was given in 
only one formulary and it referred to diabetic and adipose patients. 
One formulary stated that a meta-analysis of double-blind studies 
on the prophylaxis in abdominal hysterectomy had shown that a 
significant reduction in infectious complications was obtained with 
prophylactic antibiotics (14). Vaginal hysterectomy was included 
in 8/13 (62%) of the old formularies and in 18/20 (90%) of the 
new ones. Prophylaxis was given in 7/8 (88%) of the old formula­
ries and in all 18 (100%) of the new formularies. The antibiotics 
used in this surgical procedure are shown in Table 2. All drugs 
were given intravenously. 
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TABLE 2 
VAGINAL HYSTERECTOMY 
Prophylactic antibiotics recommended by 33 antibiotic formularies from Dutch hospitals 
Old formularies New formularies Total 
1 dose 3 13 16 
2 doses I 1 
3 doses 3 5 8 
Choice of drugs 
Co-amoxiclav 4 12 16 
Amoxycillin/metronidazole 1 1 
Cefuroxime/metronidazole 3 3 
Cefazolin/metronidazole 2 2 
Co-trimoxazole/metronidazole 1 1 
Metronidazole 1 1 
Gentamicin/clindamycin 1 1 
Of the 16 formularies in which co-amoxiclav was used, 10 ad­
vised a single dose of 2.2 g (2 g amoxycillin plus 200 mg clavu-
lanic acid). Four formularies recommended a dosage of 3 χ 1.2 g, 
whereas dosages of 2 χ 2.2 g and 3 χ 2.2 g were used in one for­
mulary each. Two formularies recommended the combination of 
cefuroxime and metronidazole in a dosage of 1.5 g, followed by 2 
χ 750 mg cefuroxime + 3 χ 500 mg metronidazole and one 
formulary used a single dose of cefuroxime and metronidazole in a 
dosage of 1.5 g each. 
For both types of hysterectomy, the first dose of antibiotic was 
given 30-60 minutes before the initiation of surgery in all Dutch 
formularies. 
Ceasarian section was included in 5/13 (38%) old formularies and 
in 15/20 (75%) new formularies. Prophylaxis was given in all 
hospitals which included this procedure in the formulary. The 
specification of the antimicrobial agents used in the prophylaxis 
are presented in Table 3. 
TABLE 3 
CAESARIAN SECTION 
Prophylactic antibiotics recommended by 33 antibiotic formularies Trom Dutch hospitals 
Old formularies New formularies Total 
I dose 1 9 10 
3 doses 4 6 10 
Choice of drugs 
Co-amoxiclav 1 11 12 
Cefuroxime 1 1 2 
Cefoxitin 1 1 
Cefuroxime/metronidazole 1 1 
Cefazolin/metronidazole 2 2 
Co-trimoxazole/metronidazole 1 I 
Gentamicin/Clindamycin 1 1 
All drugs were given intravenously. Of the 20 formularies in 
which caesarian section was included, 11 (55%) specified that 
prophylaxis was only indicated in "high risk" patients. Only 3 
formularies specified the "high risk" patients as a secondary 
caesarian section in the presence of prolonged (over 12 h) ruptured 
membranes. 
The first dose of the prophylactic antibiotic was given im-
mediately after clamping of the umbilical cord. 
DISCUSSION 
The choice of an antimicrobial drug for prophylaxis in surgery 
should depend on the following criteria: 
- desired antimicrobial spectrum in relation to the bacterial flora 
present at the site of the operation. 
- results of clinical studies 
- side-effects 
- pharmacokinetic properties 
- cost 
- antibiotic policy and local antibiotic resistance patterns 
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Desired antimicrobial spectrum 
Vaginal secretions contain about 108 to 109 anaerobes/ml and 
about 10 fold less aerobes. The most important anaerobes are 
lactobacilli, peptostreptococci and peptococci and to a lesser extent 
also Bacteroides spp. (1). Enterobacteriaceae are usually found in 
much lower numbers (< lOVml). Postoperative vaginal flora 
contains increased numbers of enterococci, Gram-negative bacilli 
and Bacteroides spp. (13). 
Postoperative infections after vaginal hysterectomy are often 
polymicrobial. Enterococci, staphylococci, aerobic Gram-negative 
bacilli and Bacteroides spp. are the most frequently isolated 
organisms from wound infections. Antimicrobial prophylaxis 
should therefore, be targeted against these organisms. 
First and second generation cephalosporins have good activity 
against Staphylococcus aureus and most Gram-negative bacilli, but 
only limited activity against Bacteroides spp. All cephalo-sporins 
are inactive against enterococci. Third generation cephalosporins 
are very active against Gram-negative bacilli, and only moderately 
active against S. aureus. They are inactive against enterococci and 
anaerobes. 
Ampicillin and amoxycillin are very active against enterococci, but 
are not reliably active against all the other organisms considered 
above. Extended spectrum penicillins, such as mezlocillin (no 
longer available in the Netherlands) and piperacillin are not always 
effective against Escherichia coli and are often inactive against 
S. aureus. 
Co-amoxiclav is usually effective against all micro-organisms 
commonly involved in surgical wound infections following ab-
dominal or vaginal hysterectomy. The activity against Entero-
bacteriaceae is variable, but most strains of E.coli, Proteus and 
Klebsiella are suscepible to co-amoxiclav. 
Results of clinical studies 
Despite the fact that the antimicrobial spectra of cephalosporins 
and penicillins are different, little or no differences have been 
observed in the incidence of wound infections following hys-
terectomy between first, second and third generation cephalo-
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sporins and penicillins (1). The incidence of postoperative 
infectious complications lies between 0 and 12% for all beta-
lactams, with no significant differences between the drugs (1). 
The most important pathogens involved in surgical wound infect-
ions are E.coli and S.aureus. Coverage of these micro-organisms is 
provided by first and second generation cephalosporins and by co-
amoxiclav (7). It is questionable whether coverage of anaerobes, 
such as Bacteroides spp. is essential for drugs used in the prophy-
laxis of hysterectomy (7). Cefazolin is recommended by the 
American Society of Hospital Pharmacists (13). In a small-scale 
study, cefuroxime proved to be more effective than metronidazole, 
whereas the combination of both drugs was as effective as 
cefuroxime alone (4). On the other hand, a combination of 
cephacetrile and ornidazole, covering aerobic and anaerobic 
bacteria respectively, was more effective than either drug alone 
(7)· 
For both types of hysterectomies, a single dose, to be given 30 to 
60 minutes before surgery, appears to be as effective as a mul-
tiple-dose schedule (1). Prophylaxis lasting longer than 24 h 
cannot be recommended (1). 
Side-effects 
As all cephalosporins and penicillins are usually well tolerated, 
especially in short term prophylaxis, development of side-effects is 
not a very important criterion in the selection of an agent for 
prophylaxis in surgery. 
Cost 
There are important differences in cost between various 
cephalosporins and penicillins, although they depend of course on 
the dosages employed. The cost of first generation cephalosporins, 
amoxycillin, ampicillin and metronidazole is relatively low in most 
countries. Co-amoxiclav is 2-3 fold more expensive, whereas 
second and third generation cephalosporins and broad-spectrum 
penicillins such as piperacillin are considerably more expensive. 
Due to the large differences in cost, this is often the most im-
portant criterion for the selection of an agent in antibiotic 
prophylaxis in surgery. 
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Pharmacokinetic properties 
The pharmacokinetics of most cephalosporins and penicillins are 
roughly similar concerning their volume of distribution, elimina-
tion half-life and tissue penetration. If a surgical procedure lasts 
longer than approximately 3-4 h, effective concentrations at the 
operation site cannot be guaranteed for most beta-lactam an-
tibiotics, due to their relatively short half-life of 1-2 h. An extra 
dose of the same drug may be necessary to avoid subtherapeutic 
concentrations (15). 
Some cephalosporins, such as ceftriaxone, have an extended half-
life, which means that tissue concentrations are maintained for 
longer periods. An extra dose is not necessary for this drug. 
Antibiotic policy 
A distinction between antibiotics used in prophylaxis and those 
used in therapy is desirable for logistic reasons. If prophylactic 
antibiotics are not (routinely) used in therapy, an unwanted prolon-
gation of the "prophylaxis" on the hospital ward is impossible, if 
the drugs are not available there, but are only to be found in the 
operation theatre. 
Some drugs, such as broad-spectrum penicillins and third gene-
ration cephalosporins, have an important place in the treatment of 
infections. Although no studies are available that show a clear 
relation between the (short term) prophylactic use of antibiotics 
and the development of resistance, their prophylactic use in 
surgery may theoretically induce the development of resistance 
and is therefore undesirable. For the same reason the use of 
aminoglycosides and fluoroquinolones in surgical prophylaxis is 
not recommended. 
First generation cephalosporins are used only to a limited extent in 
general practice in the Netherlands and are very infrequently used 
in the treatment of infections in Dutch hospitals (16). This makes 
these drugs very attractive for use in prophylaxis. 
In Dutch hospitals, second generation cephalosporins are used both 
in the treatment of infections and in surgical prophylaxis. 
Co-amoxiclav is used mainly in prophylaxis, but some Dutch 
hospitals use the drug also in the treatment of infections (16). 
The situation is quite different in other countries. In Belgium, oral 
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first generation cephalosporins are used on a wide scale in general 
practice and co-amoxiclav is used in the treatment of hospital 
infections on a much wider scale than in the Netherlands, resulting 
in a 3-4 fold higher usage of the drug in hospitals (16, 17). 
GYNAECOLOGICAL PROPHYLAXIS IN THE NETHER-
LANDS 
The need for prophylaxis in hysterectomy 
The need for antimicrobial prophylaxis in vaginal hysterectomy is 
clear. Antibiotics, such as penicillins and cephalosporins, with or 
without metronidazole, result in a decreased febrile morbidity and 
lower incidence of wound infections in comparison with placebo 
(1). Prophylaxis was given in all new Dutch antibiotic formularies 
and in all but one of the old formularies. 
The necessity of antibiotic prophylaxis in abdominal hysterectomy 
is still open for debate. Prophylaxis was advised routinely in 72% 
of all Dutch hospital formularies, independent of the year of 
publication. A meta-analysis of studies in abdominal hysterectomy 
showed that postoperative infections occurred in 19.5% of the pa-
tients in the placebo group and in 9.3% in the antibiotic-treated 
groups (14). Another study comparing cefuroxime + metronidazole 
with placebo showed no difference in the incidence of wound 
infections, but a significantly lower incidence of urinary tract 
infections was observed in the antibiotic-treated group (18). 
None of the formularies that did not include abdominal or vaginal 
hysterectomy or Caesarian section made any statements on the 
(absence of) usefulness of prophylactic antimicrobials for surgical 
procedures that were not mentioned in the formulary. 
Choice and dosage of prophylactic agents in hysterectomy 
The use of antimicrobial prophylaxis in gynaecological surgery in 
Dutch hospitals has been studied before by Wttewaal-Evelaar in 
1987 (19). Of all surgeons that responded to the questionnaire, 
46% used single-agent prophylaxis. This has now increased to 
68% in vaginal hysterectomy. Metronidazole was the most 
frequently used single-agent drug in the study by Wttewaal-
Evelaar (13%), followed by co-amoxiclav (12%) and piperacillin 
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(12%). Metronidazole and piperacillin are no longer used in the 
new formularies of Dutch hospitals in the present study. 
Co-amoxiclav is by far the most important prophylactic agent in 
gynaecological surgery in the Netherlands, especially in the for­
mularies from 1991 to 1993. Five comparative studies in 
gynaecological surgery have been published with this drug. Three 
studies employed a single 2.2 g dose (20-22) and two other studies 
used a dosage of 3 χ 1.2 g (23, 24). 
The clinical efficacy of the drug was similar to that of piperacillin 
and to the combinations of cefuroxime/metronidazole and cephra-
dine/metronidazole but superior to metronidazole alone (23, 24). 
The optimal dose of co-amoxiclav remains to be established. A 
single 2.2 g dose is relatively inexpensive and its efficacy has 
been documented in 3 clinical studies. The majority of Dutch 
hospitals that use the drug in gynaecological prophylaxis use this 
dose. There seems to be no clear reason for dosages such as 2 χ 
2.2 g and 3 χ 2.2 g. These dosages have not been tested in clinical 
studies, are more expensive and increase the work load on the 
hospital wards. 
It is surprising to see that first or second generation cephalo­
sporins are not used alone (without addition of other antibiotics) in 
any Dutch hospital for this indication. In the U.S.A., first 
generation cephalosporins are considered as drugs of choice for 
this indication (13). From several personal communications it 
became clear that the lack of activity of cephalosporins against 
anaerobes and enterococci was the main reason to choose for co-
amoxiclav. 
Some hospitals use a combination of cefuroxime or cefazolin with 
metronidazole, in order to improve the anaerobic coverage. Again 
a variety of dose recommendations was observed. For all regimens 
of prophylaxis in hysterectomies a single dose is as effective as 
multiple dosage regimens (1). 
The combination of gentamicin and clindamycin, as was used in 
one formulary for vaginal hysterectomy, cannot be recommended. 
Aminoglycosides should not be used as drugs of first choice in 
prophylaxis, because of their important place in the treatment of 
infections. Another, mostly theoretical, disadvantage of ami­
noglycosides is their possible interference with postoperative 
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recovery due to their action on neuromuscular transmission. 
There is little doubt concerning the timing of antibiotic ad-
ministration. Classen et al. (12) showed that administration in the 
two hours prior to surgery (in comparison with earlier or later 
administration) reduced the risk of surgical wound infections. All 
Dutch formularies state that prophylactic antibiotics in hysterec-
tomies should be given between 30 and 60 minutes before surgery. 
The need for prophylaxis in caesar ¡an section 
Postoperative infections such as endometritis and surgical wound 
infection are relatively common following caesarian section. The 
relationship between febrile morbidity and documented infections 
is not always completely clear (13). 
The most important risk factor for the development of post-
operative infections is prolonged labour in the presence of ruptu-
red membranes. Other risk factors include frequent vaginal ex-
aminations, poor hygiene, social status, systemic illness, obesity, 
general anaesthesia and anaemia (13). 
The need for prophylaxis in low risk women is still being debated. 
In a large scale study, involving over 1800 low-risk patients, 
Ehrenkranz et al. have shown a 5-fold reduction in the incidence 
of endometritis and a 3.7-fold reduction in wound infections with 
or without endometritis in the group receiving antibiotics in 
comparison with the group without systemic prophylaxis (25). The 
methodology of the study was not ideal, however, as case controls 
were used and the study was not blinded. 
Similar results were obtained from a meta-analysis of the ran-
domized controlled trials of the value of antibiotic prophylaxis in 
caesarian section. A 3-fold reduction in infection rates was found 
in the patients who were treated with an antibiotic, compared to 
those in the placebo-treated group (26). Many of the patients 
involved in this meta-analysis were relatively high-risk patients 
and it is not yet certain whether all patients need to receive anti-
biotic prophylaxis (6, 10). 
This controversy is also found in the Dutch formularies. Although 
antibiotic prophylaxis was given in all formularies in which 
caesarian section was included, 55% of the formularies limited the 
prophylaxis to high-risk patients. This group was specified in only 
116 
3 of these 11 formularies as a secondary caesarian section with 
prolonged rupture of the membranes. 
The timing of the administration of prophylactic antibiotics is 
different with caesarian section from that with hysterectomies. To 
minimize the exposure of the child, antibiotics are usually given 
after clamping of the umbilical cord. As far is is known, this does 
not influence the clinical efficacy of the prophylaxis (10, 13). 
All the Dutch antibiotic formularies that made clear statements on 
the timing of administration advised starting the prophylaxis after 
the cord has been clamped. 
Choice and duration of prophylaxis in caesarian section 
The choice of antibiotics is similar to that in hysterectomies. First 
and second generation cephalosporins have been proved effective 
prophylactic agents (6, 13). The majority of Dutch formularies 
preferred co-amoxiclav to the cephalosporins. Although this agent 
is a good choice regarding its activity against the organisms invol-
ved in surgical wound infections and endometritis, we have not 
been able to find any study in which the efficacy of the drug in 
the antibiotic prophylaxis of caesarian section is documented. 
As can be seen in Tables 2 and 3, most formularies used similar 
regimens for prophylaxis in vaginal hysterectomies and caesarian 
section. Some formularies recommended the use of a cepha-
losporin (cefuroxime or cefoxitin) without the addition of 
metronidazole in caesarian section. 
A single dose of an antibiotic given after clamping of the cord is 
an effective prophylactic regimen and there are no indications that 
a longer prophylaxis is necessary (13). It is interesting to see that 
single dose prophylaxis was advised in only 20% of the old Dutch 
formularies but in 60% of the new ones. The number of old 
formularies including caesarian section (only 5) was too small to 
draw any conclusions from this observation. 
CONCLUSIONS 
Prophylaxis in gynaecological surgery is given in most Dutch 
hospitals. There is a consensus on the need for prophylaxis in 
vaginal hysterectomy and most formularies also advise giving 
117 
prophylactic agents in abdominal hysterectomy and in caesarian 
section, although several formularies state that "high risk" groups 
(without further specification) should receive antimicrobial pro-
phylaxis. 
The antibiotic used most frequently is co-amoxiclav. This drug is 
well documented in hysterectomies, but not in caesarian section. 
First and second generation cephalosporins have but a modest role 
in prophylaxis in the Netherlands. 
The timing of prophylaxis was correct in all Dutch formularies 
and the majority of new formularies used a single dose regimen. 
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SUMMARY 
The results of an inquiry among Dutch hospital pharmacists on the 
monitoring of aminoglycosides are presented and the relevance of 
monitoring is discussed. 
The vast majority of Dutch hospitals (47 of 65) use 
aminoglycosides in a twice daily dosage regimen, whereas 12 
hospitals use a once daily dose. The timing of peak level sampling 
is usually 30 min after the end of an intravenous infusion of 20-30 
min. Mean "therapeutic" peak levels of gentamicin were 7-13 mg/1 
in the once daily group, 6.4-9.6 mg/1 in the twice daily group and 
5-9 mg/1 in the small 3 times daily group. 
Little or no evidence has been published to substantiate a real 
therapeutic range for aminoglycosides, concerning a relationship 
between peak or trough levels of aminoglycosides and clinical 
efficacy, ototoxicity and nephrotoxicity. All studies have been 
performed with the conventional 3 times daily regimen. No 
therapeutic range can be defined yet for once daily or twice daily 
aminoglycosides. Monitoring of aminoglycosides may be helpful 
to reduce the variability in serum levels after a standard dose. 
INTRODUCTION 
Therapeutic drug monitoring of aminoglycosides has been a 
routine procedure for a prolonged period of time. Recently the use 
of routine monitoring of aminoglycosides has been questioned by 
McCormack and Jewesson (1). 
The "therapeutic range" of aminoglycosides is based on a 3 times 
daily dosing schedule. Nowadays, in most cases the 
aminoglycosides are used in a once daily or twice daily manner. 
An inquiry was performed among Dutch hospital pharmacists to 
gain insight into the monitoring of aminoglycosides in Dutch 
hospitals in relation to the frequency of administration. 
MATERIAL AND METHODS 
An inquiry was held among 95 Dutch hospital pharmacists, 
investigating the therapeutic drug monitoring of aminoglycosides. 
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Data were collected on the following items: 
a) The usual dosing frequency of aminoglycosides in a patient 
with normal renal and hepatic function (once daily, twice 
daily, 3 times daily or continuous infusion). 
b) Adaptation of the dose in patients with a diminished renal 
function: estimated creatinine clearance < 80 ml/min 
(lowering of the dosage, prolonging the dosage interval or 
a combination of both). 
c) The period of time (hours) after initiating the 
aminoglycoside therapy at which it is usual to determine 
the first peak/trough levels, in relation to the estimated 
creatinine clearances ( > 80 ml/min, 50-80 ml/min, 30-50 
ml/min, 10-30 ml/min and < 10 ml/min). 
d) The usual timing (min) of sampling of a peak level 
determination after an intramuscular injection, an 
intravenous injection or an intravenous infusion. 
e) The "normal values" for a peak and trough level for 
amikacin, for gentamicin and tobramycin and for 
netilmicin, in relation to the usual dosing frequency in the 
hospital in question. 
f) Literature references upon which the data mentioned under 
e) were based. 
g) Data on the use of aminoglycosides and the number of 
serum level determinations were collected for nine 
hospitals. 
The data were collected in a database program, DBase 3 (Ashton-
Tate, Torrance CA; USA) and were indexed on the dosing 
frequency of aminoglycosides. 
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RESULTS 
A total of 65 hospitals responded to the inquiry. Twelve hospitals 
used a once daily dosage regimen for aminoglycosides, 47 a twice 
daily and only 6 hospitals used aminoglycosides in the traditional 
3 times daily way. All hospitals used gentamicin, tobramycin or 
netilmicin. Amikacin was not used in most hospitals. 
There was no consensus in the mode of dose adaptation in the 
presence of renal disease. In the once daily group 7 hospitals 
lowered the dose, 2 hospitals prolonged the dosage interval and 3 
hospitals used a combination of both. In the twice daily group 
only 3 hospitals lowered the dose, 22 prolonged the dosage 
interval and 20 used a combination of both, 2 hospitals did not 
answer this question. In the 6 hospitals using a 3 times daily 
dosage regimen, one lowered the dose, 2 prolonged the interval 
and 3 used the combination. 
The timing of sampling in relation to the initiation of 
aminoglycoside therapy is shown in Table 1. 
TABLE 1 
TIMING OF THE FIRST SERUM LEVEL DETERMINATION AFTER THE INITIATION 
OF THE AMINOGLYCOSIDE THERAPY, IN RELATION TO THE RENAL FUNCTION 
Timing Creatinine clearance (ml/min) 
(h) >80 50-80 30-50 10-30 <10 
(number of hospitals) 
12 
24 
36 
48 
72 
96 
not used 
unknown 
7 
23 
3 
15 
8 
I 
8 
5 
26 
2 
18 
6 
8 
4 
27 
3 
16 
7 
8 
4 
31 
1 
12 
6 
1 
2 
8 
6 
26 
10 
5 
2 
8 
8 
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No significant differences were observed between the groups or 
when specified for the dosage frequency. 
The timing of blood sampling after an intramuscular injection was 
60 min in 23 hospitals and 45 min in 1 hospital, the other 
hospitals did not use intramuscular aminoglycosides. In 20 
hospitals intravenous bolus injections of aminoglycosides were 
(infrequently) used; 9 hospitals used a sampling time of 30 min 
and 10 hospitals used a sampling time of 60 min, one hospital 
sampled after 15 min. Intravenous infusion, with an infusion time 
of 20-30 min, was the most usual mode of administration for 
aminoglycosides. In all 18 hospitals using a once daily or 3 times 
daily regimen, peak levels were determined 30 min after the 
termination of the infusion. There was less agreement in the 
(larger) twice daily group: 30 min in 35 hospitals, 60 min in 6 
hospitals, 120 min in 2 hospitals and 45 min, 15 min and 10 min 
in one hospital each. One hospital in this group used intramuscular 
injections. 
The "normal" therapeutic serum levels for aminoglycosides in the 
Dutch hospitals are shown in Table 2. 
TABLE 2 
NORMAL RANGES FOR PEAK (lower range, higher range and mean; mg/l) AND TROUGH 
LEVELS OF AMINOGLYCOSIDES IN THE NETHERLANDS 
ONCE DAILY (N-=12) 
Gentamicin/tobramycin 
Netilmicin 
TWICE DAILY (N=47) 
Gentamicin/tobramycin 
Netilmicin 
3 TIMES DAILY (N=6) 
Gentamicin/tobramycin 
Cmax 
low 
70 
10 
64 
77 
50 
Cmax 
high 
13 
16 
96 
123 
9.0 
Cmax 
mean 
10 
13 
go 
10 
70 
Cmin 
<16 
<13 
<16 
<2 0 
<13 
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A variety of literature references was given upon which the 
therapeutic range of aminoglycosides was based. The book 
"Medicatiebegeleiding" (2) was mentioned by far most frequently. 
The data on the use of aminoglycosides, expressed as defined 
daily dose (DDD/100 bed days), and the number of serum level 
determinations in relation to the use of aminoglycosides are shown 
in Table 3. 
TABLE 3 
AMINOGLYCOSIDE USE AND SERUM LEVEL ASSAYS IN 9 DUTCH HOSPITALS 
No. of 
beds 
>500 
<500 
<500 
<500 
>500 
<500 
<500 
>500 
<500 
Mean 
DDD/100 
beddays 
0 96 
0 25 
135 
1 80 
2 20 
0 88 
0 89 
0 72 
134 
1 15 
Serum level 
per 100 
0 22 
0 14 
0 35 
0 47 
0 49 
0 25 
0 40 
0 17 
0 22 
0 30 
assays 
beddays 
Ratio DDD/serum 
level assays 
441 
1 84 
3 89 
381 
4 49 
3 50 
221 
4 15 
5 89 
3 80 
DISCUSSION 
The monitoring of aminoglycosides is considered to be important 
because of the unpredictable serum levels after intravenous 
infusion and because of the relationship between peak and trough 
levels with clinical efficacy, ototoxicity and nephrotoxicity. 
Several articles have questioned the usefulness of routine 
monitoring of these drugs recently (1, 3). Before monitoring of a 
drug can be considered useful it is necessary that a relationship 
between peak and/or trough levels with clinical efficacy or toxicity 
has been shown. 
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RELATIONSHIP BETWEEN PEAK LEVEL AND 
CLINICAL EFFICACY 
The relationship between aminoglycoside peak levels in serum and 
clinical efficacy is very difficult to investigate for a variety of 
reasons. Aminoglycosides are (virtually) always used in 
combination with broad-spectrum betalactam antibiotics, such as 
the penicillins and the second or third generation cephalosporins. 
These agents have a very good in-vitro activity against most 
Gram-negative bacteria, which makes it rather difficult to evaluate 
the efficacy of an aminoglycoside which is added to these 
cephalosporins. 
Clearly a rigid therapeutic range of peak levels for 
aminoglycosides does not take into account the in-vitro sensitivity 
of the micro-organism, the localization of the infection and the 
clinical situation of the patient. If a patient is treated for a urinary 
tract infection, the concentrations at the site of the infection will 
be much higher than in case of pneumonia or meningitis. 
"Therapeutic levels" of aminoglycosides will not be the same if 
the infecting micro-organism is a Pseudomonas aeruginosa with a 
minimum inhibitory concentration (MIC) of 4 mg/1 or an 
Escherichia coli with a MIC of 0.12 mg/1. Patients with a severely 
impaired immune function will need higher dosages and higher 
levels than healthy young subjects. 
Several methodological problems play an important role in the 
interpretation of the "evidence" for a therapeutic range of 
aminoglycosides. The 6 studies that provide evidence of a 
therapeutic peak level of aminoglycosides were not randomized, 
prospective and blinded, while 5 of these were published > 7 years 
ago (1). Other antibiotics that were used in the treatment of these 
patients were not always clearly identified, which complicates the 
interpretation of the data on the efficacy of aminoglycosides in 
relation to peak levels. The duration of the infusion was not stated 
in 5 of the 6 studies. Peak serum concentrations were determined 
60 min after termination of the infusion in all studies (1). 
In 53 of the 65 Dutch hospitals, peak serum levels were 
determined 30 min after an intravenous infusion of 20-30 min, but 
a variety of other sampling times, such as 10, 15, 45, 60 and 120 
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min, were also used. In one hospital levels were determined after 
2 and 6 h, and peak and trough levels were calculated by back-
extrapolation. It is clear that different sampling and calculations 
times will result in different "peak" levels. It is important to keep 
in mind that the sampling time of peak levels in the Dutch 
hospitals (usually 30 min) deviates from the studies (60 min) on 
which the "therapeutic range" of aminoglycosides is based. 
The sampling time after an intravenous bolus injection should be 
60 min. When a sampling time of 30 min is used, this may result 
in relatively high "peak" levels, because the distribution may take 
up to 45 min (4). A relatively large proportion of UK hospitals 
also used a 30 min sampling time after an intravenous bolus 
injection (4). 
Jeliffe et al. proposed sampling aminoglycoside levels immediately 
after the end of the infusion (most informative time for alterations 
in the volume of distribution) and an estimated 1.44 half-lives later 
(most informative time for alterations in the half-life (5). 
No consensus has been obtained in the Netherlands on the 
sampling time in relation to the initiation of the aminoglycoside 
therapy. In patients with normal renal function this period of time 
ranges from 12 to 96 h, with most assays performed after 24 or 48 
hours after the start of therapy. No clear trend towards different 
sampling times was observed in patients with a diminished renal 
function. In 8 hospitals aminoglycosides were not used in patients 
with a severely impaired renal function. A steady state level of 
aminoglycosides is reached after 5 half-lives. A steady state will 
therefore be reached within a day in patients with normal renal 
function, but this may take many days in patients with a poor 
renal function. 
The problem with this approach is that the elimination half-life of 
an aminoglycoside is not known in a specific patient before serum 
levels have been determined. In patients with impaired renal 
function, the determination of serum levels before a steady-state 
has been reached may be useful to prevent potentially toxic levels. 
A determination of the peak and trough levels after 24 to 48 h will 
be adequate in the vast majority of patients with normal renal 
function. 
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Another very important aspect that has to be considered is the fact 
that the traditional peak levels of aminoglycosides are based on a 
3 times daily dosage schedule. In animal experiments and in 
(limited) clinical trials some reduction or no change in the toxicity 
was observed with once daily administration in comparison with 3 
times daily dosing (6). The effects of once daily or twice daily 
administration on the clinical efficacy appear to be similar to the 
conventional schedule (7-9). 
Again this is difficult to study because aminoglycosides are used 
in combination with other antibiotics. The clinical evidence for 
once daily dosing of aminoglycosides is still limited, but the 
results appear to be encouraging (6, 10). 
It is important to keep in mind that no studies have been 
performed on the relationship between peak levels of 
aminoglycosides and clinical efficacy after once or twice daily 
dosing. It is questionable to use the same peak levels with these 
schedules as with the thrice daily dosing (11). In 4 of 8 hospitals 
using once daily dosages of gentamicin, peak levels of 4-12 mg/1 
are considered as therapeutic, whereas in 4 other hospitals peak 
levels of 10-20 mg/1 are aimed at. For the 5 hospitals using once 
daily netilmicin a more uniform peak level of 10-15 mg/1 is used. 
The average range for the peak levels of twice daily gentamicin is 
6-10 mg/1 and only 4 of 47 hospitals use higher levels of 8-20 
mg/1. Too few hospitals used amikacin to draw any conclusions 
for this drug. 
Although it seems attractive to use three-fold higher peak serum 
levels for the once daily and 1.5-fold higher levels for the twice 
daily dosing in comparison with the conventional 3 times daily 
dosing, this has not been substantiated in any study. In most 
hospitals the "therapeutic" peak levels with once or twice daily 
dosing are relatively low. The rate of killing of bacteria by 
aminoglycosides is highly dependent on the ratio serum level/MIC. 
At high ratios a much higher killing rate (with less regrowth) is 
seen than at lower ratios (12). 
In conclusion, there is very little evidence to substantiate a 
relationship between peak serum levels of aminoglycosides and 
clinical efficacy, especially with once or twice daily dosing. 
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RELATIONSHIP BETWEEN TROUGH LEVELS AND 
CLINICAL EFFICACY 
In all hospitals trough levels were determined immediately prior to 
the next dose. 
There are no prospective, controlled studies that show any relation 
between aminoglycoside trough levels and clinical efficacy of 
these drugs (1). The same methodological problems that have been 
described above also apply to this aspect (combination therapy, 
frequency of dosing, sensitivity of the micro-organism). 
Aminoglycosides have a significant postantibiotic effect against 
Gram-negative bacteria such as P.aeruginosa, E.coli, Klebsiella 
pneumoniae, Enterobacter cloacae and Acinetobacter calco-
aceticus (13). This permits less frequent (once or twice daily) 
dosing of aminoglycosides with no loss of activity. Very little data 
are available on the postantibiotic effect of aminoglycosides 
against Gram-positive bacteria, such as enterococci, pneumococci 
and staphylococci (13). 
Again it is unlogical to use the same trough levels with once daily 
dosing in comparison with 3 times daily use. Yet the reported 
trough levels in the Dutch hospitals are not different in the once 
daily, twice daily and 3 times daily groups. 
RELATIONSHIP BETWEEN ADJUSTING OF SERUM 
LEVELS AND CLINICAL EFFICACY 
Few well-designed studies are available that have evaluated the 
effectiveness of adjusting serum concentrations of aminoglycosides 
to improve the clinical efficacy (14, 15). No studies of this kind 
have been performed with once or twice daily dosing of 
aminoglycosides. 
Although it seems quite logical to adjust the dosage on the basis 
of low peak levels, a relation between dose adjustment and clinical 
efficacy is difficult to study, because aminoglycosides are always 
used in combination with other potent antimicrobial agents and 
because of differences in the susceptibility of the infecting micro-
organisms. If no dose modifications are performed, monitoring of 
aminoglycosides will be useless! 
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RELATIONSHIP BETWEEN SERUM LEVELS AND 
OTOTOXICITY 
Ototoxicity is the most serious complication of the use of 
aminoglycosides, because it is usually permanent and may cause 
disabling loss of hearing or impaired balance. It is usually, but not 
always, preceded by tinnitus or a feeling of fullness in the ears. 
The incidence of clinical ototoxicity ranges between 0.5 and 5% 
(15). Vestibular toxicity is seen most with gentamicin and auditory 
toxicity appears to be the highest for amikacin. Although some 
experimental studies suggest that netilmicin may be less toxic than 
other aminoglycosides, this has not been clearly demonstrated in 
comparative clinical studies (10). 
McCormack and Jewesson have reviewed the "evidence" of a 
relationship between high peak or trough levels of 
aminoglycosides and ototoxicity (1). A total of 7 retrospective 
studies was evaluated. None of these studies provided clear 
evidence of a relationship between aminoglycoside levels and 
ototoxicity. A correlation was found between the duration of 
treatment, the number of treatment courses with aminoglycosides, 
the total dose of aminoglycosides given, age and pre-existing renal 
function impairment and the risk of developing ototoxicity. If a 
patient has recieved previous courses with aminoglycosides or has 
an impaired renal function, the use of aminoglycosides should be 
avoided whenever possible. There is no convincing evidence to 
substantiate the use of trough levels below 2 mg/1 for gentamicin 
to prevent ototoxicity. 
Again absolutely no studies have been performed that investigate 
the relationship between aminoglycoside peak and trough levels 
and ototoxicity, using a once or twice daily dosage schedule. 
It is probably better to focus on a short duration of 
aminoglycoside therapy (3-5 days) than on specific serum levels to 
prevent serious ototoxicity. Daily control of early signs of 
ototoxicity (tinnitus, sense of fullness in the ears, headache, 
nausea, vertigo) may help to reduce (but not totally prevent) the 
risk of serious ototoxicity. If available, high tone audiograms are 
sensitive indicators of early hearing loss (10). 
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RELATIONSHIP BETWEEN SERUM LEVELS AND 
NEPHROTOXICITY 
Nephrotoxicity of aminoglycosides is clinically less important than 
ototoxicity. It is usually mild and transient in nature and is almost 
always reversible upon discontinuation of therapy. A total of 13 
studies on the relationship between aminoglycoside levels and 
nephrotoxicity has been reviewed (1). Some of these studies 
showed a significant difference between the trough levels of 
aminoglycosides in patients with or without relevant 
nephrotoxicity. This difference was much more marked in the final 
trough level (at the end of therapy) than in the initial trough level 
(at the start of therapy). In these studies it is at least as likely that 
the increased trough levels of aminoglycosides were caused by a 
reduced renal function as vice versa. No specific aminoglycoside 
level could be related to the development of nephrotoxicity. 
As is the case with the other items, no studies have been 
performed to document a relationship between peak and trough 
levels of aminoglycosides and the risk of nephrotoxicity with once 
or twice daily dosage. 
The best method to prevent nephrotoxicity is to minimize the 
duration of aminoglycoside therapy to 3-5 days and not to use 
these drugs in patients with pre-existing renal function impairment. 
A determination of beta-2 microglobulin is a sensitive marker of 
early nephrotoxicity, but it is not very specific (14). 
It is not completely clear whether trough levels of 
aminoglycosides are more informative to detect nephrotoxicity of 
these drugs than a routine determination of the serum creatinine 
level (1). 
HOW TO USE AND MONITOR AMINOGLYCOSIDES? 
In most Dutch hospitals, aminoglycosides have a role in the 
treatment of serious infections (probably) caused by Gram-
negative bacteria and in the treatment of endocarditis. They are 
used in combination with other broad-spectrum antimicrobial 
agents such as the penicillins and the second or third generation 
cephalosporins. An attractive aspect of this combination is the fact 
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that aminoglycosides and betalactam antibiotics are frequently 
synergistic, at least in-vitro. This synergy is most marked during 
the first 3 days of therapy. In-vivo synergy is not as convincing as 
in-vitro synergy, however (10). 
In most cases it will be possible to stop the use of 
aminoglycosides after 3-5 days and to maintain the patient on 
monotherapy with a broad spectrum antimicrobial drug, or (if the 
infective micro-organism has been identified and the sensivity 
pattern is known) with a specific agent. 
Underdosing of aminoglycosides should be avoided if their use is 
considered necessary. A total daily dose of 4-6 mg/kg in one or 
two daily dosages is advisable in the treatment of serious 
infections in patients with normal renal function. If the treatment 
duration is limited to 3-5 days, the risk of toxicity is low (16). It is 
not completely clear whether the monitoring of aminoglycosides 
offers any benefit if these drugs are used for no longer than 5 days 
and in combination with other broad-spectrum antimicrobial 
agents. 
Most Dutch hospitals (including my own) are using 
aminoglycosides on a twice daily basis, although virtually no 
literature of this dosage schedule is available! The literature on the 
safety and efficacy of once daily aminoglycosides is more 
convincing, although clinical experience is still limited. The twice 
daily dosage is a compromise between the well documented 3 
times daily regimen and the convenient once daily regimen, 
because most clinicians are reluctant to use aminoglycosides once 
daily (personal communications). 
Whenever possible aminoglycosides should be avoided in patients 
who run the risk for developing serious toxicity: pre-existing renal 
function impairment, elderly patients, recent previous treatment 
with aminoglycosides, ototoxic or nephrotoxic comedication, pre-
existing hearing problems (17). In almost all cases monotherapy 
with a third generation cephalosporin or a combination with a 
fluoroquinolone is a possible alternative in these patients. 
If a prolonged use of aminoglycosides is absolutely necessary, 
monitoring of these drugs might be indicated, but it must be 
remembered that the normal therapeutic range of aminoglycosides 
has not been clearly defined, especially with once or twice daily 
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dosing. It is advisable to aim at peak levels of at least 4-8 χ the 
MIC of the infecting micro-organism (18). In many hospitals 
MICs of bacteria cultured from patients on the intensive care are 
routinely available. The monitoring of aminoglycosides may be 
helpful to reduce the variability in serum levels after a standard 
dose. This is especially true in children, but no studies have been 
published defining a therapeutic range for aminoglycosides in 
children. Monitoring may also be useful in patients with ascites or 
in patients with cystic fibrosis to avoid underdosing. 
Future prospective studies on the monitoring of (once or twice 
daily) aminoglycosides in relationship to clinical efficacy and 
ototoxicity and nephrotoxicity must show whether this is a useful 
procedure. 
It is of importance to standardise sampling times of peak and 
trough levels in relation to dose and duration of treatment, e.g. 30 
min after the end of an intravenous infusion or 60 min after an 
intravenous bolus injection for peak levels and immediately prior 
to the next dose for trough levels, taken 24 to 48 h after the 
initiation of aminoglycoside therapy. 
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CHAPTER Χ 
FLUOROQUINOLONES 
Use of clinical data to aid formulary choice by the System of 
Objective Judgement Analysis (SOJA) method 
R. Janknegt 
Excerpt from Pharmacoeconomics 1994: in press 
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SUMMARY 
Fluoroquinolones are used in many hospitals for the treatment of 
complicated urinary tract infections, gastrointestinal infections, 
hospital acquired pneumonia and osteomyelitis. A review of the 
fluoroquinolones by the System of Objective Judgement Analysis 
(SOJA) method is presented. The following selection criteria were 
involved in the study: the number of registered indications, the 
number of dosage forms, the ratio between the area under the 
plasma concentration-time curve (AUC) and the MIC
 90, variability 
of the oral bioavailability, drug interactions, dosage frequency, 
equal dosage for oral and parenteral use, development of 
resistance, clinical efficacy, adverse events, cost and 
documentation. Both the oral and the parenteral formulation were 
included in the study. 
Ofloxacin shows the highest score, mostly because of the lower 
incidence of drug interactions, dosage frequency, cost and (relative 
to ciprofloxacin) a similar dosage for oral and parenteral use. 
Ciprofloxacin is the best documented drug. Pefloxacin shows the 
lowest SOJA score. 
Users of this method are free to determine the relative weight of 
the various selection criteria that they consider to be correct, 
although some of the criteria are internationally valid. 
Fluoroquinolones have gradually obtained an important place 
among the various antibiotics used in hospitals. A study conducted 
in 1991 demonstrated that only 16 out of 30 Dutch hospital 
antibiotic formularies included a quinolone (1). A study of 
antibiotic formularies published from 1991 to 1993 demonstrated, 
however, that quinolones were used in a wide range of infections. 
The indications for quinolones stated in these formularies are sum-
marised in Table 1. The percentage given in the formularies for 
the use of a quinolone in a certain type of infection is included in 
this table. Not every infection is included in each formulary. As to 
use in uncomplicated cystitis, quinolones are recommended in a 
number of formularies as drugs of first choice in patients who 
contract cystitis in the hospital. 
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TABLE 1 
INDICATIONS FOR FLUOROQUINOLONES IN 12 ANTIBIOTIC FORMULARIES, 
PUBLISHED IN 1991 TO 1993, USED IN 22 DUTCH HOSPITALS 
Infection 1st choice 2nd choice 
17% 
25% 
42% 
42% 
8% 
33% 
50% 
8% 
Urinary tract infections 
Cystitis 
Pyelonephritis 
Acute prostatitis 
Chronic prostatitis 
Gastrointestinal infections 
Typhoid fever 
Salmonellosis 
Shigellosis 
Salmonella carriers 
Travellers diarrhea 
Sepsis 
Salmonella spp 
Ρ aeruginosa 
unknown aetiology 
Pneumonia 
unknown aetiology 
Gram negative bacilli 
Ρ aeruginosa 
Osteomyelitis 
Salmonella 
Gram negative bacilli 
ENT infections 
Malignant otitis externa 
25% 
8% 
25% 
17% 
42% 
25% 
17% 
33% 
25% 
25% 
8% 
8% 
33% 
25% 
17% 
17% 
17% 
25% 
17% 
8% 
Most formularies, however, do not recommend routine use of 
quinolones as drugs of first choice in general practice. Norfloxacin 
was mostly used in the treatment of uncomplicated cystitis. 
Quinolones were mainly used in complicated urinary tract 
infections, gastrointestinal infections, pneumonia and 
osteomyelitis. 
A few years ago a review of possible selection criteria for fluoro­
quinolones was presented (2). On the basis of the current views on 
quinolones, a SOJA (System of Objective Judgement Analysis) 
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score (3) has been calculated for these agents. Norfloxacin, which 
is only used in urinary tract infections, was not scored. 
SELECTION CRITERIA 
A review of the selection criteria and assigned weighting factors is 
presented in Table 2. 
TABLE 2 
SELECTION CRITERIA AND WEIGHTING FACTORS FOR FLUOROQUINOLONES 
Criterion Weighting factor 
Number of approved indications 20 
Number of formulations 10 
AUC/MICW ratio 120 
Variation in bioavailability 20 
Interactions 50 
Dosage frequency 60 
Number of tablets/injections per day 10 
Identical oral/parenleral dose 10 
Development of resistance 60 
Efficacy 280 
Tolerability 200 
Acquisition cost 100 
Documentation 60 
Total 1000 
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Number of indications 
The number of registered indications is a good measure of the 
applicability and documentation of the quinolones. The percentage 
of the maximum score for approved indications was obtained as 
follows: Urinary tract infection (20), prostatitis (10), gonorrhoea 
(10), meningitis (10), respiratory tract infections (10), sepsis (10), 
gastrointestinal infections (10), skin/soft tissue infections (10), 
infections in immunocompromized patients (10). 
Number of formulations 
The second criterion is the number of formulations. A liquid oral 
administration form has advantages for patients with swallowing 
complaints. When various oral tablet doses are available, 
increasing or reducing the dosage becomes easier, without having 
to break tablets. 
The score is obtained by adding all relevant percentages of the 
maximal score as follows: at least one injectable or tablet/capsule 
strength (60), two or more strengths (20), liquid oral form(20). 
AUC/MIC ratio 
The number of possible pharmacokinetic and microbiological 
selection criteria which could play a role in the choice of an 
antibiotic, is extremely high. They include bioavailability, first-
pass effect, protein binding, tissue concentrations, metabolism, 
renal elimination, half-life, area under the plasma concentration-
time curve (AUC), minimal inhibitory concentration (MIC), 
antimicrobial spectrum and post antibiotic effect, and many others. 
The relative importance of each selection criterion, however, is 
difficult to interpret. Pharmacokinetic and microbiological 
selection criteria can not be evaluated separately. 
Animal experiments have demonstrated that the AUC/MIC ratio 
has good predictive value for the clinical efficacy of fluoroquino-
lones (4). A ratio of at least 40 is desirable for clinical efficacy. 
That is why so few separate pharmacokinetic or microbiological 
selection criteria have been included in this SOJA score. Instead, 
the AUC/MIC ratio, to which a relatively heavy weight has been 
assigned in the evaluation of quinolones, has been used. There are 
differences in tissue penetration among ciprofloxacin, ofloxacin 
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and Pefloxacin, but these are generally small and do not have any 
known consequences for the clinical efficacy of or resistance to 
these agents. Tissue penetration is, therefore, not included in the 
SOJA score. 
Variation in bioavailability 
Variation in bioavailability is the only pharmacokinetic selection 
criterion which is included in the score. A therapy may fail 
because of great differences in bioavailability and incomplete 
absorption. The score is based on the mean bioavailability of the 
fluoroquinolones after oral administration. If the bioavailability is 
nearly 100%, the maximal score is given for this criterion, and the 
relative score is proportional to the mean bioavailability. This 
criterion obviously does not play a role in the injection form. 
Drug interactions 
Drug interactions with fluoroquinolones have been described 
regularly in the literature. Interactions play a role only in patients 
who, in addition to a fluoroquinolone, are given other agents 
known to interact, such as theophylline, antacids, sucralfate or iron 
salts. The SOJA score should first be seen as a formulary 
decisionmaking model. Other patient-related selection criteria also 
play an important role in the choice of individual therapy. The 
evaluation of drug interactions takes into account the frequency 
and severity with which these interactions occur. 
Dosage frequency 
Dosage frequency is a great deal less important in short-term 
treatments, such as antibiotic treatment, than in chronic treatments, 
such as for hypertension. This criterion, therefore, carries a 
relatively lower weight than in the SOJA score for beta blockers 
(5). The score for the dosage frequency was determined as 
follows: once daily (100), once-twice daily (90), twice daily (80), 
3 times daily (40), 4 times daily (10). 
Number of tablets per day 
In addition to dosage frequency, the number of tablets which must 
be taken each day also plays a (minor) role in the patient's 
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comfort. If the daily dosage consists of 1 tablet, 100% of the 
maximal score is awarded. One or two tablets per day yield 90% 
of the maximal score, 2 tablets daily 80%; and 50% is given if 
more than two tablets have to be swallowed each day. A similar 
score is given to the number of injections which must be prepared 
and administered each day. In addition, 20% of the maximal score 
is deducted when a dose increase involves breaking tablets (for 
example, ofloxacin 300 mg twice daily). 
Identical parenteral/oral dosage 
Identical dosages in parenteral or oral use of drugs is "physician-
friendly" and reduces the risk of mistakes. This criterion is not 
very important, which is why it is only awarded 10 points. Those 
preparations for which the oral and parenteral dosage is the same, 
are awarded 100% of this score. When the oral and parenteral 
dosages differ, no points are given. 
Resistance development 
Development of resistance is always an important selection 
criterion for antibiotics, although it is often difficult or even 
impossible to establish differences in the extent of resistance 
development within a group of antibiotics. The evaluation of 
resistance development has considered results of in-vitro studies as 
well as clinical resistance development in (large-scale) use of 
fluoroquinolones. 
Efficacy 
Clinical efficacy is always the most important selection criterion 
for any group of drugs. In general, the differences in efficacy 
among representatives of the same pharmacotherapeutic group are 
small (5-7). To evaluate this criterion, comparative studies with 
other antibiotics, in a wide range of infections were mainly used 
as well as well-designed, noncomparative studies. Comparative 
studies between quinolones have been very rare. Up to 280 points 
(100% cure for all applications) were assigned for this criterion. 
The score per quinolone has been established on the basis of 
relative cure rates in the major indications. 
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Adverse effects 
The extent and severity of adverse effects is another important 
selection criterion for drugs. The importance of this criterion has 
been increased by the fact that the new fluoroquinolone, tema-
floxacin, has recently been taken off the market because of serious 
adverse effects, such as haemolytic uraemic syndrome and severe 
allergic reactions (8). The evaluation of adverse effects has been 
based on the results in comparative studies, the overall results in 
phase III and phase IV studies, and on post-marketing surveillance 
data. The comparison of incidence and severity of adverse effects 
is complicated by the fact that data from different countries cannot 
be compared directly. There are always fewer reported adverse 
effects in Japan than in Europe, and the number of adverse effects 
is greatest in the US (9). 
Acquisition cost 
The acquisition cost of antibiotics is an important criterion, 
because antibiotics constitute a considerable part of the total cost 
of drugs used in the hospital. The comparison has been based on 
the official wholesale prices. In case of ciprofloxacin, 250 mg 
tablets were used. The 500 and 750 mg tablets (on a mg basis) are 
much more expensive, and are not entirely reimbursed by the GVS 
(Geneesmiddelenvergoedingssysteem - system for the reimburse-
ment of costs of drugs). In view of the high cost of the injection 
form, oral administration should be used whenever possible. The 
evaluation of oral administration cost has been based on the 
dosage generally used in systemic infections. 
The cheapest oral quino lone (reimbursement price per day 
according to the official price list) was assigned 100% of the total 
score (100 points). With every 1% increase in price of a product 
in comparison to this agent, 1% of the maximal score is deducted. 
The cheapest parenteral agent was given only 40% of the maximal 
score, due to the relatively high cost of the parenteral 
formulations. For every guilder increase in cost 1% is deducted 
from the score. 
The final cost for individual hospitals depends, however, on the 
bargaining results with the companies concerned. This price can 
differ considerably from the official price. However, this cannot be 
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included in the SOJA score, because these prices vary from 
hospital to hospital. 
Documentation 
It is not easy to determine a "firm" score for the documentation of 
a drug. The evaluation of the documentation in this score has 
mainly been based on the available comparative and non-
comparative clinical studies, both qualitative and quantitative. Data 
on adverse effects and results of post-marketing surveillance have 
also been used, as well as available data on bacteriology, phar-
macokinetics, resistance development and drug interactions. 
DESCRIPTION OF THE SOJA SCORE 
Number of indications 
The indications for quinolones registered in the Netherlands are 
presented in Table 3. This table demonstrates that pefloxacin has 
considerably fewer indications than ciprofloxacin or ofloxacin. The 
evaluation of the indications is complicated by the fact that the 
patient package inserts of the various agents do not correspond. 
On the basis of the number of indications registered, cipro-
floxacin and ofloxacin are assigned 14 points (70% of the maxi-
mum score) and pefloxacin 6 points (30% of the maximum sore). 
Number of formulations 
On the basis of the above-mentioned considerations, cipro-
floxacin, of which 3 tablet concentrations (250 mg, 500 mg and 
750 mg) and two infusion solutions (100 mg in 50 ml and 200 mg 
in 100 ml) are available, as well as an injection concentrate of 100 
mg, is assigned 10 points for the parenteral formulations and 8 
points for the oral forms. 
Ofloxacin, of which 200 mg and 400 mg tablets are available, as 
well as three infusion solutions (100 mg, 200 mg and 400 mg), is 
also assigned 10 and 8 points, respectively. 
Pefloxacin is available as 400 mg tablets and 400 mg in 5 ml 
injections. Pefloxacin injection must be added to an infusion 
solution prior to use, thus leading to extra work and cost (10). 
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TABLE 3 
APPROVED INDICATIONS IN THE NETHERLANDS FOR CIPROFLOXACIN (C), 
OFLOXACIN (O) AND PEFLOXACIN (Ρ). 
Indication О 
Urinary tract infections 
Renal Infections 
Gonorrhoea 
Lower respiratory tract infections 
Higher respiratory tract infections, 
caused by Ρ aeruginosa 
Gastrointestinal infections 
Shigella dysentery 
Serious S typhi infections 
Sepsis 
Skin and soft tissue infections 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
Infection prophylaxis in 
patients with granulocytopenia 
Pefloxacin is therefore assigned 6 points for both the oral and 
parenteral form. 
AUC/MIC90 ration 
The AUC/MIC90 ratio for the 3 fluoroquinolones is presented in 
Table 4. Some differences obviously exist in both pharmaco­
kinetics and in-vitro activity. The values presented in Table 4 are 
mean values of several studies, in which all 3 quinolones were 
studied simultaneously (11-20). 
An AUC/MIC ratio of 40 or higher has been associated with good 
clinical efficacy, whereas lower ratio may result in a higher 
incidence of therapeutic failures (21). 
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TABLE 4 
AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE TO MINIMUM 
CONCENTRATION INHIBITORY TO 90% OF TESTED STRAINS (AUC/MICM) RATIO 
FOR CIPROFLOXACIN (C), OFLOXACIN (O) AND PEFLOXACIN (Ρ) 
Pathogen C O P 
Citrobacter spp 
Enterobacter spp 
Escherichia colt 
Klebsiella spp 
Proteus spp 
Providencia spp 
Salmonella spp 
Serratia spp 
Shigella spp 
Haemophilus influenzae 
Neisseria gonorrhoe 
Pseudomonas aeruginosa 
Staphylococcus aureus 
Streptococcus pneumoniae 
Enterococcus faecalis 
80 
40 
80 
80 
160 
40 
320 
40 
320 
640 
1280 
20 
10 
5 
5 
40 
40 
80 
80 
160 
20 
160 
40 
160 
640 
1280 
10 
20 
10 
5 
30 
60 
60 
60 
120 
30 
240 
60 
480 
960 
1920 
15 
30 
4 
8 
The AUC/MIC ratio following oral administration of ofloxacin is 
somewhat lower than that of Pefloxacin and ciprofloxacin for a 
number of Enterobacteriaceae. 
The differences are usually not very clinically relevant, because 
the AUC/MIC ratio for the majority of bacteria is very high except 
for Providencia spp. and P.aeruginosa. The AUC/MIC ratio of all 
quinolones for Gram-positive bacteria is considerably lower than 
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that for Enterobacteriaceae. Ofloxacin scores similarly or better 
than ciprofloxacin for these bacteria. 
None of the fluoroquinolones shows an ideal AUC/MIC ratio, the 
ratio for Providencia spp., Serratia spp. , P. aeruginosa and Gram-
positive cocci is relatively low. On the basis of these numbers, ci-
profloxacin and pefloxacin are awarded 75% of the maximal score 
(90 points), and ofloxacin 70% of the maximal score (84 points). 
The situation is different for parenteral administration. The 
registered parenteral dosages, especially for ciprofloxacin, are 
relatively low in comparison with those used in other countries. 
The AUC/MIC ratio of 200 mg twice daily ciprofloxacin intrave-
nously is lower than the score with 500 mg twice daily orally. 
Compared to the bioavailability of approximately 70% of oral 
ciprofloxacin, the AUC/MIC ratio of the intravenous form is lower 
than the oral form by almost a factor of 2. 
Intravenous pefloxacin scores the highest, followed by ofloxacin. 
The AUC/MIC ratio is almost identical to the ratio following oral 
administration. Ciprofloxacin has the lowest AUC/MIC ratio. 
Pefloxacin scores 75% (90 points) for this criterion, ofloxacin 70% 
(84 points) and ciprofloxacin 60% (72 points). 
Variation in bioavailability 
Both ofloxacin and pefloxacin are absorbed almost completely; 
bioavailability is between 90 and 100%. The bioavailability of 
ciprofloxacin shows greater variation; mean bioavailability is 
between 50 and 85% (17-20). The importance of the lesser 
bioavailability of ciprofloxacin is, as far as is known, not very 
great. No mention has been made that treatment with cipro-
floxacin has failed because of insufficient absorption, except for 
when interactions have occurred with antacids, for example. 
Ofloxacin and pefloxacin score 100% (20 points) for this cri-
terion, and ciprofloxacin 75% (15 points). It goes without saying 
that all agents score 100% (20 points) if administered intra-
venously. 
Drug interactions 
Drug interactions which may occur with fluoroquinolones are 
summarised in Table 5. 
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TABLE 5 
DRUG INTERACTIONS 
Drug С О 
Theophylline (Th) 
Decrease in Th clearance 18-32% 4-12% 18-31% 
Increase in Th AUC 22-86% 4-11% 19-87% 
Caffeine (Ca) 
Decrease in Ca clearance 36-46% 0% 
Increase in Ca AUC 60-65% 0% 
Antacids 
Reduction in bioavailability 84-91% 22-66% 55% 
of qumolone 
Iron salts 
Reduction in bioavailability 42-63% 11-36% 
of qumolone 
Calcium salts 
Reduction in bioavailability 0-36% 0% — 
of qumolone 
Sucralfate 
Reduction in bioavailability 90-95% 60-70 
of qumolone 
Compiled from references 22-26 
С ciprofloxacin О ofloxacin 
Ρ Pefloxacin — no data avalable 
The degree of the interaction between either ciprofloxacin or 
Pefloxacin with theophylline varies greatly and also depends on 
the quinolone dosage. 
Milk and yoghurt do not affect the absorption of ofloxacin (27), 
but the bioavailability of ciprofloxacin was reduced by 30-36% 
when these dairy products were taken simultaneously (28). 
In Japan a number of cases have been reported in which convul­
sions occurred following the use of enoxacin with the fenbufen 
(neither agent is available in the Netherlands). This effect was 
most pronounced with enoxacin and least pronounced with ofloxa-
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ein (of the quinolones discussed in this article) (29). Within the 
framework of post-marketing surveillance, possible interactions of 
ofloxacin with various NSAIDs were studied. There is so far no 
evidence of an increased risk of adverse effects on the central 
nervous system of ofloxacin and NSAIDs used in combination 
(30). 
No detailed information is available on ciprofloxacin and Pe-
floxacin, but so far, there is no indication of a clinically relevant 
interaction with NSAIDs. 
On the basis of its more favourable interaction profile, ofloxacin is 
awarded 80% of the maximal score (40 points). Ciprofloxacin 
scores 50% of the maximal score (25 points), its interactions being 
more numerous and more serious. Relatively few data on 
Pefloxacin are available. On the basis of the disadvantage of 
doubt, pefloxacin also scores 25 points. 
Interactions with antacids, iron salts and sucralfate do not play a 
role following iv administration. Ofloxacin has no relevant interac-
tions following iv administration and scores 100% (50 points). 
Ciprofloxacin and pefloxacin score 80% (40 points). 
Dosage frequency 
The recommended dosage frequency of ofloxacin is once daily. 
The once daily dosage of ofloxacin, however, has not yet been 
approved for all indications. It has only been approved for mild to 
moderate respiratory infections and uncomplicated urinary tract 
infections. The other two quinolones should be administered twice 
daily. A twice daily dosage of ofloxacin is used in most clinical 
studies. Since ofloxacin is usually given twice daily in practice, 
despite the fact that once daily dosing has been approved, 
ofloxacin is awarded 90% (54 points). Both ciprofloxacin and 
pefloxacin score 80% (48 points) for this selection criterion. 
Number of tablets per day 
Because in the Netherlands the price of 500 mg and 750 mg 
ciprofloxacin tablets is a great deal higher in comparison with the 
same daily dose in 250 mg tablets, a twice daily dosage of two 
250 mg tablets is generally used. The daily dose of ofloxacin (400 
mg) can be taken as one single tablet in respiratory infections and 
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urinary tract infections. The daily pefioxacin dose (800 mg) can be 
taken in two tablets. Conversely, higher dosages are often used in 
more serious infections; 750 mg twice daily ciprofloxacin or 300 
mg twice daily ofloxacin, for example. In this case, ciprofloxacin 
again has an advantage over the other agents, because the tablets 
do not have to be broken. Ofloxacin is awarded 70% (90% minus 
20% for breaking tablets) of the total score (7 points) for this 
criterion, pefioxacin 60% (6 points) and ciprofloxacin 50% (5 
points) on this basis. 
Ofloxacin may be given as a single injection of 400 mg, although 
the experience with this form is still limited. Two injections must 
be given for ciprofloxacin and pefioxacin. Ofloxacin scores 90% 
(9 points) for the parenteral form, whereas the other quinolones 
are awarded 80% (8 points). 
Identical parenteral/oral dosage 
The oral and parenteral dosages of both ofloxacin and pefioxacin 
are identical. Both agents score 100% (10 points). The parenteral 
dosage of ciprofloxacin differs from the oral dosage. It is 
noteworthy that the parenteral dosage (200 mg twice daily) is 
relatively low compared to the oral dosage of 500 mg twice daily. 
The bioavailability of oral ciprofloxacin is on average 70%. This 
is also expressed by a relatively low AUC/MIC^ ratio for the 
parenteral dosage. Ciprofloxacin scores no points for this criterion. 
Development of resistance 
Because of the rapid development of resistance as often occurs 
with nalidixic acid, much attention has been paid to the possible 
development of resistance to the fluoroquinolones during their 
development. 
Quinolones have the advantage that plasmid-bound resistance 
development does not occur. If resistance occurs, it is often caused 
by chromosomal mutations. 
The two major resistance mechanisms against fluoroquinolones are 
changes in bacterial DNA gyrase and in the extent of penetration 
into the bacterial cell. The first resistance mechanism leads to 
high-level resistance and full cross-resistance among the 
fluoroquinolones themselves (31). The second mechanism often 
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leads to a relatively low-level resistance and possibly also to the 
development of cross-resistance with betalactam antibiotics (32). 
The frequency of spontaneously resistant mutants of Enterbac-
teriaceae, P.aeruginosa and S. aureus at a quinolone concentration 
of 4-10 times the MIC is < 10'8. Substantial differences in the 
frequency of spontaneous mutants among ciprofloxacin, ofloxacin 
and Pefloxacin do not appear to exist (16, 33, 34). Large-scale use 
of fluoroquinolones in human and veterinary infections has led to 
a slow but steady increase in resistance against these agents. Thus, 
the introduction of enrofloxacin (a derivate of ciprofloxacin) in the 
poultry sector was accompanied in our country by an increase in 
resistance of Campylobacter spp. to fluoroquinolones in both poul-
try and human isolates (35). 
Initially, resistance development in hospitals mainly involved 
S.aureus and P.aeruginosa (36). However, more resistant En-
terobacteriaceae are increasing gradually, especially in Southern 
Europe, but also in countries in which fluoroquinolones are used 
on a large scale in general practice, such as in Germany (37, 38). 
A restrained use of quinolones in infections which can also be 
treated with other groups of antibiotics, such as uncomplicated 
urinary tract infections or bronchitis, for example, is recom-
mended in order to prevent increased resistance development. 
There are no indications of mutual differences in the extent of 
resistance development among ciprofloxacin, ofloxacin or Pe-
floxacin. AU agents therefore score 70% of the maximal score (42 
points) for this selection criterion. 
Efficacy 
The clinical efficacy of fluoroquinolones has been demonstrated in 
numerous comparative and non-comparative clinical studies. The 
number of studies with ciprofloxacin especially, is impressive. 
Not all infections were included in the clinical efficacy evaluation. 
The efficacy of all fluoroquinolones is very high in uncomplicated 
lower urinary tract infections and there are no differences in 
efficacy among the various agents. In addition, fluoroquinolones 
are not drugs of choice for this indication. 
The results of the treatment of infections with fluoroquinolones are 
summarized in Table 6. 
152 
TABLE 6 
REVIEW OF CLINICAL EFFICACY 
Lower respiratory tract 
infections 
Cystic fibrosis 
Osteomyelitis 
Complicated urinary 
tract infections 
Prostatitis 
Gonorrhoea 
Chlamydia infections 
Skin/soft tissue 
infections 
Typhoid fever 
Ciprofloxacin 
Cure rates 
clin bact 
88% 83% 
94% 
57-84% 
73-91% 75-97% 
58-80% 75-100% 
100% 
46-72% 
77% 78% 
97% 
Ofloxacin 
Cure rates 
clin bact 
88% 
93% 
70% 
87% 
100% 
81% 
76-86% 
75% 
100% 
95% 
92% 
Pefloxacin 
Cure rates 
clin bact 
82% 81% 
86% 
86% 
100% 
76% 68% 
96% 
clin 
bact 
From references 39-84 
clinically cured or markedly improved 
bacteriologically cured: eradication of the infecting micro-organism 
Although there are great differences in the number of clinical 
studies done with ciprofloxacin or pefloxacin, there are no 
significant differences in clinical efficacy among the 3 quinolones, 
with the single exception of ofloxacin which is more effective in 
the treatment of Chlamydia infections. This indication, however, is 
not an important indication for quinolones. On the basis of the 
results in the infections presented in Table 6, all quinolones are 
awarded 85% of the maximal score (240 points). 
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Adverse effects 
The adverse effect profiles of ciprofloxacin and ofloxacin have 
been extensively documented in both phase III and phase IV 
studies. The methodologies of both studies were comparable. 
General practioners and specialists were asked to complete questi­
onnaires on efficacy and adverse effects in order to leam about 
their prescribing habits. No such study has been done with 
Pefloxacin (85). 
The adverse effects of ciprofloxacin, ofloxacin and Pefloxacin 
during phase III studies have been summarized in Table 7 as well 
as phase IV studies of ciprofloxacin and ofloxacin. These numbers 
cannot be compared directly due to dosage variation and the 
countries in which the studies were done. 
TABLE 7 
ADVERSE EFFECTS (%) OF CIPROFLOXACIN (C), OFLOXACIN (О) AND 
PEFLOXACIN (Ρ) DURING PHASE 3 AND PHASE 4 STUDIES 
No. of patients 
Phase 
Dose (g) 
Gastrointestinal 
CNS 
Cardiovascular 
Skin 
Metabolic 
Miscellaneous 
С 
9,473 
3 
0.2-2 
4 2 
1 4 
0.2 
1 1 
4 4 
1.6 
С 
12,404 
4 
47 
1.4 
04 
0.8 
29 
О 
13,717 
3 
0.3-0.6 
1 9 
0.7 
0.1 
04 
О 
28,889 
4 
52 
29 
0.2 
1.0 
0 3 
Ρ 
1,181 
3 
0.8 
5.6 
0.9 
2.2 
The use of fluoroquinolones in children is still limited, because 
cartilage abnormalities were found in young dogs (86). 
Studies in children concentrate, therefore, on effects on cartilage. 
Adverse effects in children are best documented for ciprofloxacin. 
Adverse effects occurred in 12.6%. Arthralgia occurred in 8 of 
634 children under 18 years (1.3%) (87). None of 37 children with 
mucoviscoidosis treated with ofloxacin developed arthralgia. 
Arthralgia occurred in 9 of 63 children treated with Pefloxacin 
(85). 
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Although the adverse effect profiles of the quinolones are not 
identical, there are no indications of major differences in degree or 
incidence of adverse effects between ciprofloxacin and ofloxacin. 
Much less data are available on pefloxacin. It appears from the 
limited data that skin reactions in adults and arthralgia in children 
occur more frequently with pefloxacin than with ciprofloxacin or 
ofloxacin. 
The number of comparative studies of the individual quinolones is 
too small and the studies are too small-scale to permit con-
clusions about relative tolerance. 
Ciprofloxacin and ofloxacin are awarded 70% of the maximal 
score (140 points) and pefloxacin 65% (130 points) for this 
selection criterion, due to the somewhat higher incidence of side 
effects and the poorly documented side-effects profile. 
Acquisition cost 
The daily price (reimbursable price according to KNMP Taxe) of 
the three quinolones is presented in Table 8. 
Oral ofloxacin and pefloxacin are equally expensive. 
Ciprofloxacin, given as two 250 mg tablets twice daily, is more 
expensive by NLG 1,67 per day. When 500 mg tablets are used, 
the difference is much greater. 
TABLE 8 
DAILY COST (NLG) 
Ciprofloxacin two 250 mg tablets twice daily 9 92 
one 500 mg tablet twice daily 12 32 
200 mg IV twice daily 118 92 
Ofloxacin two 200 mg tablets daily 8 26 
400 mg IV daily 116 10 
Pefloxacin one 400 mg tablet twice daily 8 26 
400 mg IV twice daily 125 30* 
including NLG 6 00 voor infusion fluid 
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The oral administration form of ofloxacin and Pefloxacin is 
awarded 80% (80 points) and ciprofloxacin, which costs 20% 
more scores 60% (60 points). 
The parenteral form of the fluoroquinolones is very expensive 
(relatively speaking), when compared with the oral form. The 
differences in cost of the parenteral formulations are very small, 
certainly in proportion to the high cost. Pefloxacin is only avail-
able as a 400 mg dose, which is a disadvantage when higher 
dosages must be used. In addition, it must be added to an infusion 
solution prior to use. A supplement of NLG 6.00 per day has been 
added to the cost for this. This cost of the 100 mg injection of 
ofloxacin is half the price of the 200 mg injection form. The 100 
mg form of ciprofloxacin is relatively expensive: NLG 35.00 per 
injection vs. NLG 29.50 for ofloxacin. Ofloxacin injection is 
awarded 40% (40 points), ciprofloxacin injection 37% (37 points), 
and Pefloxacin injection 30% (30 points). 
Documentation 
• Oral administration 
The number of comparative studies between ciprofloxacin, 
ofloxacin and/or Pefloxacin is very small, making a direct com-
parison of their relative efficacy and tolerability impossible. Docu-
mentation on ciprofloxacin is impressive. It largely surpasses the 
other two quinolones, especially pefloxacin, in the number of 
bacteriological as well as clinical studies. As ciprofloxacin is often 
considered to be the standard quinolone in in-vitro studies as well 
as in clinical studies, the documentation on this agent increases 
even more. Ciprofloxacin shows, therefore, the highest score, 95% 
of the maximal (57 points). 
Ofloxacin is also well documented, but not to the same extent as 
ciprofloxacin. The clinical documentation is lacking with regard to 
the use of ofloxacin in nosocomial pneumonia, mucoviscidosis, 
gastrointestinal infections, sepsis and malignant otitis externa. 
Ofloxacin is the most extensively documented agent of the three 
with regard to adverse effects. Ofloxacin scores 80% of the 
maximal score (48 points) for documentation. 
Pefloxacin is the least documented of all three quinolones. Its 
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documentation is of less value than that of ciprofloxacin or 
ofloxacin in all fronts. This is also manifest by the limited number 
of approved indications for Pefloxacin. The clinical documentation 
of Pefloxacin especially, clearly leaves room for improvement. 
There are still insufficient data available on its efficacy in 
respiratory infections, mucoviscidosis, osteomyelitis, prostatitis, 
Chlamydia infections, skin and soft tissue infections and gastroin-
testinal infections. In addition, the post-marketing surveillance of 
adverse effects leaves much to be desired in comparison with the 
other two drugs. Pefloxacin scores 30% (18 points) for documen-
tation. 
• Parenteral administration 
There is less documentation on the parenteral forms than on the 
oral forms. The number of studies and the number of patients 
treated is only a fraction of the number for oral administration. 
All three quinolones are arbitrarily awarded 10% less than for the 
oral administration: ciprofloxacin 51 points, ofloxacin 42 points 
and Pefloxacin 9 points. 
CONCLUSIONS 
The SOJA scores of the oral and parenteral administration forms 
of the quinolones are presented in Tables 9 and 10. 
The scores for the oral dosage forms are higher than those for the 
parenteral formulations, due to the higher cost and the poorer 
documentation of the injections in comparison with the oral forms. 
Ofloxacin scores higher than the other two quinolones, because of 
drug interactions, dosage frequency, acquisition cost and (with 
regard to ciprofloxacin) identical oral and parenteral dosage. 
The advantage of ciprofloxacin is excellent documentation. In 
addition, ciprofloxacin has a favourable score compared to 
Pefloxacin with regard to the number of approved indications and 
the number of formulations. Pefloxacin does not have any marked 
advantages or disadvantages over the other quinolones. Pefloxacin 
looses points especially with regard to documentation and, as a 
result, number of approved indications. 
157 
TABLE 9 
SOJA SCORE FOR ORAL FLUOROQUINOLONES 
Criterion C O Ρ 
Number of approved indications 
Number of formulations 
AUC/MIG,, ratio 
Variation in bioavailability 
Interactions 
Dosage frequency 
Number of tablets per day 
Identical oral/parenteral dose 
Development of resistance 
Efficacy 
Tolerability 
Acquisition cost 
Documentation 
14 
g 
90 
15 
25 
48 
5 
0 
42 
240 
140 
80 
57 
14 
8 
84 
20 
40 
54 
7 
10 
42 
240 
140 
100 
48 
6 
6 
90 
20 
25 
48 
6 
10 
42 
240 
130 
100 
18 
The score presented here is specific for the Dutch situation. To 
make it more internationally applicable, the scores have been 
expressed as a percentage of the maximal score. Of course, every 
user of this method is free to determine the relative weight of the 
various selection criteria considered to be correct. Several criteria 
are internationally valid: AUC/MIC ratio, variation in bioa­
vailability, drug interactions, identical oral and parenteral dose, 
development of resistance, efficacy, tolerance and documentation. 
Other criteria are country and time-dependent: number of approved 
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indications, number of formulations, dosage frequency, number of 
dosage units per day and cost. 
On the basis of these results, our hospital has decided to use 
ofloxacin as the fluoroquinolone of choice. 
TABLE 10 
SOJA SCORE FOR PARENTERAL FLUOROQUINOLONES 
CriterioD C O P 
Number of approved indications 
Number of formulations 
AUC/MICW ratio 
Variation in bioavailability 
Interactions 
Dosage frequency 
Number of vials per day 
Identical oral/parenteral dose 
Development of resistance 
Efficacy 
Tolerability 
Acquisition cost 
Documentation 
Total 
14 
10 
72 
20 
40 
48 
8 
0 
42 
240 
140 
37 
51 
722 
14 
10 
84 
20 
50 
54 
9 
10 
42 
240 
140 
40 
42 
755 
6 
6 
90 
20 
40 
48 
8 
10 
42 
240 
130 
30 
9 
679 
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SUMMARY 
The pharmacokinetic, economic and practical aspects of se-
quential therapy with iv and oral cephalosporins are reviewed. 
New broad spectrum oral cephalosporins, such as Cefixime, Cefpo-
doxime proxetil and Cefetamet pivoxil achieve serum concentra-
tions above the MICs for most Enterobacteriaceae for at least as 
long as is for parenteral cefuroxime. Substantial cost reductions 
are possible with an early switch from iv to oral cephalosporins. 
The clinical studies that have been performed so far have impor-
tant shortcomings. Well designed clinical studies are necessary to 
prove the feasibility of sequential therapy with cephalosporins for 
serious infections in hospitalised patients. 
INTRODUCTION 
It is common hospital practice to start antimicrobial therapy of 
serious infections with iv antibiotics. Most clinicians change to 
oral antibiotics as soon as the condition of the patient is improved 
and oral treatment is possible, a practice which may be referred to 
as sequential, step-down or follow-on therapy. Drugs such as 
amoxycillin, flucloxacillin, co-trimoxazole, fluoroquinolones and 
doxycycline may be used in this way. Oral bioavailability of the 
latter three agents is high. Both penicillins however are incom-
pletely absorbed after oral administration, for amoxycillin 75% in 
healthy subjects, but less effectively in ill patients and for 
flucloxacillin, 55%. Furthermore the oral doses (usually 500 mg 3 
times daily) may be lower than intravenous dosage (1 g 4 times 
daily), despite their incomplete absorption. Higher oral dosages are 
poorly tolerated. Very few studies have investigated the safety and 
efficacy of sequential therapy with penicillins or other antibiotics. 
The few studies that have been published were performed in chil-
dren (1-3). 
Several potent oral cephalosporins, such as cefuroxime axetil, 
Cefpodoxime proxetil and Cefixime have recently been introduced. 
These drugs have a good in-vitro activity against a broad range of 
Gram-negative bacteria and are therefore potentially useful as a 
sequential oral therapy following treatment with intravenous 
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cephalosporins, such as cefuroxime and cefotaxime. In this article 
the theoretical and practical aspects of such therapy and clinical 
implications are reviewed. 
PHARMACODYNAMIC CONSIDERATIONS 
Betalactam antibiotics have almost always been given as intermit-
tent doses. This concept was based on the idea that some bacterial 
regrowth was necessary to obtain bactericidal activity. Therefore, 
the usual dosage schedules for most of these antimicrobial agents 
were 3 or 4 times daily, despite the relatively short half-lives of 
the penicillins and cephalosporins. 
This traditional approach to the antibacterial action of betalactams 
is now being questioned. It has become clear from animal 
experiments that the most reliable predictor of betalactam in-vivo 
activity is the period during each dosage interval when the 
antibiotic serum concentration exceeds the MIC for the infecting 
micro-organism (4). The very high initial serum concentrations 
obtained after iv injection do not seem to contribute to the in-vivo 
activity of betalactams. The rate and extent of bactericidal activity 
of betalactam antibiotics apparently do not greatly improve with 
increasing concentration, provided that MICs for pathogens are 
exceeded. Also, betalactam antibiotics do not possess a marked 
post-antibiotic effect against Enter-obacteriaceae, and therefore 
these bacteria will start to multiply almost immediately after the 
serum concentration has fallen below the MIC. 
In treatment of Klebsiella pneumonia in neutropenic rats, Roos-
endaal et al. (5) showed that a continuous infusion of ceftazidime 
was much more effective than the same daily dose given as three 
iv injections. Interpretation of these results, must take into 
consideration that the half-life of ceftazidime in rats (30 min) is 
much shorter than in man. 
The potential of sequential therapy with iv followed by oral 
cephalosporins depends on the pharmacodynamics of iv and oral 
cephalosporins, in particular that the serum concentration should 
exceed the MICs for most common pathogens over a 24 h period. 
These data are presented in Tables 1 and 2. 
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TABLE 1 
MIC„ OF CEPHALOSPORINS 
Cefuroxime Cefpodoxime Cefixime Cefetamet Cefotaxime 
E coli 
Klebsiella spp 
Enterobacter spp 
Citrobacter 
Serratia 
Shigella 
Ρ mirabilis 
Ρ vulgaris 
Mmorgamt 
Providencia spp 
Salmonella 
Yersinia 
Η influenzae 
Mcatarrhalis 
S aureus 
S pyogenes 
Spneumoniae 
2 
2 
4 
2 
64 
2 
2 
64 
64 
2 
2 
4 
1 
0 5 
1 
0 008 
0015 
0 25 
0 12 
1 
1 
2 
0 25 
0 06 
0 03 
05 
0 12 
0 25 
1 
0 06 
0 25 
2 
0 008 
0 03 
0 25 
0 06 
1 
1 
05 
2 
0 03 
0 03 
2 
0 03 
0 12 
4 
0 12 
0 12 
16 
05 
05 
0 5 
0 12 
2 
1 
1 
0 25 
0 06 
0 12 
1 
0 06 
0 5 
1 
0 12 
1 
32 
0 06 
0 25 
0 06 
0 06 
0 25 
0 25 
0 5 
0 12 
0 06 
0 06 
0 5 
0 06 
0 12 
0 5 
0 03 
0 06 
1 
0 06 
0 03 
From references 6-10 
Comparison of iv and oral antibiotics in this way is preferred to 
the AUC/MIC ratio, which is usually much higher after iv admi­
nistration, or the peak serum concentration/MIC ratio, which is 
also much higher after parenteral administration and is not pre­
dictive of the in-vivo effects (4). 
The period per 24 h during which the serum concentration exceeds 
MICs for most pathogens is longer for the new extended spectrum 
oral cephalosporins than for iv cefuroxime and similar to iv cefo­
taxime. All new oral cephalosporins, except cefuroxime axetil 
have limited activity against Staphylococcus aureus. The period 
per 24 h during which the serum concentration of cefuroxime 
exceeds MICs is especially short for Serratia, Proteus vulgaris and 
Morganelli morganii. Activity against Enterobacteriaceae does not 
persist beyond 15 h per day, even after iv administration. 
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TABLE 2 
TIME (HOURS) THAT THE SERUM CONCENTRATION IS ABOVE THE MIC„ 
E coh 
Klebsiella spp 
Enterobacter 
Citrobacter 
Serratia 
Shigella 
Ρ mirabilis 
Ρ vulgaris 
Mmorganii 
Providencia 
Salmonella 
Yersinia 
Η influenzae 
Mcatarrhahs 
S aureus 
Spyogenes 
Spneumomae 
From references 11 
CEFIX 
CEFPO 
CEFU 
Cefu 
750 mg 
¡V 
3 times 
daily 
15 
15 
11 
15 
1 
15 
15 
1 
1 
15 
15 
11 
19 
24 
19 
24 
24 
-15 
Cefixime 
Cefu 
500 mg 
orally 
2 times 
daily 
10 
10 
6 
10 
0 
10 
10 
0 
0 
10 
10 
6 
14 
19 
14 
24 
24 
Cefpo 
200 mg 
orally 
2 times 
daily 
23 
24 
12 
12 
7 
23 
24 
24 
17 
24 
23 
12 
24 
23 
7 
24 
24 
Cefpodoxime proxetil 
cefuroxime 
Cefix 
200 mg 
orally 
2 times 
daily 
24 
24 
13 
13 
21 
4 
24 
24 
4 
24 
24 
0 
24 
24 
0 
21 
21 
Cefetamet 
l g 
orally 
2 times 
daily 
24 
24 
16 
22 
22 
24 
24 
24 
22 
24 
24 
22 
24 
22 
0 
24 
24 
Cefotaxime 
i g 
iv 
3 times 
daily 
24 
24 
24 
24 
24 
24 
24 
24 
24 
24 
24 
24 
24 
24 
22 
24 
24 
EFFECTS OF FOOD ON THE ABSORPTION OF ORAL 
CEPHALOSPORINS 
The bioavailability of cefuroxime axetil is increased by food. The 
absolute bioavailability of 500 mg cefuroxime axetil was 52% 
when taken together with food and 36% in the fasting state (16). 
The oral bioavailability of Cefpodoxime proxetil is increased by 
30% when the drug is taken with food (17), whereas the absorp-
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tion of Cefixime is unaffected by food (18). The bioavailability of 
Cefetamet is increased by 20% when the drug is taken 1 h after 
food in comparison with administration before "food or together 
with food (19). No studies on the effects of food on absorption of 
cephalosporins have been performed in moderately or severely ill 
patients. It is clear that such studies are needed. 
When these oral cephalosporins are used as a follow up of 
intravenous cephalosporins, it is recommended that they should be 
taken with food or one h after food. 
PLACE OF INJECTABLE CEPHALOSPORINS IN 
THERAPY 
Most Dutch hospitals have antibiotic formularies, offering guideli-
nes for antimicrobial therapy in each hospital. We have collected 
15 of these antibiotic formularies, which are used in 27 hospitals 
in the Netherlands. An overview of the indications for second and 
third generation cephalosporins in these hospitals is given in Table 
3. Besides these indications, cephalosporins are also used for the 
treatment of gonorrhea and in antibiotic prophylaxis in surgery. 
For these indications a single dose is usual and therefore an oral 
follow up is not necessary. 
Possible applications of sequential therapy include hospital-
acquired pneumonia, pneumonia caused by Gram-negative bacilli, 
sepsis of unknown origin, sepsis caused by Gram-negative bacilli, 
urological sepsis, pyelonephritis and arthritis caused by Gram-
negative bacilli. 
ARGUMENTS FOR A SEQUENTIAL THERAPY 
The switch from parenteral to oral medication not only offers the 
recovering patient more freedom of movement, but also prevents 
the occurrence of infusion-related side-effects (such as throm-
bophlebitis), reduces hospital stay, lowers the clinical workload, 
reduces the amount of hospital waste and leads to considerable 
savings in purchase and administration of antibiotics. 
A switch from iv to oral antibiotics may also result in a shorter 
hospital stay. In Israel the introduction of cefuroxime axetil 
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reduced hospital stay of patients with lower respiratory tract 
infections by 3.6 days compared to a historical control (20). 
The workload of hospital wards is reduced because dispensing oral 
tablets takes much less time than the administration of injectable 
antibiotics. 
TABLE 3 
INDICATIONS (EXPRESSED AS THE PERCENTAGE OF THE NUMBER OF 
FORMULARIES IN WHICH THIS INDICATION IS INCLUDED) FOR 
CEPHALOSPORINS IN 15 DUTCH ANTIBIOTIC FORMULARIES (27 HOSPITALS) 
Indication 
Hospital-acquired 
pneumonia 
Pneumonia, 
Gram-negative bacilli 
Sepsis of unknown origin 
Sepsis, Gram-negative 
bacilli 
Urological sepsis 
2nd 
generation 
27% 
20% 
7% 
Meningitis unknown pathogen 
Meningitis, Gram-negative 
bacilli 
Pyelonephritis 
Peritonitis 
Arthritis Gram-negative 
bacilli 
27% 
7% 
2nd 
generation + 
aminoglycosides 
27% 
7% 
60% 
60% 
27% 
27% 
3rd 
generation 
14% 
20% 
13% 
20% 
13% 
27% 
40% 
13% 
13% 
3rd 
generation + 
aminoglyosides 
14% 
13% 
13% 
13% 
An important argument for a sequential therapy is the much lower 
cost of oral cephalosporins compared with parenteral cephalo-
sporins. Gyssens et al. (21) made a detailed study of all the costs 
involved in the purchase, distribution, preparation, handling, 
monitoring and administration of antimicrobial drugs. The 
administration costs (needles, syringes, dressings, antiseptics, 
administration set, piggy bag) were NLG 5.80 per injection. The 
total administration costs per day, with 3 times daily administrati-
on are therefore NLG 17.40. The personnel costs for a tablet are 
about NLG 0.80 per dose (1 minute's work). The personnel costs 
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for a 15 min piggy bag infusion are about NLG 4 per dose. The 
total extra daily costs are therefore NLG 29.40 for 3 times daily iv 
administration of a cephalosporin and NLG 1.60 for twice daily 
oral administration. Considering the average use of about 6 dosage 
units iv cefuroxime in Dutch hospitals (22) the annual savings 
(purchase costs excluded) when 50% of parenteral cefuroxime 
would be replaced by an oral cephalosporin are: 27,80 per patient 
per day χ 10 patients/day χ 365 χ 50% = NLG 50,735! 
Purchase prices of oral cephalosporins are also considerably lower 
than those for parenteral second and third generation 
cephalosporins. In the Netherlands, Belgium and Germany, the 
daily difference in costs between iv cefuroxime 750 mg 3 times 
daily and oral cefuroxime axetil 500 mg twice daily is about NLG 
35. If this difference is again multiplied by 3,650, the total annual 
savings would be NLG 63,875. The total annual savings, if 50% 
of parenteral cefuroxime could be replaced by oral cefuroxime, 
would therefore be about NLG 114,000. Considerable savings are 
therefore possible. 
If the third generation cephalosporins are also replaced by oral 
cephalosporins, the savings are even greater: in Germany for 
instance, the average use of third generation cephalosporins in 
hospitals is about 5 DDD/100 bed days, which means that in a 500 
bed hospital, about 25 patients are treated with parenteral third 
generation cephalosporins every day (23). The difference in daily 
purchase prices between cefotaxime (1 g 3 times daily) and the 
oral cephalosporins are about NLG 75. The difference in costs 
alone for these hospitals would be about NLG 342,000 per year 
per hospital, if 50% of parenteral third generation cephalosporins 
could be replaced by oral cephalosporins. None of the oral 
cephalosporins is active against Pseudomonas aeruginosa, howe­
ver. Coupled with the savings described above, the cost implicati­
ons of a successful sequential therapy are enormous. 
METHODOLOGY OF A STUDY ON SEQUENTIAL 
THERAPY 
Despite the arguments for a sequential therapy with cephalo­
sporins, virtually no studies on this subject have been performed. 
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What should a good study on the feasibility of a sequential 
therapy look like? 
Ideally, such a study should be randomized, double-blind and 
double-dummy. 
If ethically acceptable, a third group should be included in which 
the treatment is stopped, when the other groups are either changed 
to oral therapy or maintained on iv administration. For most 
hospital infections the "generally accepted" duration of therapy is 
7-10 days, so if a switch from iv to oral antibiotics takes place 
after 2-3 days, a third group is not necessary. 
The type (and severity) of the infection to be treated should be 
clearly defined and the necessity for initial parenteral ad-
ministration should be obvious. The criteria for clinical 
cure/improvement and failure should be clearly defined and all co-
medication recorded. 
The "drops-outs" should be carefully monitored to gain in-
formation on the practical feasibility of sequential therapy. 
The switch from iv to oral cephalosporins should be clearly 
defined and be either based on clinical criteria (e.g. fever, 
leucocytes, oral administration possible) or a fixed day (day 2 or 
3) after the initiation of therapy should be chosen. The exact 
duration of both oral and iv administration should be recorded. 
The criteria for stopping the treatment should also be prospectively 
defined. 
The pathogen should be isolated and the MIC of the antibiotics to 
be studied determined and recorded to correlate the in-vitro acti-
vity, the route of administration, bacteriological cure rates and 
clinical efficacy. 
The pharmacokinetics of both the iv and oral dosage form should 
be determined to be able to correlate the time above MIC with the 
clinical efficacy. 
All side effects should be recorded, with special reference to 
infusion related side-effects and GI side-effects. 
There is a need for studies to investigate the feasibility of se-
quential therapy with the newer oral cephalosporins, such as 
Cefetamet, Cefixime and Cefpodoxime. 
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REVIEW OF THE CLINICAL "EVIDENCE" 
The results of the studies on sequential therapy with cephalo-
sporins are summarised in Table 4. These studies were performed 
on patients with community-acquired lower respiratory tract 
infections, such as pneumonia, bronchitis and acute exacerbations 
of chronic bronchitis. These infections are usually not major 
indications for second and third generation cephalosporins and 
parenteral treatment is not indicated in all cases. The majority of 
these studies have not yet been published and were presented as 
abstracts of international congresses. 
In three open, randomised comparative studies of cefuroxime and 
co-amoxiclav, both sequential therapies were equally effective (24-
26). It is not clear whether initial parenteral treatment was neces-
sary in all patients. The bacteriological eradication rates of 
pneumococci, Haemophilus influenzae and Moraxella catarrhalis 
by cefuroxime were high in all three studies. Virtually no 
Enterobacteriaceae were found in these patients. 
The bacteriological cure rates for cefuroxime were better than 
those for parenteral cefotiam (27). All five infections caused by 
Klebsiella pneumoniae responded well to the treatment with 
cefuroxime. The total duration of treatment was longer in the 
cefuroxime group (12.6 days) than in the cefotiam group (8.3 
days). 
Cefpodoxime (200 mg twice daily orally) was compared with 
ceftriaxone (1 g once daily iv) in a group of patients with commu-
nity acquired pneumonia and several other concurrent diseases 
such as cardiovascular disease, cancer, diabetes and respiratory 
insufficiency. It is not clear whether parenteral treatment with 
ceftriaxone was really indicated. The clinical and bacteriological 
results were similar in both groups. The commonest primary 
isolates were Streptococcus pneumoniae and Haemophilus influen-
zae. Parenteral second or third generation cephalosporins are not 
the drugs of choice for treatment of infections caused by these 
organisms. Gram-negative bacilli were found in 14% of the cases. 
The bacteriological cure rates with both cephalosporins were 
excellent (29). 
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TABLE 4 
RESULTS OF SEQUENTIAL THERAPY WITH CEPHALOSPORINS 
Dosage Duration Clinical Bacteriological References 
(no. of daily (days) cure (%) cure (%) 
doses) 
CEFU (n=246) 750 mg ¡ν (3) 2-3 95 82 24 
500 mg or (2) 5 
AUG (n=245) 1 2 g iv (3) 2-3 90 80 
625 mg or (3) 5 
CEFU (η=Ι66) 750 mg iv (3) 2-3 87 81 25 
500 mg or (2) 5 
AUG (n=181) I 2 g iv (3) 2-3 93 89 
375 mg or (3) 5 
CEFU (n=137) 750 mg iv (3) 2-3 86 94 26 
500 mg or (2) 5 
AUG(n=134) 1.2giv(3) 2-3 87 85 
625 mg or (3) 5 
CEFU (n=43) 1 5 g iv (3) 3 4 96 82 27 
500 mg or (2) 8-10 
CEFO (n=48) 2 g iv (2) 7-9 90 60 
CEFIX (n=44) 200 mg or (2) 11 94 89 28 
CEFTR (n=47) 1 g iv (1) II 96 
97 
05 
84 
100 
100 
CEFPO (n=44) 200 mg or (2) 10  29 
CEFTR (n=41) 1 g iv (1) 10 
AUG co-amoxiclav 
CEFIX Cefixime 
CEFO cefotiam 
CEFPO Cefpodoxime 
CEFTR ceftriaxone 
CEFU cefuroxime 
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Cefixime (200 mg twice daily orally) was compared with ceftri-
axone 1 g iv or im once daily for 11 days in the treatment of 
severe urinary tract infections. Both groups received initial treat-
ment with ceftriaxone 2 g once daily iv for 4 days. The clinical 
and microbiological cure rates were similar for both groups. There 
were eight relapses or re-infections in each study group. Seven 
minor adverse events were seen in the ceftriaxone group, whereas 
no side-effects were observed with Cefixime (28). 
CONCLUSIONS 
Although the results from these studies are encouraging, no 
definite conclusions on the feasibility of sequential therapy in 
clinical practice in hospital-acquired infections can be drawn. All 
studies examined patients with community-acquired respiratory 
tract infections and were not blinded; cefuroxime axetil may not 
be recommended for the treatment of hospital acquired infections, 
such as sepsis. Pharmacokinetic data at the time of change from iv 
to oral therapy were not given in any of the studies. Most 
infections described in the studies are usually treated with oral 
antibiotics from the start. The need for parenteral treatment was 
not clear. 
In the treatment of serious infections, such as sepsis or hospital-
acquired pneumonia, cephalosporins are often used in com-
bination with aminoglycosides. By the time a pathogen is identi-
fied (after 2-3 days), many patients may be treated with an oral 
cephalosporin alone if the pathogen is susceptible. 
The standardised switch after 2-3 days of iv treatment to oral 
antibiotics (clindamycin and metronidazole) in a Canadian hospital 
has resulted in saving of $20,000 per year. Reminders of iv to oral 
stepdown were sent to the nursing units with the parenteral dosage 
form, serving as a reminder to prescribers that oral therapy was an 
equally effective and a less expensive alternative to iv treatment. 
A similar stepdown programme has now started for ciprofloxacin 
and cefuroxime (30). The results of this study are awaited with 
interest. 
Sequential therapy with iv and oral cephalosporins seems feasible 
in terms of pharmacodynamics. Serum concentrations of oral 
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Cefpodoxime, Cefixime and Cefetamet exceeding the MICs of these 
drugs for most Enterobacteriaceae persist for longer than for iv 
cefuroxime. The duration of activity of Cefetamet is almost as long 
as that observed for iv cefotaxime. The newer oral cephalosporins, 
such as Cefetamet, Cefixime and Cefpodoxime may offer 
advantages for sequential therapy compared with cefuroxime 
axetil. No oral cephalosporin is available with activity against 
P.aeruginosa. 
Oral administration can lead to very significant savings in the 
purchase and administration costs of cephalosporins. 
The clinical studies performed so far have all been performed witn 
community-acquired respiratory tract infections, which are not 
major indications for (parenteral) cephalosporins. 
Well-designed clinical studies, with good bacteriological and 
pharmacokinetic support are necessary to prove the feasibility of 
sequential therapy with cephalosporins in serious infections, such 
as hospital-acquired pneumonia, pneumonia caused by Gram-
negative bacili, sepsis of unknown origin, urological sepsis, sepsis 
caused by Gram-negative bacilli and pyelonephritis. 
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CHAPTER XII 
CONCLUSIONS AND RECOMMENDATIONS 
R. Janknegt 
183 
The majority of Dutch hospitals have created so-called antibiotic 
formularies with guidelines for the treatment of infectious diseases 
that are specific for that hospital or for a group of collaborating 
hospitals (regional formulary). A systematic study of these 
formularies was the main subject of this Thesis. Theoretically the 
basis of an antibiotic formulary is formed by concerns about 
therapeutic efficacy of antibiotics, emergence of resistance, 
toxicity and containment of costs. 
The following statements summarize the findings in the preceding 
chapters and these can be used as a blue print for what I consider 
the optimal antibiotic formulary. These are summarized in Table 1. 
TABLE 1 
RECOMMENDATIONS FOR OPTIMAL ANTIBIOTIC POLICY 
Guidelines based on local susceptibility data 
Limited use of broad-spectrum agents 
Involvement of the whole medical staff 
Controlled compliance with the formulary 
Frequent revisions of the formulary 
Transparent selection criteria 
Continuous effort to maintain high quality standard 
Collection of data on antimicrobial drug use 
- All guidelines in the formulary are based on readily available 
data on antibiotic susceptibility of clinical isolates from the 
hospital, specified per ward and sample. 
It is highly desirable that the local susceptibility data form the 
basis of a local antibiotic policy. Susceptibility patterns may 
theoretically be quite different between hospitals. Susceptibility 
data from Dutch hospitals were not readily available, as was 
shown in Chapter 1. Only 5 out of 78 hospitals were able to 
provide these data in such a way that they could be used directly 
as a starting point for the preparation of an antibiotic formulary. 
This important criterion has not yet been fulfilled in the great 
majority of Dutch hospitals. 
184 
- The use of expensive and broad-spectrum antimicrobial agents is 
reduced by a strict antibiotic policy. 
The use of antimicrobial agents is relatively low in hospitals in the 
Netherlands in comparison with hospitals in Germany or Belgium, 
as was shown in Chapter 3. The total use of antibiotics was 34 
DDD per 100 bed days in Dutch hospitals, whereas the use of 
antibiotics in Germany and Belgium was 38 and 54 DDD per 100 
bed days respectively. The use of broad-spectrum agents, such as 
third generation cephalosporins, aminoglycosides, antipseudomonal 
penicillins and fluoroquinolones was lower in the Netherlands than 
in both other countries. At least part of the differences between the 
use of antibiotics in the Netherlands and Belgium could be 
explained by differences in written antibiotic policy. 
There are very few data on the quantitative and qualitative use of 
antibiotics in hospitals in other European countries. 
- Authoritative medical staff members are involved in the prepara-
tion of an antibiotic formulary, which will increase the compliance 
with the antibiotic policy. 
Once a formulary has been created a major concern is the 
compliance of the clinicians. The fact that a given hospital has a 
well-defined antibiotic policy, which is expressed in the antibiotic 
formulary, does not necessarily mean that this written policy is 
also kept to the letter in that hospital. This is shown in Chapter 2. 
We have introduced a ratio between the actual use of antibiotics 
and the number of indications from the antibiotic formulary. A 
very wide variation was observed between Dutch hospitals in this 
ratio, especially in the case of co-amoxiclav. These data unders-
core the need for a collaborative approach of medical staff, 
hospital pharmacist and microbiologist to reach consensus and 
thereafter maintain the compliance with the antibiotic policy in the 
hospital. Unless the antibiotic policy described in the antibiotic 
formulary is maintained in a strict manner, the enormous effort of 
preparing a local formulary can hardly be defended. 
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- The formulary must be revised at least every 3 years to keep up 
with all new developments in the treatment of infectious diseases 
and eventual changes in antibiotic susceptibility patterns. 
A frequent update (every 2-3 years) of an antibiotic formulary is 
necessary to maintain a high level of compliance with the formu-
lary and to include all new developments in antimicrobial drug 
therapy into the formulary. In most Dutch hospitals this is indeed 
the case. In a survey performed at the end of 1993, 56% of all 
formularies were less than three years old (Chapter 6). On the 
other hand 26% of these formularies was more than four years old. 
It seems unlikely that physicians comply with a formulary that is 
so old that is does not yet include the fluoroquinolones (which 
were introduced in 1988). 
- The criteria on which a selection of antibiotics is made must be 
transparent and open for discussion within the medical staff. 
Only two formularies from the Dutch hospitals have included a 
discussion section on the motivation of the antibiotic policy. One 
of these also contained data on the local susceptibility patterns 
(Chapter 1). This may be quite helpful in the preparation of a new 
antibiotic formulary. Most formularies contain no comments at all 
on the motivation of the choice of antibiotics. 
In Chapter 10 the SOJA-score is proposed for making a rational 
choice within the group of fluoroquinolones. Although a certain 
degree of subjectivity is always present, the definition of "rational 
selection criteria" and their relative importance makes the choice 
of a certain antibiotic much more transparent and discussions on 
the importance of certain selection criteria become much more 
solid. 
- A continuous effort (especially of the antibiotic formulary com-
mittee regarding literature study and discussions with clinicians) 
is needed to maintain a high quality of antibiotic policy. 
This was investigated in Chapter 4 (bacterial bronchitis), Chapter 5 
(pneumonia), Chapter 6 (sepsis), Chapter 7 (antimicrobial pro-
186 
phylaxis in bowel surgery) and Chapter 8 (antimicrobial 
prophylaxis in gynaecological surgery). 
The Dutch antibiotic formularies make a very restricted use of 
broad-spectrum antibiotics, such as the third generation cepha-
losporins, aminoglycosides and fluoroquinolones. This is also 
expressed by the drug utilisation data in Chapter 3. 
A highly variable terminology was observed in the description of 
bacterial bronchitis. No less than 14 different terms were used to 
describe bacterial bronchitis. On the other hand very few diffe-
rences were found in the treatment recommendations, amoxycillin 
and doxycycline being the most frequently used drugs. The lack of 
controlled clinical studies that have investigated the importance of 
dosing and duration of therapy in bacterial bronchitis is expressed 
in the Dutch formularies by the fact that guidelines for the 
duration of treatment are usually lacking. 
A wide variety of antimicrobial agents was recommended by the 
Dutch antibiotic formularies in nosocomial pneumonia. Sixteen 
different drugs or drug-combinations were used by the Dutch 
formularies. Cefuroxime was the drug most often recommended. 
For the treatment of sepsis of unknown aetiology aminoglycosides 
(in combination with a penicillin or cephalosporin) were the drugs 
of choice in almost all antibiotic formularies. 
First and second generation cephalosporins and co-amoxiclav were 
the preferred agents in most formularies for antibiotic prophylaxis 
in surgery, but dose recommendations and the duration of 
prophylaxis were much more variable. A single dose was used in 
less than 50% of the formularies for bowel surgery and in 64% 
and 73% for vaginal and abdominal hysterectomy, respectively. 
The newer third generation oral cephalosporins, such as Cefixime, 
Cefpodoxime proxetil and Cefetamet offer the possibility of 
sequential oral therapy after an initial intravenous start. This may 
result in important savings in acquisition cost and other costs 
involved with intravenous therapy. Although this is an attractive 
idea, the clinical evidence of the feasibility of such sequential 
therapy is insufficient, as described in Chapter 11. 
Most aminoglycosides are now used twice daily. The therapeutic 
range of aminoglycosides was based on the conventional 3 times 
daily dosing schedule. In Chapter 9 it is shown that the therapeutic 
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ranges of aminoglycosides have not been "updated" with the new 
situation. It must be kept in mind that such an update is not easy, 
as no clinical studies with twice daily aminoglycosides are 
available. The therapeutic range of amino-glycosides in patients 
receiving these drugs once daily or twice daily remains to be 
defined. 
- The actual use of antibiotics and the antibiotic policy must be 
compared with that in other hospitals in the same country or 
abroad (European network) for optimal insight into the usefulness 
of antibiotic formularies. 
A positive finding is that the use of antimicrobial agents in Dutch 
hospitals is low in comparison with that in Germany and Belgium 
and wide-spectrum antimicrobial agents are used to a limited 
degree. As such, this Dutch experience could perhaps be followed 
by other countries. An "European network" of hospitals that are 
able to provide data on antibiotic use, susceptibility data and 
antibiotic policy is desirable to improve the communication 
between European countries. 
It is concluded that the availability of local susceptibility data 
leaves much to be desired. Without these data it is impossible to 
defend the wide differences in antibiotic policy observed in the 
Dutch antimicrobial formularies. 
The motivation of the choice for a given antibiotic in a specific 
infection is quite helpful in the discussions with the medical staff 
and will improve compliance with the antibiotic policy. The SOJA 
system may be a useful tool in transparent drug-decision making. 
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SUMMARY 
A rational use of antibiotics (drugs used for the treatment of 
bacterial infectious diseases) is indicated to reduce the develop-
ment and spread of resistant bacteria as well as from an economic 
point of view. The cost of antibiotics contributes for 10-20% to 
the total drug cost in hospitals. Most Dutch hospitals have created 
so-called "antibiotic formularies" with guidelines for the treatment 
of infectious diseases. These guidelines are specific for a hospital 
or for a group of collaborating hospitals in the same region 
(regional formularies). 
In this thesis, the Dutch antibiotic formularies have been studied. 
The rationale of this study is described in Chapter 1 and a short 
summary of the various investigations is given. This Chapter also 
presents an overview of Dutch antibiotic formularies. A total of 38 
formularies were received, used in 78 hospitals. Of these 
formularies 43% were less than 3 years old. Despite the fact that 
there is a consensus on the importance of local susceptibility pat-
terns as the basis for antibiotic policy, these data were readily 
available from only a limited number of hospitals. 
The correlation between the written antibiotic policy, as expressed 
in the antibiotic formularies, and the actual use of antibiotics in 20 
Dutch hospitals is studied in Chapter 2. The number of DDD per 
100 bed days was divided by the number of indications for a 
given antibiotic in the antibiotic formulary. This ratio was highly 
variable for most groups of antibiotics. These differences could 
partly be explained by the use of antibiotics in antibiotic prophy-
laxis in surgery and by differences in the size and status of the 
hospital. Discrepancies between the written and actual antibiotic 
policy may also play a role. 
A study on the use of antibiotics in hospitals in the Netherlands, 
Germany and Belgium is presented in Chapter 3. The use of these 
drugs was expressed as Defined Daily Doses (DDD, an 
international standardised daily dose for each antibiotic) per 100 
bed days. The total use of antibiotics was significantly higher in 
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Belgium (55.6 DDD/100 bed days in the Dutch speaking part of 
Belgium and 52.0 DDD/100 bed days in the French speaking part) 
in com-parison with Germany (37.9 DDD/ 100 bed days) and the 
Netherlands (34.1 DDD/100 bed days). The use of co-amoxiclav, 
first and second generation cephalosporins, aminoglycosides and 
fluoroquinolones was much higher in Belgium than in both other 
countries. A part of this difference could be explained by dif-
ferences in written antibiotic policy in Belgium compared to the 
Netherlands. 
The antibiotic policy in Dutch hospitals in bacterial bronchitis, 
pneumonia and sepsis is described in Chapters 4, 5 and 6, 
respectively. 
The nomenclature of bacterial bronchitis in the formularies was 
highly variable and a clinical description was lacking in most 
formularies. Amoxycillin, doxycycline and co-trimoxazole were 
the most frequently used antibiotics in this infection. All for-
mularies recommended oral administration of these drugs. The 
large majority of formularies advised an amoxycillin dose of 750 
mg 3 times daily. 
The recommendations for pneumonia with unknown pathogen 
were highly variable. In the treatment of community-acquired 
pneumonia no less than 13 different (combinations of) intra-
venous antibiotics were recommended by the formularies. Amoxy-
cillin was preferred in 45% of them. Sixteen different (combina-
tions of) antibiotics were recommended for hospital-acquired 
pneumonia. The guidelines for dosage were also highly variable. 
The daily dose of benzylpenicillin ranged between 1 and 12 
million units. 
A similar pattern was observed in sepsis. In sepsis with unknown 
pathogen, a total of 16 different intravenous antibiotics (com-
binations) were used. Aminoglycoside-containing regimens were 
recommended by the large majority of formularies. These drugs 
were most frequently combined with amoxycillin, co-amoxiclav 
and cefuroxime. 
In a number of surgical procedures, it is necessary to administer 
prophylactic antibiotics to prevent surgical wound infections. This 
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is especially important in contaminated surgery, such as bowel 
surgery, as well as those surgical procedures in which the 
consequences of a wound infection are very serious, such as in 
prosthetic hip surgery. The Dutch policy regarding the use of 
antibiotics in surgical prophylaxis is presented in Chapters 7 and 
8. Co-amoxiclav and first or second generation cephalosporins 
(with or without metronidazole) were the most frequently used 
antibiotics in bowel surgery. Multiple-dose regimens were used in 
most formularies ranging from 52 to 66% for various forms of 
bowel surgery. 
Co-amoxiclav was the most frequently used drug in gynaeco-
logical and obstetric surgery. A single dose prophylaxis was 
recommended by 64% of the formularies for vaginal hysterectomy, 
by 73% for abdominal hysterectomy and by 50% for Caesarian 
section. 
Chapter 9 discusses the use of aminoglycosides in Dutch hos-
pitals. This group of antimicrobial agents has a narrow therapeutic 
margin, i.e. serious nephrotoxic and ototoxic reactions may occur. 
The serum concentration of aminoglycosides is routinely assayed 
to prevent toxic reactions as much as possible. Aminoglycosides 
were always given in a 3 times daily manner. From recent studies 
it has become evident that a once daily dosage is as effective and 
probably less nephrotoxic. 
We showed that 72% of 65 Dutch hospitals used aminoglycosides 
in a twice daily manner, whereas 18% used a once daily method 
and only 10% still used the conventional 3 times daily method. 
The twice daily dosing method turned out to be a compromise 
between once daily (microbiologist and hospital pharmacist) and 3 
times daily (clinicians). Only a limited number of hospitals have 
adjusted the "normal values" for peak and trough concentrations of 
aminoglycosides to the different dosage regimens. The serum 
concentrations of aminoglycosides in patients receiving these drugs 
in a once daily or twice daily manner are difficult to interpret, due 
to the lack of studies investigating the relationships between serum 
concentrations and efficacy or toxicity. 
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For a good compliance of the members of the medical staff it is 
essential that it is clear to all users of the formulary why certain 
decisions have been made. In the selection of a drug from a 
specific pharmaceutical group, a wide variety of (rational and 
emotional) selection criteria may play a role. Chapter 10 proposes 
the SOJA (System of Objective Judgement Analysis) system to 
make drug-decisions in a transparent way. Selection criteria are 
defined and each of these has a certain weighting factor. By means 
of this method a drug-selection has been made for the 
fluoroquinolones. Ofloxacin shows a higher score than cipro-
floxacin and Pefloxacin. 
Chapter 11 discusses various aspects of a sequential therapy with 
intravenous and oral cephalosporins. Oral administration may offer 
advantages concerning lower acquisition cost, reduction in work 
load on the hospital ward, better patient-comfort and the lack of 
infusion-related complications. Reliable absorption is essential for 
a good antimicrobial activity. A change from iv to oral 
cephalosporins after 3-5 days may result in substantial savings, 
because of the lower acquisition cost and the lower cost for 
administration of oral drugs in comparison with intravenous 
antibiotics. No conclusive clinical evidence is available, however 
to demonstrate that such an approach to infectious diseases is 
achievable. Recommendations are given for future research in this 
field. 
Chapter 12 summarizes the most important conclusions of the 
preceding chapters. Recommendations for an "ideal" antibiotic 
policy are given. 
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SAMENVATTING 
Een rationeel gebruik van antibiotica (middelen die worden 
toegepast bij de behandeling van bacteriële infectieziekten) is 
zowel van belang om de ontwikkeling en verspreiding van 
resistente bacteriën te voorkomen alsmede vanwege de hoge 
kosten die verbonden zijn aan de toepassing van antibiotica. De 
kosten van antibiotica bedragen 10-20% van de totale geneesmid-
delkosten in ziekenhuizen. 
De meeste Nederlandse ziekenhuizen hebben zogenaamde "antibio-
tica formularia" in gebruik met richtlijnen voor de behandeling van 
infectieziekten. Deze richtlijnen zijn specifiek voor dit ziekenhuis 
of voor een groep van nabijgelegen ziekenhuizen (regionale 
formularia). 
In dit proefschrift worden de Nederlandse antibiotica formularia 
bestudeerd. 
In Hoofdstuk 1 wordt beschreven waarom dit onderzoek werd 
uitgevoerd en wordt een korte samenvatting gegeven van de 
verrichte onderzoeken. Tevens wordt een overzicht gegeven van 
de in ons land gebruikte antibiotica formularia. Er werden in totaal 
38 formularia ontvangen, die in 78 Nederlandse ziekenhuizen 
werden toegepast. Van deze formularia was 43% minder dan 3 
jaar oud. Ondanks het feit dat iedereen het erover eens is dat de 
richtlijnen voor de behandeling van infectieziekten zouden moeten 
worden afgestemd op de beschikbare gegevens van het lokale of 
regionale microbiologisch laboratorium ten aanzien van de 
gevoeligheid van bacteriën voor diverse antibiotica, bleken deze 
gegevens slechts in beperkte mate beschikbaar te zijn. 
In Hoofdstuk 2 worden de gegevens ten aanzien van het geschre-
ven antibiotica beleid, zoals dat uitgedrukt is in de antibiotica 
formularia en het daadwerkelijke gebruik van antibiotica in 20 
Nederlandse ziekenhuizen aan elkaar gecorreleerd. Hiertoe werd 
het aantal DDD's per 100 bed dagen gedeeld door het aantal 
indicaties voor het betreffende middel in het antibiotica formu-
larium. De ratio hiertussen bleek zeer variabel voor de meeste 
groepen van antibiotica. Deze verschillen konden deels worden 
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verklaard door het profylactische gebruik van antibiotica en door 
verschillen in de functies van de ziekenhuizen (basis ziekenhuis of 
academisch ziekenhuis). Ook verschillen tussen het geschreven 
beleid (formularia) en het daadwerkelijk gevoerde beleid kunnen 
hiertoe hebben bijgedragen. 
In Hoofdstuk 3 wordt een onderzoek gepresenteerd naar het 
gebruik van antibiotica in ziekenhuizen in Nederland, Duitsland en 
België. Het gebruik werd uitgedrukt in Defined Daily Doses 
(DDD, een internationale gestandaardiseerde dagdosis van ieder 
antibioticum) per 100 bed dagen. Het totale gebruik van antibiotica 
was significant hoger in België (55,6 DDD per 100 bed dagen in 
Vlaanderen en 52,0 in Wallonie) dan in Duitsland (37,9 DDD/100 
bed dagen) en Nederland (34,1 DDD/ 100 bed dagen). Vooral het 
gebruik van amoxicilline-clavulaanzuur, eerste en tweede generatie 
cefalosporines, aminoglycosiden en gefluorideerde chinolonen was 
veel hoger in België dan in de beide andere landen. Een deel van 
dit verschil kon worden verklaard door een ander (geschreven) 
antibioticabeleid in België in vergelijking met Nederland. 
In de Hoofdstukken 4, 5 en 6 wordt het beleid in de Nederlandse 
ziekenhuizen beschreven bij bacteriële bronchitis, pneumonie en 
sepsis. De gebruikte terminologie van het ziektebeeld bacteriële 
bronchitis in de formularia is zeer divers en een duidelijke klini-
sche omschrijving ontbreekt zelfs in de meeste formularia. Amoxi-
cilline, doxycycline en Cotrimoxazol zijn de meest gebruikte an-
tibiotica bij deze infectie. Alle formularia adviseren een orale toe-
diening. De grote meerderheid van de formularia adviseert een 
dosering van 3 χ daags 750 mg amoxicilline. 
Bij pneumonie met een onbekende verwekker blijkt er een grote 
variatie te bestaan in de aanbevelingen in de formularia. Bij de 
behandeling van pneumonie met onbekende verwekker, verkregen 
buiten het ziekenhuis, werden liefst 13 verschillende intraveneuze 
antibiotica of combinaties van antibiotica toegepast. In 45% van de 
formularia werd amoxicilline aanbevolen. Bij pneumonie 
verkregen in het ziekenhuis werden zelfs 16 verschillende 
antibiotica (combinaties) toegepast. Ook de richtlijnen voor de 
dosering liepen sterk uiteen: de dosering voor benzylpenicilline lag 
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tussen 1 en 12 miljoen IE per dag. 
Bij het zeer ernstige ziektebeeld sepsis werd opnieuw een groot 
aantal verschillende intraveneuze antibiotica toegepast. Bij sepsis 
met onbekende verwekker werd in vrijwel alle formularia een 
aminoglycoside aanbevolen, in combinatie met amoxicilline, 
amoxicilline-clavulaanzuur of Cefuroxim. In totaal werden 16 
verschillende antibiotica (combinaties) toegepast. 
Bij een groot aantal chirurgische ingrepen is het noodzakelijk 
gebleken om profylactisch antibiotica toe te dienen teneinde 
wondinfecties te voorkomen. Dit is vooral van belang indien de 
ingreep plaatsvindt in een "gecontamineerd" gebied zoals de darm, 
of indien de gevolgen van een eventuele wondinfectie zeer ernstig 
kunnen zijn, zoals bijvoorbeeld bij een "totale heup". In de 
Hoofdstukken 7 en 8 wordt een overzicht gegeven van het beleid 
in Nederlandse ziekenhuizen ten aanzien van de antibiotische 
profylaxe in de chirurgie. In de darmchirurgie worden vooral 
amoxicilline-clavulaanzuur en eerste of tweede generatie 
cefalosporines, al dan niet in combinatie met metronidazol 
toegepast. In de meeste formularia (52 tot 66%) werden meer-
doses profylaxe-regimes toegepast. In de gynaecologische en 
obstetrische chirurgie was amoxicilline-clavulaanzuur veruit het 
meest toegepaste middel. Een 1-dosis profylaxe werd aanbevolen 
door 64% van de formularia voor vaginale hysterectomie, door 
73% voor abdominale hysterectomie en door 50% voor een 
keizersnede. 
In Hoofdstuk 9 wordt het gebruik van de aminoglycosiden in 
Nederlandse ziekenhuizen bestudeerd. Deze groep van antibiotica 
heeft slechts een beperkte "therapeutische breedte", dat wil zeggen 
dat ernstige toxische reacties, met name op de nierfunctie en het 
gehoor, kunnen optreden. Daarom wordt van deze middelen de 
concentratie in het bloed bepaald om deze toxische reacties zoveel 
mogelijk te kunnen voorkomen. Traditioneel werden deze mid­
delen altijd 3 χ daags toegepast. Uit recent onderzoek is gebleken 
dat een 1 χ daagse toepassing even effectief is en mogelijk minder 
toxisch is voor de nier. Uit het in dit hoofdstuk beschreven onder­
zoek blijkt dat 72% van de 65 ondervraagde Nederlandse 
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ziekenhuizen een 2 χ daagse dosering gebruiken, 18% 1 χ daags 
en 10% 3 χ daags. Dit ondanks het feit dat er vrijwel geen 
literatuur over een 2 χ daagse toepassing beschikbaar is. De 2 χ 
daagse toepassing bleek een compromis te zijn tussen 1 χ daags 
(microbioloog en apotheker) en 3 χ daags (clinici). Niet alle 
ziekenhuizen hadden de "normaalwaarden" voor de "top en dal" 
aminoglycoside-concentraties in serum aangepast aan het veran­
derde doserings-regime. De serumconcentraties van aminoglycosi-
den bij een 1- of 2 χ daagse toepassing zijn moeilijk te correleren 
aan effectiviteit en toxiciteit, door het ontbreken van onderzoek. 
Voor een goede "gedragenheid" onder de medische staf van een 
formularium is het van groot belang om duidelijk te maken 
waarom een bepaalde beleidsbeslissing is genomen. Bij de keuze 
van een geneesmiddel binnen een bepaalde farmacotherapeutische 
groep spelen een groot aantal rationele en emotionele factoren een 
rol. In Hoofdstuk 10 wordt een scoringssysteem opgevoerd (SOJA 
score), waarbij keuzecriteria worden gedefinieerd en elk criterium 
een relatief gewicht krijgt. Door middel van deze methode wordt 
dan een preparaatkeuze gemaakt voor de gefluorideerde 
chinolonen. Ofloxacine vertoont een hogere score dan de beide 
andere middelen Ciprofloxacine en pefloxacine. 
In Hoofdstuk 11 worden de diverse aspecten van een oraal 
vervolg van een parenteraal gestarte therapie met cefalosporines 
besproken. Orale behandeling biedt voordelen ten aanzien van kos­
ten, werkdruk, patiënten-comfort en het minder optreden van in-
fuus-gerelateerde bijwerkingen. Voor een goede werking is echter 
een betrouwbare orale absorptie noodzakelijk. Het blijkt dat een 
snelle overgang naar een orale behandeling van infecties tot zeer 
aanzienlijke kostenbesparingen kan leiden, door een vermindering 
van de personeelskosten en de veel lagere aanschafprijs van orale 
middelen in vergelijking met parenterale middelen. Er is echter 
nog vrijwel geen onderzoek verricht dat "hard" maakt dat een 
dergelijke aanpak van ernstige infectieziekten in het ziekenhuis 
daadwerkelijk mogelijk is. In dit hoofdstuk worden aanbevelingen 
gedaan hoe een dergelijk onderzoek eruit zou kunnen zien. 
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In Hoofdstuk 12 worden de belangrijkste conclusies van de 
voorgaande hoofdstukken samengevat en worden aanbevelingen 
voor een "ideaal" antibioticumbeleid gedaan. 
197 
198 
DANKWOORD 
Aan dit proefschrift heeft een groot aantal mensen in aktieve of 
passieve zin een bijdrage geleverd. 
Dr. W.J.A. Wijnands, longarts te Deventer en mevr. Dr. E.E. 
Stobberingh, medisch microbiologe te Maastricht. Beste Giel en 
Ellen: Wat ooit begon als een "interessant project" is nu uit-
gegroeid tot een heuse promotie. Ik heb de zeer prettige samen-
werking met jullie beiden altijd zeer gewaardeerd. Jullie waren 
veelal kritischer dan het mij lief was, doch dat heeft mij behoed 
voor een dreigende oppervlakkigheid van de artikelen. Juist het 
feit dat jullie reacties doorgaans zeer verschillend waren maakte de 
discussies boeiend. Het verheugt mij dat deze promotie niet zal 
betekenen dat er een abrupt einde komt aan de samenwerking met 
jullie, maar dat wij "gewoon" doorgaan. 
Prof. Dr. J.W.M, van der Meer, hoogleraar algemeen interne 
geneeskunde te Nijmegen. Beste Jos: Na een aarzelend begin en 
veel wanhoop is er nu dan toch een proefschrift tot stand geko-
men. Jouw aanvullingen en de stimulerende discussies hebben een 
duidelijke meerwaarde gehad. 
Ik ben de manuscriptcommissie, bestaande uit Prof. Dr. J.A.A. 
Hoogkamp-Korstanje, Prof. Dr. F. Gribnau en Dr. Y.A. Hekster, 
zeer erkentelijk voor hun kritische opmerkingen. Hun commentaar 
heeft de kwaliteit van dit proefschrift in belangrijke mate 
verhoogd. 
Dr. B.I. Davies, medisch microbioloog te Heerlen. Beste Ben: Dat 
dit proefschrift in begrijpelijk Engels is geschreven is voor een 
belangrijk deel aan jou te danken. Ik ben je zeer erkentelijk voor 
jouw talrijke taalkundige en inhoudelijke correcties. 
Dr. P.M. Hooymans, Dr. J.J.H.M. Lohman en mevr. drs. M.H.G. 
Schols-Hendriks, ziekenhuisapothekers te Sittard. Beste Piet, Sjef 
en Marga: Jullie hebben van het begin af aan alle ups en downs 
van mijn plannen kunnen meemaken. Jullie stonden altijd met raad 
en daad voor mij klaar en gaven mij de volledige ruimte om aan 
dit proefschrift te werken. Ik heb dat steeds bijzonder 
gewaardeerd. 
Drs. H. Brummelman, arts, verbonden aan Roussel Nederland BV 
en de heer R. Kruijff, verbonden aan Hoechst Holland Pharma 
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BV. Beste Henk en Rene: Een project dat een aantal jaren geleden 
startte als een "niet product-gebonden service" heeft nu 
geresulteerd in dit proefschrift. Jullie hebben de mogelijkheid 
geschapen om Giel, Ellen en mij regelmatig om de tafel te krijgen, 
met een groot aantal artikelen tot gevolg. Ik heb het altijd zeer 
gewaardeerd dat jullie je niet met de inhoudelijke discussies 
hebben bemoeid. Productnamen zijn tijdens alle bijeenkomsten niet 
eens genoemd. Een lichtend voorbeeld voor hoe de farmaceutische 
industrie kan werken! 
Mevr. B. Monsma-Wielens en mevr. M. Bos-Mertens, secretares-
ses van de afdeling Klinische Farmacie van het Maasland Zie-
kenhuis te Sittard. Vooral in de maanden januari tot april kwam ik 
op de meest ongelegen momenten binnenvallen om "snel" even 
iets te printen. Dat "iets" was dan meestal een vrij tot zeer om-
vangrijk document. Dat zal nu zeker minder worden, doch helaas 
waarschijnlijk niet al te veel. 
Alle apothekers-assistentes van het Maasland Ziekenhuis. Jullie 
hebben mij de gelegenheid gegeven om me af en toe op mijn 
kamer terug te trekken om te werken aan dit proefschrift. Met 
name in Geleen was de concurrentieslag voor een plekje achter de 
PC soms hevig. Dank voor jullie medewerking. 
En dan tenslotte, zoals gebruikelijk "Last but not least", dank ik 
het thuisfront. Lieve Irene, Ronald en Laura. Jullie hebben mij de 
gelegenheid gegeven om thuis hard te werken aan de promotie. 
Hoewel de overgrote meerderheid van het werk zich in de 
huiskamer afspeelde, waardoor ik in ieder geval tot op zekere 
hoogte bij het sociale gebeuren betrokken bleef, waren er ook 
talrijke momenten dat ik mij achter de PC moest terugtrekken. 
Jullie hebben daar bewonderenswaardig weinig over geklaagd. 
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STELLINGEN 
Behorend bij het proefschrift 
ANTIBIOTIC POLICY IN DUTCH HOSPITALS 
A survey of Dutch antibiotic formularies 
R. Janknegt 
Nijmegen, 12 oktober 1994 
1. De beschikbaarheid van gegevens over de in-
vitro gevoeligheid van micro-organismen voor 
antimicrobiéle middelen in Nederlandse zieken-
huizen laat nog veel te wensen over. 
(dit proefschrift) 
2. Het verbruik van antibiotica in Nederlandse 
ziekenhuizen is laag in vergelijking met zieken-
huizen in Duitsland en België. 
(dit proefschrift) 
3. Voor een breed draagvlak is het van groot 
belang dat de medische staf op ruime schaal 
betrokken is bij het opstellen van een antibio-
ticum formularium. 
(dit proefschrift) 
4. Het gebruik van antibiotica komt niet altijd goed 
overeen met de richtlijnen in het formularium. 
(dit proefschrift) 
5. Het opstellen van een antibioticum formularium 
in ieder ziekenhuis afzonderlijk is alleen te ver-
dedigen als dit gebaseerd is op lokale gevoelig-
heidsgegevens en indien dit formularium een 
breed draagvlak heeft in het betreffende zieken-
huis, (dit proefschrift) 
6. Bij de behandeling van sepsis met onbekende 
verwekker wordt een zeer groot aantal ver-
schillende antibiotica toegepast in Nederlandse 
ziekenhuizen. 
(dit proefschrift) 
7. Een sequentiële therapie met intraveneuze en 
orale cefalosporines is vanuit financieel oogpunt 
zeer aantrekkelijk, doch is klinisch onvoldoende 
gedocumenteerd. 
(dit proefschrift) 
8. Het toepassen van een transparant beslis-
singsmodel bij de keuze van een geneesmiddel 
uit een farmacotherapeutische groep biedt grote 
voordelen boven vage "wetenschappelijke afwe-
gingen". 
(dit proefschrift) 
9. De Taxeprijs van generieke geneesmiddelen 
dient te worden aangepast aan de gangbare 
marktprijs. 
10. Zolang de K.N.M.P. in haar stellingname tegen 
"postorderfarmacie" niet openlijk het criterium 
"het kost ons geld" noemt, is het standpunt van 
de K.N.M.P. weinig geloofwaardig. 
11. Het verdient sterke aanbeveling om de details 
van de maatregelen die door het ministerie van 
WVC worden genomen in het vervolg langer 
dan 5 minuten van te voren bekend te maken 
aan verzekeraars, voorschrijvers en afleveraars. 
12. Goede onderlinge verhoudingen in vriendschap 
en waardering vormen de beste basis voor we-
tenschappelijk onderzoek. 
13. Een rookverbod in (gedeelten van) restaurants 
dient verplicht te worden, opdat ook astma 
patiënten uit eten kunnen gaan zonder tweemaal 
een rekening gepresenteerd te krijgen. 


